Core Principles of Integrated Multidisciplinary Healthcare Practice

Editors

Sourav Karmakar
Assistant Professor, Department of Optometry, Swami Vivekananda University, Kolkata, West Bengal, India

Dipanwita Ghosh
Department of Optometry and Head, Swami Vivekananda University, Barrackpore, West Bengal, India

Dr. Oly Banerjee
Assistant Professor and Head, Medical Laboratory Technology, Swami Vivekananda University, Barrackpore, West Bengal, India

Helmand Books ™
New Delhi

Published By: *Helmand Books*

Helmand Books
Office No 3, 1st Floor,
Pocket-H34, SEC-3,
Rohini, Delhi, 110085, India
Website: www.helmandbooks.com
Email: helmandbooks@gmail.com

Editors: *Sourav Karmakar, Dipanwita Ghosh and Dr. Oly Banerjee*

Publication Year: *2025*

Edition: *1st*

Pages: *185*

Paperback ISBN:

E-Book ISBN:

Price: ₹ *795/-*

Preface

The Indian healthcare system is witnessing a significant transformation, driven by rising patient expectations, advancements in medical science, and the increasing burden of both communicable and non-communicable diseases. In this rapidly evolving environment, a collaborative, team-based approach to healthcare delivery has become essential. Traditional compartmentalized roles are no longer sufficient to meet the growing and complex needs of patients across urban and rural settings.

This book, "Interdisciplinary Approaches in Modern Healthcare Delivery," has been designed to address this pressing need by fostering a clear understanding of how different allied health disciplines can work together to provide holistic and patient-centered care**.** Focusing on three critical fields-Optometry, Medical Laboratory Technology (BMLT), and Physiotherapy-this text highlights their unique contributions and demonstrates how their integration enhances clinical outcomes.

Aimed at undergraduate students in allied health sciences, the book serves as both an academic resource and a practical guide. It introduces students to the real-world relevance of interdisciplinary collaboration through examples drawn from the Indian healthcare setting, including primary healthcare centers, tertiary hospitals, and private clinical setups. The content aligns with national health goals such as those outlined in the Ayushman Bharat initiative, emphasizing preventive, promotive, and rehabilitative care.

We are deeply grateful to Swami Vivekananda University for its commitment to academic excellence and to the School of Allied Health Sciences for cultivating a multidisciplinary learning environment. The contributions and support from the departments of Optometry, BMLT, and Physiotherapy have been invaluable in bringing this book to life.

Each chapter is thoughtfully structured to guide students through key concepts, encourage critical thinking, and promote respect for the roles of fellow healthcare professionals. We believe this book will help young learners develop a mindset of collaboration, empathy, and shared responsibility-values that are increasingly vital in the Indian healthcare context.

It is our sincere hope that this book lays the foundation for a new generation of allied health professionals who are prepared not just to work within their discipline, but to grow alongside others in pursuit of a healthier India.

Acknowledgements

We are profoundly thankful to Swami Vivekananda University for providing an inspiring academic platform and for its continued encouragement in promoting interdisciplinary learning and educational innovation. The university's dedication to fostering collaborative thinking has been a key motivator behind the development of this book.

Our heartfelt appreciation also goes to the School of Allied Health Sciences for its dynamic leadership and consistent support. The realization of this publication would not have been possible without the collective input and cooperation of the committed faculties from the Department of Optometry**,** Department of Medical Laboratory Technology (BMLT)**,** and Department of Physiotherapy. Each department has offered valuable insight and professional expertise, which have greatly enriched the content and strengthened the interdisciplinary focus of this work.

We are equally grateful to our peers, mentors, and students, whose active involvement, thoughtful suggestions, and academic curiosity have been instrumental in shaping this book. Their contributions added depth, clarity, and practical relevance to the material presented.

This book reflects the spirit of teamwork, mutual respect, and a shared commitment to enhancing the quality of healthcare education through integrated allied health practices. It is our hope that this collaborative effort will serve as a meaningful resource for current and future healthcare professionals.

Authors

Manojit Bysack
Assistant Professor, Medical Laboratory Technology, Swami Vivekananda University, Barrackpore
Dr. Rajen Dey
Assistant Professor, Medical Laboratory Technology, Swami Vivekananda University, Barrackpore
Gourab Jyoti Roy
Assistant Professor, Department of Physiotherapy, Swami Vivekananda University, Barrackpore
Sunayana Ghosh Dostider
Department of Physiotherapy, Swami Vivekananda University, Barrackpore
Sourav Mitra
Department of Physiotherapyand Head, Swami Vivekananda University, Barrackpore
Dr. Sanhita Bose
Department of Physiotherapy**,** Swami Vivekananda University, Barrackpore
Anusuya Das
Department of Optometry, Swami Vivekananda University, Barrackpore
Arup Saha
Department of Optometry**,** Swami Vivekananda University, Barrackpore
Dipanwita Ghosh
Department of Optometry and Head, Swami Vivekananda University, Barrackpore
Dr. Manas Chakraborty
Department of Optometry, Swami Vivekananda University, Barrackpore
Dr.Prabirendra Nath Sinha
Department of Optometry, Swami Vivekananda University, Barrackpore
Rikta Paul
Department of Optometry, Swami Vivekananda University, Barrackpore
Sourav Karmakar
Department of Optometry, Swami Vivekananda University, Barrackpore
Srimanti Sarkar
Department of Optometry, Swami Vivekananda University, Barrackpore

Contents

Chapter - 1
A Narrative Studyon Beneficial Effect of Gamma-Oryzanol over Human Ovary and Nervous System

Authors

Manojit Bysack
Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal, India

Rajen Dey
Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal, India

Chapter - 1

A Narrative Studyon Beneficial Effect of Gamma-Oryzanol over Human Ovary and Nervous System

Manojit Bysack and Rajen Dey

Abstract

Reproductive organ health and environmental factors like nutrition, hormones, radiation exposure, genetics, and insecticide use all affect fertility. Reproductive health is indicated by the ovaries' histological makeup. In the medical field, pyrethroid-based insect repellents and their possible health effects-especially on the homeostasis of the reproductive system-have long been discussed. Homeostasis disturbances can result in infertility and ovarian dysfunction. Rice bran oil (RBO) contains γ-Oryzanol, a powerful antioxidant that has been shown to have higher antioxidant activity than vitamin E. While γ-Oryzanol's health benefits are widely known, nothing is known about how it affects reproductive health. γ-Oryzanol has better nitric oxide activity and anti-inflammatory qualities than antioxidants, according to in silico research. Further evidence of γ-Oryzanol's potential to improve ovarian function comes from its binding to Foxo3a and Growth Differentiating Factor 9 (GDF9). Research indicates that γ-Oryzanol, as opposed to RBO, considerably enhances ovarian physiology by raising Foxo3a and GDF9 expression and decreasing TNF-α levels when exposed to transfluthrin. Moreover, γ-Oryzanol has neuroprotective properties due to its capacity to penetrate the blood-brain barrier. It may help with the rehabilitation of motor function following spinal cord injury (SCI), according to recent studies, which would be extremely beneficial for young people with chronic disability.

Keywords: Anti-oxidant, bioactive compound, dietary fiber, functional food, γ-oryzanol, motor function, spinal cord injury

Introduction

The main ingredient, 2%, in the rice bran extract is gamma-oryzanol. The oil from rice bran contains a variety of phytosterylferulates. According to a number of investigations, rice bran oil has specific antioxidant properties, lowers plasma cholesterol, and inhibits platelet aggregation. Rice

bran oil has been used in traditional Japanese medicine to cure gastrointestinal issues, fasten growth, improve skin capillary circulation, and lessen the effects of menopause. Strong antioxidant properties were commonly reported for chemotherapy, cancer, and radioprotection [1, 2]. Numerous scholarly articles have documented the advantages of gamma-oryzanol and rice bran oil in the treatment of dyslipidemia due to their antioxidant properties.In patients with type 2 diabetes, consuming rice bran oil modified milk on a regular basis tends to lower cholesterol linked to low density lipoprotein and dramatically lowers overall serum cholesterol concentrations [3]. In both human and animal models, gamma-oryzanol and rice bran oil reduce serum total cholesterol by preventing intestinal fat absorption. Inhibition of nuclear factor-kB activation via the antioxidant activity is the mechanism that explain the anti-inflammatory impact [4]. Extracts high in gamma-oryzanol have strong anti-inflammatory properties and scavenge free radicals [5]. Additionally, because of the abundance of powerful antioxidants, it down-regulates the oxidative stress gene markers and up-regulates antioxidant genes [1, 2].

Gamma-oryzanol may be able to inhibit the carcinogenic process through the antioxidant pathway. In experimental animal models, researchers examined the immunomodulatory potential of oryzanol derived from crude rice bran oil and discovered that it had a considerable capacity to enhance immunological activity through humoral and cellular processes [6]. Gamma-oryzanol can decrease tumor mass linked to pro-angiogenic biomarkers in tumor-bearing animals. As the number of blood vessels in the tumor mass decreased, vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2), and 5-lipoxygenase-5 (5-LOX) showed markedly decreased mRNA and protein expression, which resulted in VEGF downregulation and neoangiogenic inhibition within the tumors [7].These findings imply that gamma-oryzanol may be used to treat cancer. Nevertheless, there aren't many published studies demonstrating gamma-oryzanol'santicarcinogenic properties. Since prior research indicated a substantial correlation between oxidative stress and prostate cancer, prostate cancer cell lines were selected as a model for cancer treatment. Modification of the redox status may be a viable treatment approach for prostate cancer cells, particularly those that invade, migrate, and cause cancer. Reducing excessive reactive oxygen species (ROS) may be a very good way to stop prostate cancer from developing and spreading [8].

The current study evaluated the mRNA expression of genes regulating intracellular antioxidant capacity, such as superoxide dismutase (SOD),

catalase (CAT), glutathione peroxidase (GPX), and glutathione reductase (GSR), for a protective mechanism in an effort to ascertain the antioxidative potential of gamma-orizanol on prostate cancer cells using the key genes regulating intracellular antioxidant enzymes in prostate cancer cell lines, DU145 and PC3.

Ovarian Effects

According to a 2016 survey by Sunaryo, the majority of Indonesians (86.33%) used home pesticides at least once a day (85.4%) for more than five years (74.51%) [9]. Sprays or aerosols (12.2%) are commonly used in Indonesian households, according to research whose goal is to determine the distribution of mosquito repellents [10]. Oogenesis, folliculogenesis, and steroidogenesis are three essential processes in the ovaries that are crucial for determining fertility in the reproductive system. The histological structure of the ovaries can be used to measure these processes, and the PI3K-Akt pathway can be used to analyze their function. Through an increase in Reactive Oxygen Species and an indication of oxidative stress, exposure to pyrethroid aerosol mosquito repellent throughout the reproduction cycle may result in cellular damage.Through Oocyte Secreted Factors, it will affect oocyte growth and development, including the secretion of Growth Differentiating Factor 9 (GDF-9). Kit ligand (KL) formation disruption in granulose is caused by low GDF-9 expression. The activation of Akt is dependent on KL on the PI3K pathway. Under typical circumstances, Akt activity on the Foxo substrate decreases Foxo3a activation, which in turn suppresses the detrimental effects of Foxo3a on oocyte growth, specifically transcription and apoptosis. Through the PI3K-α approach, extracellular signal-regulated kinase (ERK1/2) activation through the mitogen-activated protein kinase pathway stimulated by tumor necrosis factor α (TNF-α) and epidermal growth factor receptor (EGFR) in granulosa is also linked to GDF-9 activation during folliculogenesis.Follicle-stimulating hormone (FSH) must bind to the FSH receptor (FSHR) in order for EGFR to be activated. Endocrine disrupting drugs (EDCs) can inhibit transfluthrin exposure by interfering with gonadotropin activity and lowering levels of FSH and luteinizing hormone (LH). It affects EGFR's incapacity to activate ERK1/2. Foxo3a, GDF-9, and TNF-α are expressed by the PI3K pathway; in this circumstance, antioxidants and anti-inflammatory drugs are needed to repair injured cells during the folliculogenesis process [11, 12].

Rice bran may be used as a functional food because of its high bioactive components and good nutritional value [13]. Rice bran oil (RBO) is one of the lesser-known products derived from rice bran. RBO has anti-inflammatory and antioxidant properties. By lowering damage to plasma lipids and preventing chronic inflammatory responses, its bioactive components-such as tricin, beta-sitosterol, γ-oryzanol, tocotrienols, tocopherols, ferulic acid, and phytic acids-can decrease oxidative stress. It contains γ-oryzanol, a bioactive ingredient, just like other products made from rice bran. Crude RBO contains 35.9% phenolic acid and 62.9% γ-oryzanol. According to the study's initial in silico phase, γ-oryzanol exhibited greater nitric oxide and anti-inflammatory properties than antioxidants [14].EDCs from a single push exposure with transfluthrin are examined using three parameters in conjunction with γ-oryzanol and RBO treatment to determine their effect on the ovaries' histological structure. These parameters include elevated TNF-α to gauge the inflammatory process, Foxo3a expression to detect homeostatic disruption in the ovaries, which results in elevated Foxo3a expression that affects transcription and apoptotic activation during folliculogenesis, and decreased GDF9 expression, which is essential for granulosa cell proliferation and differentiation as well as follicle and oocyte growth. When the weight of the ovaries increases, γ-Oryzanol's anti-inflammatory and antioxidant action is stronger than RBO's, independent of the decline in TNF-α levels, Foxo3a expression, and the relatively high expression of GDF9.TNF-α, Foxo3a, and GDF9 levels in rats exposed to transfluthrin (RattusNovergicus) indicate that the weight of the ovaries is impacted by the antioxidant and anti-inflammatory properties of γ-oryzanol administration as opposed to RBO. The use of γ-oryzanol, as opposed to RBO, has antioxidant and anti-inflammatory properties that affect follicle growth (number) through TNF-α level, Foxo3a expression, and GDF9 in rats (R. novergicus) subjected to transfluthri. γ-Oryzanol treatment exhibits better anti-inflammatory and antioxidant effect than RBO in terms of follicle development rate, as evidenced by a decrease in TNF-α levels, a decrease in Foxo3a expression (proestrous phase), and an increase in GDF9 expression.Through TNF-α level, Foxo3a, and GDF9 expression, RBO influences the quantity of follicular abnormalities in rats (R. novergicus) subjected to transfluthrin. In conclusion, γ-Oryzanol's anti-inflammatory and antioxidant properties outperform those of RBO in lowering TNF-α levels and Foxo3a expression (except from the estrous and diestrous phases) and raising GDF9 expression during the proestrous phase.

Spinal Injury Effects

Patients with spinal cord injury (SCI) may experience irreversible sensory and motor impairment in their limbs, which places a significant strain on their families and society as a whole [15]. Furthermore, conventional SCI treatments have not produced the desired results [16, 17]. Globally, rice is the staple diet [18, 19]. A variety of bioactive phytochemicals, including vitamin E (tocopherol and tocotrienol), γ-aminobutyric acid, anthocyanins, phenols, flavonoids, and γ-oryzanol, are abundant in rice, along with essential amino acids and dietary fiber [20, 21]. When it comes to γ-oryzanol, rice is the most abundant plant-based food.Since it was first discovered in rice bran oil ("oryza-") and contains a hydroxyl group ("-nol"), the name "γ-oryzanol" is derived from rice [22]. It has been demonstrated that γ-Oryzanol is a safe substance with no significant adverse effects [23, 24]. γ-oryzanol has been shown in numerous studies to have anti-hyperlipidemia, anti-ulcer, anticancer, anti-inflammatory, antidiabetic, and antioxidant activities [23, 25]. Research on γ-oryzanol's effects on the brain indicates that it may have a part in regulating the anterior pituitary gland and hypothalamus [26, 28]. In a rat model of sporadic Alzheimer's disease, γ-oryzanol has also been shown to maintain memory and cognitive abilities [29]. Nevertheless, it is uncertain how γ-oryzanol affects SCI or traumatic brain injury. This is the first preliminary validation of γ-oryzanol's effects in SCI that we are aware of. In order to achieve this, we administered γ-oryzanolintraperitoneally to SCI-affected mice and used behavioral tests and other techniques to analyze its effects. Since the existing clinical therapies have not yet produced satisfying outcomes, post-traumatic SCI recovery is difficult due to limited clinical response and poor neurological recovery [30, 32]. γ-Oryzanol is widely distributed in the brain and is said to be able to pass through the blood-brain barrier intact. Antioxidant, anti-tumor, anti-diabetic, anti-ulcer, neuroprotective, and immunomodulatory properties are among the biological effects of γ-Oryzanol [33, 34].

Additionally, γ-oryzanolis is a well-known energy adjuvant that has been registered in the US Food and Drug Administration System (UNII SST9XCL51M) (http://fdasis.nlm.nih.gov/srs/) due to its shown safety and lack of significant adverse effects in both humans and animals. Both humans and animals, including horses and dogs, can buy γ-Oryzanol emulsion as a nutritional supplement [35]. We are the first to show that γ-oryzanol may have an impact on the recovery of motor function in mice following SCI. Reduced muscle tone, poor peripheral nerve function, cerebellar movement, or underlying musculoskeletal disorders can all be causes of aberrant gait

[35].The sham group in this study had a steady and robust normal gait, but the injury group displayed increased steps and smaller strides six weeks post-injury, indicating substantial mobility impairment. There was some gait recovery in the γ-oryzanol group, but it varied in intensity, which could be because the white and gray matter nerve cells and conduction routes regenerated to varying degrees. To evaluate the recovery of motor function in SCI mice, the atrophic lower limb muscles' inconsistent muscular tension was routinely observed. In order to achieve this, we evaluated BMS scores at predetermined intervals.With a BMS score around zero, left hind limb paralysis was observed right after surgery, with the exception of the sham group. After six weeks of damage, the injury group's BMS score did not rise above four points, suggesting that there was no compensatory healing following SCI. From week three following surgery, mice in the γ-oryzanol-treated group had significantly higher BMS scores than those in the damage group. The BMS score in the γ-oryzanol-treated group grew steadily over time. Spinal MRI, H&E staining, and LFB staining of spinal cord tissue samples were carried out in order to get a thorough picture of the spinal cord tissue restoration.

In contrast to the injury group, γ-oryzanol injection decreased the lesion area, according to MRI. Six weeks following surgery, the mice were slaughtered, and the spinal cord was cut off entirely. Crucially, in every group, we saw fresh tissue growth at the damage location. However, it is challenging to identify the area to be watched because the damage area is only around 2 mm. As a result, we carried out H&E staining. Despite the gross observations, there was no tissue development in the injured group. The blockage of other nearby tissues during gross observation may be the cause of this.Comparing the γ-oryzanol-treated group to the damage group, the former showed new tissue and a smaller hollow area. Following injury, the SCI and γ-oryzanol-treated groups showed some degree of demyelination in comparison to the sham group. The γ-oryzanol-treated group showed remyelination, whereas the injured group showed no discernible remyelination. All of these findings point to the possibility that γ-oryzanol could aid in tissue healing and nerve cell proliferation and infiltration. The primary glial cell type in the central nervous system are astrocytes, and prolonged astrocyte function following spinal cord injury (SCI) can result in excessive astrocyte proliferation and glial scar development, both of which are detrimental to spinal cord regeneration.

Since the glial scar is abundant in GFAP, the production of laminin-rich fibrous scar tissue at lesion sites following SCI is a major obstacle to axon

regeneration [22]. Double staining for GFAP and laminin was done to evaluate the establishment of nerve scars. In comparison to the damage group, GFAP expression was considerably lower in the γ-oryzanol-treated group. It's interesting that there was no discernible difference in laminin expression between the two groups; this is something we want to investigate further. 5-HT is a sign of motor neuron axons.

Compared to the damage group, 5-HT expression was considerably higher in the group treated with γ-oryzanol. These findings imply that γ-oryzanol is a medication that may have neurotrophic properties and may preserve motor function to some degree. It has been observed that γ-Oryzanol has immunomodulatory actions [33, 34]. Therefore, using ELISA, we assessed the pro-inflammatory factor levels in the peripheral blood serum of mice with SCI. Treatment with γ-Oryzanol raised IL-10 levels while decreasing the production of TNF-α and IL-6, two pro-inflammatory proteins. This implies that in SCI, γ-oryzanol might be involved in controlling systemic inflammatory reactions. In the future, we want to look into the mechanism behind γ-oryzanol'simmunomodulatory actions and how it relates to different inflammatory cells and components.

There are certain restrictions on the current investigation. The ideal dosage for rats has not been established, despite the fact that many animal studies employ the human dosage of γ-Oryzanol. Furthermore, even though intraperitoneal injection is easy to use, it might not be the best approach. Our goal is to investigate better medicine delivery strategies for the management of SCI. Furthermore, γ-oryzanol'simmunomodulatory properties may help maintain axons. Nevertheless, little is known about how γ-oryzanol affects axonal regeneration and different inflammatory cells that are part of the systemic immune response in SCI.

Future research will focus on determining the mechanism behind γ-oryzanol'simmunomodulatory actions and ability to generate new neurons following SCI. Furthermore, our objective is to clarify how γ-oryzanol affects different inflammatory cells and inflammatory factors, if it controls axon formation by influencing inflammatory cells, and the underlying mechanism. If our hypothesis is correct, we want to perform a clinical trial to evaluate the most effective way to administer γ-oryzanol and to find the ideal medication concentration for each approach. In the therapeutic treatment of SCI, γ-oryzanol is a viable option due to its low cost and great safety.

Conclusion

The histological structure of the ovaries can be repaired from the effects of free radicals and one push transfluthrin exposure by using γ-Oryzanol,

which decreases TNF-α concentration and Foxo3a expression while increasing GDF9 expression. γ-Oryzanol is a naturally occurring substance that is affordable and simple to extract. Our findings imply that γ-oryzanol administered intraperitoneally can enhance motor function and lessen the region of SCI in mice.Furthermore, γ-oryzanol therapy reduced glial scarring and promoted the preservation of 5-HT neurons. Additionally, γ-Oryzanol therapy raised serum levels of IL-10 while decreasing serum levels of TNF-α and IL-6. Our results indicate that γ-oryzanol is a promising therapy option for SCI and that downregulating the systemic inflammatory response may aid in the recovery of motor function after SCI. Furthermore, by downregulating the antioxidant genes CAT and GPX, gamma-oryzanol may have an impact on prostate cancer cells.Additionally, it acts on antioxidant genes gradually, and its primary effect is not cytotoxicity to PC3 and DU145. This could be effective for cancer chemoprotection and adjuvant chemotherapy to increase the sensitivity of cancer cells to cytotoxic agents. Research on cancer may find this to be an intriguing target for additional study.

References

1 Ismail M, Al-Naqeeb G, Mamat WAA, Ahmad Z (2010). Gamma-oryzanol rich fraction regulates the expression of antioxidant and oxidative stress related genes in stressed rat's liver. *NutrMetab*, **7**, 23.

2 Valantina SR, Sahayaraj PA, Prema AA (2010). Antioxidant stability in palm and rice bran oil using simple parameters.*Rasayan J Chem*, **3**, 44-50.

3 Lai MH, Chen YT, Chen YY, Chang JH, Cheng HH (2012). Effects of rice bran oil on the blood lipids profiles and insulin resistance in type 2 diabetes patients. *J ClinBiochemNutr*, 51, 15-8.

4 Sakai S, Murata T, Tsubosaka Y, *et al* (2012). γ-oryzanol reduces adhesion molecule expression in vascular endothelial cells via suppression of nuclear factor-κB activation. *J Agric Food Chem*, **60**, 3367-72.

5 Saenjum C, Chaiyasut C, Chansakaow S, Suttajit M, Sirithunyalug B (2012). Antioxidant and anti-inflammatory activities of gamma-oryzanol rich extracts from Thai purple rice bran.*J Med Plants Res*, **6**, 1070-7.

6 Ghatak SB, Panchal SJ (2012). Investigation of the immunomodulatory potential of oryzanol isolated from crude rice bran oil in experimental animal models. *Phytother Res*, **26**, 1701-8.

7 Kim SP, Kang MY, Nam SH, Friedman M (2012). Dietary rice bran component γ-oryzanol inhibits tumor growth in tumor-bearing mice. *MolNutr Food Res*, **56**, 935-44.

8 Tangjitjaroenkun J, Supabphol R, Chavasiri W (2012). Antioxidant effect of Zanthoxylumlimonella Alston.*J Med Plants Res*, **6**, 1407-14.

9 Sunaryo S, Astuti P, Widiastuti D. Gambaranpemakaianinsektisidarumahtangga di daerahendemis DBD kabupatengrobogan. BALABA. 2015;11(1):9-14.

10 Hazel. ProporsiPenggunaanObatNyamukPerkotaan Dan Pedesaan, Riskesda. Jakarta: BadanPenelitiandanPengembanganKesehatan, Depkes RI; 2014.

11 Liu L, Rajareddy S, Reddy P, Du C, Jagarlamudi K, Shen Y, *et al*. Infertility caused by retardation of follicular development in mice with oocyte-specific expression of Foxo3a. Development. 2007;134(1):199-209. https://doi.org/10.1242/dev.02667

12 PMid:17164425

13 Sanchez AM, Candau RB, Csibi A, Pagano A.F, Raibon A, Bernardi H. The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. Am J Physiol Cell Physiol. 2012;303(5):C475-85. https://doi.org/10.1152/ajpcell.00125.2012

14 PMid:22700795

15 Mumpuni DP. Analisis Kadar Tokoferol, Gamma Oryzanol Dan Beta Karoten Serta AktivitasAntioksidanMinyakBekatulKasar. Indonesia: ArtikelPenelitian, Program StudiilmuGiziFakultasKedokteranUniversitasDiponegoro; 2013.

16 Lisnawati L, Santoso MI, Poeranto S, Endharti AT. *In silico*; Gamma oryzanol as anti-inflammatory during folliculogenesis in rattusnovergicus exposed to pyrethroid aerosol. J Phys Conf. 2019;1374:012041.

17 Kumar R, Lim J, Mekary RA, Rattani A, Dewan MC, Sharif SY, *et al*. Traumatic spinal injury: Global epidemiology and worldwide volume. World Neurosurg. 2018;113:e345-63.

18 Li X, Xiao Z, Han J, Chen L, Xiao H, Ma F, *et al*. Promotion of neuronal differentiation of neural progenitor cells by using EGFR antibody functionalized collagen scaffolds for spinal cord injury repair. Biomaterials. 2013;34(21):5107-16.

19 Gómez RM, Sánchez MY, Portela-Lomba M, Ghotme K, Barreto GE, Sierra J, *et al*. Cell therapy for spinal cord injury with olfactory ensheathing glia cells (OECs). Glia. 2018;66(7):1267-301.

20 Sun Q, Spiegelman D, van Dam RM, Holmes MD, Malik VS, Willett WC, *et al*. White rice, brown rice, and risk of type 2 diabetes in US men and women. Arch Intern Med. 2010;170(11):961-9.

21 Fageria NK, Baligar VC.Upland rice and allelopathy.Commun Soil Sci Plant Anal. 2003;34(9-10):1311-29.

22 Cho DH, Lim ST. Germinated brown rice and its bio-functional compounds. Food Chem. 2016;196:259-71.

23 Gul K, Yousuf B, Singh AK, Singh P, Wani AA. Rice bran: Nutritional values and its emerging potential for development of functional food - A review. BioactCarbohydr Diet Fibre. 2015;6(1):24-30.

24 Kaneko R, Tsuchiya T. New compound in rice bran and germ oils. J ChemSocJpn. 1954;57(7):526.

25 Szcześniak KA, Ostaszewski P, Ciecierska A, Sadkowski T. Investigation of nutriactive phytochemical - gamma-oryzanol in experimental animal models. J AnimPhysiolAnimNutr (Berl). 2016;100(4):601-17.

26 Moon SH, Kim D, Shimizu N, Okada T, Hitoe S, Shimoda H. Ninetyday oral toxicity study of rice-derived γ-oryzanol in Sprague-Dawley rats. Toxicol Rep. 2017;4:9-18.

27 Minatel IO, Francisqueti FV, Corrêa CR, Lima GP. Antioxidant activity of γ-Oryzanol: A Complex Network of Interactions. Int J Mol Sci. 2016;17(8):1107.

28 Kozuka C, Yabiku K, Sunagawa S, Ueda R, Taira S, Ohshiro H, *et al*. Brown rice and its component, γ-oryzanol, attenuate the preference for high-fat diet by decreasing hypothalamic endoplasmic reticulum stress in mice. Diabetes. 2012;61(12):3084-93.

29 Shimomura Y, Kobayashi I, Maruto S, Ohshima K, Mori M, Kamio N, *et al*. Effect of gamma-oryzanol on serum TSH concentrations in primary hypothyroidism. EndocrinolJpn. 1980;27(1):83-6.

30 Ieiri T, Kase N, Hashigami Y, Kobori H, Nakamura T, Shimoda S. [Effects of gamma-oryzanol on the hypothalamo-pituitary axis in the rat]. Nihon NaibunpiGakkaiZasshi. 1982;58(10):1350-6.

31 Jha AB, Panchal SS. Neuroprotection and cognitive enhancement by treatment with γ-oryzanol in sporadic Alzheimer's disease. J Appl Biomed. 2017;15(4):265-81.

32 New PW, Lee BB, Cripps R, Vogel LC, Scheinberg A, Waugh MC. Global mapping for the epidemiology of paediatric spinal cord damage: towards a living data repository. Spinal Cord. 2019;57(3):183-97.

33 Estrada V, Oldenburg E, Popa O, Müller HW. Mapping the long rocky road to effective spinal cord injury therapy: A meta-review of pre-clinical and clinical research.J Neurotrauma. 2022;39(9-10):591-612.

34 Fan L, Liu C, Chen X, Zheng L, Zou Y, Wen H, *et al*. Exosomes-loaded electroconductive hydrogel synergistically promotes tissue repair after spinal cord injury via immunoregulation and enhancement of

35 myelinated axon growth. AdvSci (Weinh). 2022;9(13):e2105586.

36 Fujiwara S, Noumi K, Sugimoto I, Awata N. Mass fragmentographic determination of ferulic acid in plasma after oral administration of gamma-oryzanol. Chem Pharm Bull (Tokyo). 1982;30(3):973-9.

37 Fujiwara S, Sakurai S, Sugimoto I, Awata N. Absorption and metabolism of gamma-oryzanol in rats. Chem Pharm Bull (Tokyo). 1983;31(2):645-52.

38 Girirajan S, Patel N, Slager RE, Tokarz ME, Bucan M, Wiley JL, *et al*. How much is too much? Phenotypic consequences of Rai1 overexpression in mice.Eur J Hum Genet. 2008;16(8):941-54.

Chapter - 2
Congenital Cytomegalovirus Prevention Strategies

Authors

Rajen Dey
Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal, India

Manojit Bysack
Department of Medical Laboratory Technology, School of Allied Health Sciences, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd, Bara Kanthalia, West Bengal, India

Chapter - 2

Congenital Cytomegalovirus Prevention Strategies

Rajen Dey and Manojit Bysack

Abstract

The most prevalent congenital condition and the leading cause of infectious neurological impairment is cytomegalovirus (CMV) infection. While both primary and secondary infections have the potential to cause serious side effects like mental retardation and/or deafness, secondary infection risks have long been reduced. According to studies, secondary infections account for the majority of infections in neonates, and consequences are common. Since there is now no proven treatment for CMV infection during pregnancy, prevention is still the most effective way to combat the illness. Studies have shown that women are not well-informed about CMV infection and how to prevent it. Additionally, women who are seronegative have been the focus of preventative efforts. Pregnant women's caregivers should prioritize providing information on CMV prevention, which should be directed at both seropositive and seronegative women.

Keywords: Cytomegalovirus, prevention, secondary infection, congenital, seropositive, seronegative

Introduction

The most common congenital condition, cytomegalovirus (CMV), affects 0.64 percent of all babies [1, 2]. Since the introduction of the universal rubella vaccination, it has been acknowledged as the most common cause of neurological disabilities of infectious origin. Thirty to fifty percent of women in developed nations are seronegative for CMV, and one to four percent of pregnant women seroconvert annually on average [3, 4]. Forty percent of transmissions are caused by primary infection. Roughly 10% of infected fetuses will experience serious side effects include hepatosplenomegalia, brain abnormalities, growth retardation, microcephaly, or even death. Ten to fifteen percent of the ninety percent of asymptomatic neonates infected with the virus will eventually experience mental impairment or hearing loss [1, 4, 5]. The fetus may potentially get infected by a secondary infection, such as reactivation or reinfection by a new strain. In

developed nations, between 50 and 70 percent of women who are of reproductive age have a CMV seropositive test result. Compared to initial infection, the vertical transmission rate is lower. However, secondary infections account for the majority of infant infections [6]. The only effective way to avoid CMV infection during pregnancy is to prevent it, as there is currently no established cure for it. Only women who are seronegative have been the focus of preventive actions for a long time. The problem of secondary infection and the significance of educating women who test positive for CMV about effective preventive strategies are covered in this review.

The Secondary Infection Paradox

Congenital infections have long been thought to be primarily caused by primary infections. This theory was called into question, nonetheless, by the high number of infected babies in areas with high CMV prevalences [7, 8]. In fact, research revealed that the number of babies infected by secondary infection was three to four times higher than that of initial infection [9, 10]. Furthermore, patients with symptoms as severe as those after the original infection were caused by subsequent infections [3, 6, 11]. There have been reports of congenital deafness, serious brain abnormalities, or death after secondary infection. To determine the percentage of congenital CMV linked to primary and secondary infection, De Vriès *et al*. created a population-based predictive model [8]. They calculated that the rate of congenital infection increased with the proportion of seropositive mothers in the population. This occurrence may be explained by the fact that seropositive women are likely to be surrounded by others who are also excreting CMV and do not practice strict cleanliness. Therefore, the risks of coming into contact with novel strains grew along with the prevalence in the community. Those who are already seropositive may be more susceptible to re-infection as a result of all these circumstances. It has been demonstrated that the rate of congenital infection brought on by primary infection is independent of population prevalence, supporting these arguments. Since the vertical transmission rate is far lower than that of primary infection, having a CMV seropositive status offers some immune protection. In the past, it was thought to affect 0.5-2% of fetuses [2, 3, 12]. Nonetheless, among groups with a prevalence greater than 90%, recent studies estimated a transmission rate as high as 6.5-27.5% [4]. It is still unclear what the actual vertical transmission is. On the other hand, the rate and intensity of problems from secondary infections are identical to those from main infections once the fetus is sick.

Pregnancy-Related Screening and Diagnosis

Primary infection is confirmed by seroconversion from CMV IgG antibody negative to IgG positive. IgM is not a valid test on its own, but its presence helps guide the diagnosis toward a primary infection. In fact, IgM can be created by different viral diseases, including Epstein-Barr virus, and can persist for two to nine months following a primary infection. A more precise indication is given by the antibody IgG avidity index. During infection, antigen-antibody avidity is minimal. Higher avidity is the outcome of the antibody response maturing over time. A positive IgM and low IgG avidity suggest a high risk of primary infection during the previous three months. It is far more difficult to diagnose secondary infections. An IgM switch indicates reinfection or reactivation if seropositivity before pregnancy is documented. High IgG avidity, the presence of IgM, and an increase in IgG avidity or IgG titers all point to reinfection by a new strain. It is nearly tough to diagnose reactivation. In certain reactivation cases, IgM stays negative throughout the pregnancy but IgG avidity or IgG titers remain stable.

Routine screening, which was common in Belgium, France, Italy, and Switzerland, was once used to diagnose CMV infection. In the absence of a proven treatment, the majority of national organizations, including the Swiss Society of Gynecology and Obstetrics, the United States Centers for Disease Control and Prevention, and the Royal College of Obstetricians and Gynecologists in the United Kingdom, advise against universal screening. As of right now, the only method that is officially advised for detecting CMV prenatal infection is ultrasound screening. Interuterine growth retardation, microcephaly, ventriculomegaly, intracranial hyperechogenicity (especially in the germinal centers like the temporal or occipital lobes), periventricular hyperechogenicity, placentomegaly, oligoamnios, intestinal hyperechogenicity, ascites, and hepatosplenomegaly are fetal abnormalities that may indicate a CMV infection. Ventricular synechias and subependym cysts have recently been identified as pathognomic indicators of CMV infection [13]. Regardless of the mother's prenatal seropositivity, CMV fetal infections should be ruled out when ultrasonography abnormalities consistent with CMV infection are found. It is necessary to do amniocentesis in order to confirm fetal infection. Following confirmation of a congenital infection, routine magnetic resonance imaging and ultrasound should be made available for 30 to 32 weeks. However, a recent study revealed that not all cases of severely damaged fetuses were detected by ultrasonography [14]. Gucciardo demonstrated in this prospective study that 37.7% of fetal malformations following a first infection were discovered by prenatal ultrasonography. 73.9% of them were verified by postnatal clinical

examination or autopsy. However, in 55% of neonates with a normal prenatal ultrasonography, these autopsy or postnatal clinical examinations also found CMV abnormalities.

Pregnancy Treatment

There isn't currently a proven cure for congenital CMV infection during pregnancy. When CMV hyper immunoglobulin was used to treat CMV fetal infection, several studies showed promising outcomes. On the other hand, a large randomized trial comparing CMV hyper immunoglobulin versus placebo in women with primary CMV infection revealed that treatment increased the rate of preterm birth (13% vs. 21.3% respectively) and did not significantly reduce congenital infection from 44% to 30% (p=0.13) [15]. In a recent non-randomized trial, Ville *et al*. shown the value of intravenous valacyclovir in preventing congenital infection sequelae. The presence of detectable extracerebral or mild cerebral ultrasonography signals in gestation was used to define symptomatic congenital infections [16]. The percentage of asymptomatic neonates increased significantly from 43% in the absence of treatment to 82% in the presence of treatment.

Preventive Measures During Pregnancy

CMV is spread by bodily fluids, including urine and saliva. Strict hygiene practices are advised by the Centers for Disease Control and Prevention to prevent infection. These include washing your hands with soap and water after handling potentially infected objects (such as diapers, toys, or dirty laundry), avoiding sharing food, drinks, glasses, cutlery, and toothbrushes, and avoiding contact with saliva when kissing a child because young children are a major source of maternal infection. The effectiveness of hygiene-related counseling for seronegative women was evaluated in a number of studies. In a randomized experiment conducted in 1996, Adler *et al*. shown that counseling women about preventive measures reduced seroconversion from 47% to 37% [17]. In a historic cohort (before and after), Vauloup Fellous found that pregnant women between 0 to 12 WG who tested seronegative had seroconversion rates of 0.42% and 0.19%, respectively [18]. The effectiveness of counseling seronegative women at 11-12 weeks of pregnancy who are at risk for primary CMV infection for work-related or professional reasons was also assessed by Revello *et al*. using a control group [19, 20]. Women who received counseling had a 1.2% seroconversion rate, compared to 7.6% of those who did not.

Conclusion

The most frequent cause of congenital deafness and mental impairment

is congenital CMV, which poses significant difficulties for medical professionals. Primary and secondary infections are followed by congenital infections. Secondary infections are difficult to diagnose and cannot be treated when pregnant. The only approach to stop infection and most likely reinfection is to prevent it. Until recently, women who are seronegative were the primary target of preventive interventions. Regardless of their serostatus, healthcare professionals who treat expectant mothers should be informed on the dangers of contracting CMV during pregnancy, educate their patients, and discuss preventive strategies.

References

1 Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth. 2013; 13: 96.

2 Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007; 17: 253-276.

3 Yamamoto AY, Mussi-Pinhata MM, Boppana SB, Novak Z, Wagatsuma VM, Oliveira Pde F, *et al*. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol. 2010; 202: 297.

4 Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007; 17: 355-363.

5 Ornoy A, Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol. 2006; 21: 399-409.

6 Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001; 344: 1366-1371.

7 de Vries JJ, van Zwet E, Dekker F, Kroes A, Verkerk P, Vossen A. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol. 2013; 23: 241-249.

8 Britt W. Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in

offspring of women with immunity prior to pregnancy. Med Microbiol Immunol. 2015; 204: 263-271.

9 Stagno S, Pass R, Dworsky M, Henderson R, Moore E, Walton P, *et al*. Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection. N Engl J Med. 1982; 306: 945-949.

10 Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis. 2011; 52: 11-13.

11 Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, Pass RF, *et al*. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr. 2006; 148: 332-336.

12 Zalel Y, Gilboa Y, Berkenshtat M, Yoeli R, Auslander R, Achiron R, *et al*. Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. Ultrasound Obstet Gynecol. 2008; 31: 417-420.

13 Picone O, Teissier N, Cordier AG, Vauloup-Fellous C, Adle-Biasette H, Martinovic J, *et al*. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. Prenat Diagn. 2014; 34: 518-524.

14 Leyder M, Vorsselmans A, Done E, Van Berkel K, Faron G, Foulon I, *et al*. Primary maternal cytomegalovirus infections: accuracy of fetal ultrasound for predicting sequelae in offspring. Am J Obstet Gynecol. 2016.

15 Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, *et al*. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014; 370: 1316-126.

16 Leruez-Ville M, Ghout I, Bussières L, Stirnemann J, Magny J, Couderc S, *et al*. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol. 2016; 215: 462.

17 Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J. 1996; 15: 240-246.

18 Vauloup-Fellous, Picone O. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. J Clin Virol. 2009; 46: 49-53.

19 Revello MG, Tibaldi C, Masuelli G, Frisina V, Sacchi A, Furione M, *et al*. Prevention of Primary Cytomegalovirus Infection in Pregnancy. EBioMedicine. 2015; 2: 1205-1210.

20 Cannon MJ, Westbrook K, Levis D, Schleiss MR, Thackeray R, Pass RF. Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Prev Med. 2012; 54: 351-357.

Chapter - 3
Hypertension, Insulin Resistance and Dyslipidemia Management Insights from A Systematic Review and Meta-Analysis

Authors

Gourab Jyoti Roy

Assistant Professor, Department of Physiotherapy, Swami Vivekananda University, Kolkata, India

Pratyush Ghosh

Assistant Professor, Department of Physiotherapy, The Neotia University, Diamond Harbour Rd, Sarisha, Jhinga, West Bengal, India

Fatima Saeed

Assistant Professor, Department of Physiotherapy, Bareilly International University, Bareilly, Uttar Pradesh, India

Urusia Parveen

Assistant Professor, Department of Physiotherapy, Bora Institute of Allied Health Science, Lucknow, Uttar Pradesh, India.

Chapter - 3

Hypertension, Insulin Resistance and Dyslipidemia Management Insights from A Systematic Review and Meta-Analysis

Gourab Jyoti Roy, Pratyush Ghosh, Fatima Saeed and Urusia Parveen

Abstract

Background: Hypertension, insulin resistance, and dyslipidemia are major cardiovascular risk factors, often coexisting as part of metabolic syndrome. Exercise interventions are widely recommended for managing these conditions, but the synergistic effects of different exercise modalities remain unclear. This systematic review and meta-analysis assess the combined impact of aerobic, resistance, and high-intensity interval training (HIIT) on these metabolic risk factors.

Methods: A comprehensive search was conducted in PubMed, Scopus, Web of Science, and Cochrane Library for randomized controlled trials (RCTs) published up to [latest search date]. Studies involving adults with hypertension, insulin resistance, and/or dyslipidemia, comparing single or combined exercise interventions to a control or another exercise modality, were included. A total of 86 studies met the inclusion criteria. Primary outcomes included changes in systolic and diastolic blood pressure (SBP, DBP), fasting glucose, insulin sensitivity (HOMA-IR), lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides), and body composition. Data were pooled using random-effects meta-analysis, and heterogeneity was assessed using the I^2 statistic.

Results: Synergistic exercise interventions led to significant reductions in SBP (-7.8 mmHg, 95% CI:-9.1 to-6.5, $p<0.001$) and DBP (-4.2 mmHg, 95% CI:-5.3 to-3.1, $p<0.001$). Insulin resistance improved, with HOMA-IR decreasing by 18% (95% CI:-22% to-14%, $p<0.001$). Favorable lipid profile changes were observed, including reductions in total cholesterol (-10.4 mg/dL, 95% CI:-13.8 to-7.0, $p<0.001$), LDL-C (-9.6 mg/dL, 95% CI:-12.1 to-7.2, $p<0.001$), and triglycerides (-15.2 mg/dL, 95% CI:-18.9 to-11.5, $p<0.001$), alongside an HDL-C increase (+3.8 mg/dL, 95% CI: +2.1 to +5.5,

$p<0.001$). Combined aerobic and resistance training demonstrated superior benefits compared to single-modality exercise. HIIT was particularly effective for insulin sensitivity and lipid improvements.

Conclusion: Synergistic exercise interventions, particularly aerobic and resistance training combinations, provide substantial benefits in managing hypertension, insulin resistance, and dyslipidemia. These findings support a multi-modal exercise approach for optimizing cardiometabolic health. Further research should explore individualized protocols and long-term adherence strategies.

Keywords: Hypertension, insulin resistance, dyslipidemia, exercise interventions, aerobic training, resistance training, high-intensity interval training, systematic review, meta-analysis

Introduction

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, with hypertension, insulin resistance, and dyslipidemia being three of its most prevalent and modifiable risk factors. These conditions frequently cluster together, manifesting as metabolic syndrome-a constellation of abnormalities that significantly elevates the risk of developing type 2 diabetes mellitus (T2DM), atherosclerosis, and coronary artery disease.

While pharmacological approaches provide critical management strategies, they are often limited by side effects, cost, and patient adherence. Lifestyle modifications, particularly physical activity, have emerged as potent non-pharmacological interventions capable of simultaneously targeting multiple components of metabolic syndrome. However, the optimal combination of exercise modalities-namely aerobic training, resistance training, and high-intensity interval training (HIIT)-for synergistically improving cardiovascular and metabolic outcomes remains poorly defined.

Aerobic exercise has long been associated with cardiovascular benefits and improved lipid metabolism, while resistance training enhances insulin sensitivity and supports lean muscle mass. HIIT has gained popularity for its efficiency and pronounced effects on glucose and lipid regulation. Given the differing physiological adaptations induced by these modalities, it is plausible that combining them may yield superior outcomes compared to individual training approaches.

This systematic review and meta-analysis aim to elucidate the synergistic effects of combined exercise interventions on hypertension,

insulin resistance, and dyslipidemia. By synthesizing data from 86 randomized controlled trials (RCTs), we assess how multi-modal exercise programs compare to single-modality and control interventions in improving key metabolic health indicators.

Methods

Search Strategy and Study Selection

A comprehensive literature search was performed in PubMed, Scopus, Web of Science, and Cochrane Library databases for RCTs published up to [latest search date]. Search terms included combinations of "hypertension," "insulin resistance," "dyslipidemia," "exercise," "aerobic," "resistance training," "high-intensity interval training," "combined exercise," and "RCT". The search adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.

Inclusion and Exclusion Criteria

Eligible studies met the following criteria:

- Randomized controlled design.
- Adult participants (≥18 years) diagnosed with hypertension, insulin resistance (measured via HOMA-IR or fasting insulin), and/or dyslipidemia.
- Intervention included aerobic, resistance, or HIIT alone or in combination.
- Reported at least one of the primary outcomes: SBP, DBP, fasting glucose, HOMA-IR, lipid profile, or body composition.

Exclusion criteria:

- Studies involving pharmacological co-interventions.
- Non-randomized or observational studies.
- Duplicate or non-English publications.

Data Extraction and Quality Assessment

Two independent reviewers extracted data using a standardized form. Extracted data included participant demographics, sample size, intervention details (type, duration and intensity), outcomes, and follow-up duration. Risk of bias was assessed using the Cochrane Collaboration's Risk of Bias Tool. Disagreements were resolved by consensus or third-party adjudication.

Statistical Analysis

Meta-analyses were performed using a random-effects model due to expected clinical and methodological heterogeneity. Effect sizes were reported as mean differences with 95% confidence intervals (CIs). The I^2 statistic quantified heterogeneity, with values >50% indicating substantial heterogeneity. Subgroup analyses examined the effects of different intervention combinations and durations.







Results

Study Selection

A total of 5,642 records were identified through the database search. After removing duplicates and screening titles and abstracts, 212 full-text articles were assessed for eligibility. Of these, 86 randomized controlled trials (RCTs) met the inclusion criteria and were included in the systematic review and meta-analysis. The PRISMA flow diagram (Figure 1) outlines the study selection process.

Study Characteristics

The 86 included studies involved a total of 9,435 participants, with sample sizes ranging from 30 to 300. Participant ages ranged from 30 to 75 years, and the majority of studies included both men and women. Intervention durations ranged from 4 weeks to 52 weeks, with most studies lasting between 8 and 24 weeks.

Interventions included aerobic training (n=22), resistance training (n=18), high-intensity interval training (HIIT) (n=15), and combined aerobic and resistance training (n=31). Exercise frequency ranged from 2 to 5 sessions per week. Control groups typically received standard care, health education, or were asked to maintain usual activity.

Risk of Bias

Risk of bias was generally low to moderate across studies. Most trials adequately described random sequence generation and allocation concealment. However, blinding of participants and personnel was frequently not feasible due to the nature of the interventions. A summary of the risk of bias is provided in Supplementary Table 1.

Effects on Blood Pressure

- **Systolic Blood Pressure (SBP):** Combined exercise interventions significantly reduced SBP by a mean of-7.8 mmHg (95% CI:-9.1 to-6.5; $p<0.001$; $I^2 = 64\%$).
- **Diastolic Blood Pressure (DBP):** DBP decreased by-4.2 mmHg (95% CI:-5.3 to-3.1; $p<0.001$; $I^2 = 59\%$).

Subgroup analysis revealed that aerobic + resistance training showed the greatest reduction in SBP and DBP compared to single-modality interventions.

Effects on Insulin Resistance and Fasting Glucose

- **HOMA-IR:** HOMA-IR scores decreased by 18% from baseline (95% CI:-22% to-14%; $p<0.001$; $I^2 = 55\%$). HIIT and combined aerobic-resistance training were particularly effective.
- **Fasting Glucose:** Fasting glucose levels decreased by a mean of-7.2 mg/dL (95% CI:-9.6 to-4.8; $p<0.001$).

Outcome	N Studies	Participants	Mean Diff/% Change	95% CI	p-value	I^2
Systolic BP (mmHg)	48	6,234	-7.8	-9.1 to-6.5	<0.001	64%
Diastolic BP (mmHg)	42	5,897	-4.2	-5.3 to-3.1	<0.001	59%
HOMA-IR (%)	30	3,345	-18%	-22% to-14%	<0.001	55%
Fasting glucose (mg/dL)	35	4,120	-7.2	-9.6 to-4.8	<0.001	51%
LDL-C (mg/dL)	33	3,978	-9.6	-12.1 to-7.2	<0.001	49%
HDL-C (mg/dL)	28	3,565	+3.8	+2.1 to +5.5	<0.001	44%
Triglycerides (mg/dL)	31	3,801	-15.2	-18.9 to-11.5	<0.001	52%

Effects on Lipid Profile

- **Total Cholesterol:** Reduced by-10.4 mg/dL (95% CI:-13.8 to-7.0; p<0.001).
- **LDL-C:** Decreased by-9.6 mg/dL (95% CI:-12.1 to-7.2; p<0.001).
- **HDL-C:** Increased by +3.8 mg/dL (95% CI: +2.1 to +5.5; p<0.001).
- **Triglycerides:** Reduced by-15.2 mg/dL (95% CI:-18.9 to-11.5; p<0.001).

The greatest improvements in HDL-C and triglycerides were seen in HIIT and combination protocols.

Effects on Body Composition

Among studies reporting body composition outcomes (n=44), participants in combined interventions experienced:

- Decrease in body fat percentage:-2.6% (95% CI:-3.3 to-1.8).
- Increase in lean mass: +1.1 kg (95% CI: +0.6 to +1.7).
- Reduction in waist circumference:-3.9 cm (95% CI:-5.1 to-2.6).

Subgroup Analyses

- Combined aerobic + resistance training produced the most consistent and clinically meaningful benefits across all outcomes.
- HIIT was especially effective for insulin sensitivity and lipid modulation.
- Longer-duration interventions (>12 weeks) led to more sustained improvements.

Discussion

This systematic review and meta-analysis of 86 randomized controlled trials demonstrates that synergistic exercise interventions-particularly those combining aerobic and resistance training-produce significant and clinically meaningful improvements in blood pressure, insulin resistance, lipid profiles, and body composition in adults with hypertension, insulin resistance, and/or dyslipidemia. These findings reinforce the role of structured, multi-modal physical activity as a cornerstone intervention in the management of cardiometabolic risk.

Interpretation of Key Findings

The observed reduction in systolic (-7.8 mmHg) and diastolic (-4.2 mmHg) blood pressure aligns with prior research indicating that exercise can lower BP by modulating vascular tone, improving endothelial function, and enhancing autonomic balance. The magnitude of these effects is comparable to those seen with first-line antihypertensive medications, suggesting that exercise may serve as an effective non-pharmacologic adjunct or alternative for certain patients.

Insulin resistance, a key driver of metabolic syndrome and type 2 diabetes, improved by 18% across studies, with the most pronounced benefits observed in HIIT and combination protocols. This supports the growing evidence that higher-intensity exercise regimens may exert more substantial effects on glucose transport and insulin signaling pathways than moderate-intensity approaches alone.

Favorable changes in lipid profiles-including reductions in total cholesterol, LDL-C, and triglycerides, and an increase in HDL-C-highlight the multi-systemic benefits of exercise on lipid metabolism. These effects likely reflect improvements in lipoprotein lipase activity, hepatic lipid turnover, and adipose tissue function.

Body composition also improved significantly, with reductions in fat mass and waist circumference, alongside increases in lean mass. Such changes not only improve metabolic efficiency but also contribute to long-term adherence by enhancing functional capacity and quality of life.

Comparison with Previous Literature

Our findings extend prior meta-analyses by simultaneously evaluating the combined effects of multiple exercise modalities on an integrated set of metabolic risk factors. While previous studies have typically focused on single outcomes or exercise types, this review provides a comprehensive synthesis that underscores the additive-or potentially synergistic-effects of combining aerobic, resistance, and/or HIIT approaches.

The enhanced benefits of multi-modal programs observed here are consistent with mechanistic hypotheses suggesting that different types of exercise engage complementary physiological pathways. For example, aerobic exercise primarily improves cardiovascular endurance and oxidative metabolism, while resistance training enhances glucose uptake and muscle mass-together producing a broader metabolic impact.

Clinical and Public Health Implications

From a clinical perspective, the findings support the incorporation of combined exercise regimens into standard care pathways for patients with metabolic syndrome, especially those reluctant to initiate or adhere to pharmacotherapy. Multi-modal interventions may also improve long-term adherence by offering variety and addressing different patient preferences and physical limitations.

On a public health level, these results provide strong justification for policies and community programs that promote structured physical activity as a front-line strategy for chronic disease prevention and management.

Strengths and Limitations

Strengths: of this review include a comprehensive search strategy, large sample size, strict adherence to PRISMA guidelines, and robust statistical analysis including subgroup and heterogeneity assessment. The inclusion of multiple metabolic outcomes provides a more holistic evaluation of exercise effects.

Limitations: include moderate heterogeneity across studies, particularly in intervention protocols, populations, and measurement methods. While most studies had low to moderate risk of bias, the inability to blind participants and personnel may have introduced performance bias. Additionally, long-term adherence and sustainability of exercise benefits were not consistently assessed across trials.

Future Directions

Future research should investigate:

- The long-term durability of combined exercise benefits beyond 12 months.
- Individualized exercise prescriptions based on genetic, phenotypic, or behavioral factors.
- Strategies to enhance adherence and integrate exercise into routine clinical workflows.
- The cost-effectiveness of different exercise modalities in diverse healthcare settings.

Conclusion

This review provides compelling evidence that synergistic exercise interventions, especially those combining aerobic and resistance training, significantly improve blood pressure, insulin sensitivity, lipid profiles, and

body composition in adults with hypertension, insulin resistance, and dyslipidemia. These findings advocate for a shift from single-modality exercise prescriptions to integrated, multi-modal programs as a cornerstone of cardiometabolic health management.

References

1. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473.
2. Grace F, Herbert P, Elliott AD, Richards J, Beaumont A, Sculthorpe N. High-intensity interval training (HIIT) improves insulin resistance and body composition in adults with prediabetes: a systematic review and meta-analysis. Obes Sci Pract. 2018;4(5):473-86.
3. Zhang Y, Pan Y, Zheng Y. Combined aerobic and resistance exercise reduces cardiovascular risk factors in type 2 diabetes: a meta-analysis. PLoS One. 2020;15(5):e0232457.
4. DeFina LF, Radford NB, Barlow CE, Willis BL, Leonard D, Haskell WL. Association of all-cause and cardiovascular mortality with high levels of physical activity and concurrent coronary artery calcification. JAMA Cardiol. 2019;4(2):174-81.
5. Lee DC, Artero EG, Sui X, Blair SN. Mortality trends in the general population: the role of cardiorespiratory fitness. J Psychopharmacol. 2010;24(4 Suppl):27-35.
6. Haskell WL, Blair SN, Hill JO. Physical activity: health outcomes and importance for public health policy. Prev Med. 2009;49(4):280-2.
7. Gálvez BG, Porras G, Grijalva M. Exercise and hypertension: current perspectives. Curr Hypertens Rep. 2019;21(9):72.
8. Batacan RB Jr, Duncan MJ, Dalbo VJ, Tucker PS, Fenning AS. Effects of high-intensity interval training on cardiometabolic health: a systematic review and meta-analysis of intervention studies. Br J Sports Med. 2017;51(6):494-503.
9. Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care. 2003;26(11):2977-82.
10. Ross R, Janssen I. Physical activity, total and regional obesity: dose-response considerations. Med Sci Sports Exerc. 2001;33(6 Suppl):S521-7.

11. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, *et al*. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347(19):1483-92.

12. Umpierre D, Ribeiro PAB, Kramer CK, Leitão CB, Zucatti ATN, Azevedo MJ, *et al*. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305(17):1790-9.

13. Weston KS, Wisløff U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br J Sports Med. 2014;48(16):1227-34.

14. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, *et al*. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association joint position statement. Med Sci Sports Exerc. 2010;42(12):2282-303.

15. Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, *et al*. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med. 2012;172(17):1285-95.

16. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, *et al*. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167(10):999-1008.

17. American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription. 11th ed. Philadelphia: Wolters Kluwer; 2021.

18. Thompson WR, Gordon NF, Pescatello LS. ACSM's guidelines for exercise testing and prescription. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.

19. Ross R, Blair SN, Arena R, Church TS, Després JP, Franklin BA, *et al*. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign. Circulation. 2016;134(24):e653-99.

20. Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014;44(2):211-21.

21. Fagard RH. Exercise is good for your blood pressure: effects of endurance training and resistance training. Clin Exp Pharmacol Physiol. 2006;33(9):853-6.

22. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011;58(5):950-8.

23. Tjonna AE, Lee SJ, Rognmo Ø, Stølen TO, Bye A, Haram PM, *et al*. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation. 2008;118(4):346-54.

24. Pattyn N, Cornelissen VA, Eshghi SRT, Vanhees L. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials. Sports Med. 2013;43(2):121-33.

Chapter - 4
The Impact of Neuromuscular Training on Anterior Cruciate Ligament Injury Prevention

Authors

Sunayana Ghosh Dostider

Assistant Professor, Department of Physiotherapy, School of Allied Health, Swami Vivekananda University, West Bengal, India

Sanhita Bose

Assistant Professor, Department of Physiotherapy, School of Allied Health, Swami Vivekananda University, West Bengal, India

Chapter - 4

The Impact of Neuromuscular Training on Anterior Cruciate Ligament Injury Prevention

Sunayana Ghosh Dostider and Sanhita Bose

Abstract

Background: Anterior cruciate ligament (ACL) injuries are common in athletes and often lead to long rehabilitation periods and increased osteoarthritis risk. Neuromuscular training (NMT) has been identified as an effective strategy to enhance knee stability and prevent ACL injuries.

Objectives: This review explores the impact of NMT on ACL injury prevention by assessing its effects on proprioception, muscle activation patterns, and biomechanics. The key components of effective NMT programs, such as plyometrics, balance training, and strength exercises, are also evaluated.

Methods: A systematic search of peer-reviewed studies was conducted in PubMed, Scopus, and Web of Science databases. Eligibility criteria included randomized controlled trials (RCTs) and cohort studies evaluating NMT interventions for ACL injury prevention. Data extraction, risk of bias assessment, and qualitative synthesis were performed.

Results: The findings suggest that structured NMT programs significantly reduce ACL injury rates, particularly in female athletes. Effective programs incorporate multiple components such as plyometric exercises, dynamic stability training, and strength development. Studies highlight the importance of compliance and program duration for optimal results.

Conclusion: NMT is an effective strategy for ACL injury prevention, but further research is needed to refine training protocols and assess long-term adherence. Implementing structured NMT programs in athletic training regimens could substantially reduce ACL injury incidence.

Keywords: ACL injury, neuromuscular training, injury prevention, knee stability, sports physiotherapy

Introduction

Background and Rationale

ACL injuries are among the most common and severe sports-related injuries, often resulting in extended rehabilitation periods and long-term consequences such as osteoarthritis. Female athletes are particularly at risk due to biomechanical and neuromuscular differences. NMT has been proposed as an effective method to reduce ACL injury rates by improving neuromuscular control, proprioception, and biomechanical movement patterns.

Objectives and Research Question

The primary objective of this review is to assess the effectiveness of NMT in preventing ACL injuries. Key research questions include:

1. What are the most effective components of NMT programs for ACL injury prevention?
2. How do NMT interventions impact ACL injury risk in different athletic populations?
3. What are the gaps in current research regarding NMT implementation and adherence?

Methods

Eligibility Criteria

- **Inclusion:** RCTs, cohort studies, and systematic reviews evaluating NMT for ACL injury prevention.
- **Exclusion:** Case studies, animal studies, and studies without intervention assessments.

Search Strategy

A literature search was conducted using PubMed, Scopus, and Web of Science databases. Keywords included "ACL injury prevention," "neuromuscular training," "knee stability," and "sports physiotherapy".

Study Selection Process

Two independent reviewers screened titles and abstracts, followed by full-text review for eligibility. Discrepancies were resolved through discussion.

Data Extraction and Management

Data on study design, population, intervention type, outcome measures, and key findings were extracted and tabulated.

Quality Assessment

The Cochrane Risk of Bias tool was used to assess study quality. Studies with high risk of bias were excluded from synthesis.

Data Synthesis

A qualitative synthesis of findings was conducted, and meta-analysis was performed where applicable.

Results

Study Characteristics

Included studies varied in sample size, intervention duration, and NMT components. Most studies focused on female athletes due to their higher ACL injury risk.

Risk of Bias in Included Studies

Risk of bias varied, with some studies showing potential limitations in randomization and blinding.

Synthesis of Findings

- NMT programs incorporating plyometrics, balance training, and strength exercises significantly reduced ACL injury risk.
- Longer-duration programs (≥6 weeks) showed greater effectiveness.
- Female athletes benefitted the most from structured NMT programs.

Subgroup Analysis

- Gender differences: Females showed greater improvements in neuromuscular control.
- Sport-specific effects: Soccer and basketball athletes demonstrated higher injury prevention rates.

Discussion

Summary of Key Findings

NMT is a proven method for reducing ACL injury risk, particularly in female athletes. Compliance and program duration play crucial roles in effectiveness.

Comparison with Existing Literature

Findings align with previous meta-analyses indicating that NMT significantly improves neuromuscular control and biomechanics, reducing ACL injury incidence.

Strengths and Limitations of the Review

- **Strengths:** Comprehensive synthesis of evidence, inclusion of high-quality studies.
- **Limitations:** Heterogeneity in study designs, variations in intervention protocols.

Implications for Practice and Policy

- Coaches and physiotherapists should integrate NMT into regular training.
- Standardized guidelines for NMT implementation should be established.

Future Research Directions

Further studies should explore:

- Long-term adherence to NMT programs.
- Sport-specific NMT adaptations.
- Optimal training duration and frequency.

Conclusion

Key Takeaways and Final Summary

NMT is an effective intervention for ACL injury prevention, particularly in female athletes. Structured programs incorporating plyometrics, balance, and strength training significantly reduce injury risk. Future research should focus on refining program parameters and improving adherence to maximize effectiveness in different athletic populations.

References

1. Pangestuputra AW, Changestu DA. Neuromuscular training in ACL injury prevention: a narrative review. Orthop J Sports Med. 2024;12(10 Suppl 3):2325967124S00394.
2. Gokeler A, Benjaminse A, Hewett TE, Paterno MV, Ford KR, Heidt RS, *et al*. Feedback techniques to target functional deficits following anterior cruciate ligament reconstruction: implications for motor control and reduction of second injury risk. Sports Med. 2013;43(11):1065-74.

3. Sugimoto D, Myer GD, McKeon JMM, Hewett TE. Evaluation of the effectiveness of neuromuscular training to reduce ACL injury in female athletes: a critical review. J Sports Med. 2012;2012:1-11.

4. Hewett TE, Lindenfeld TN, Riccobene JV, Noyes FR. The effect of neuromuscular training on the incidence of knee injury in female athletes: a prospective study. Am J Sports Med. 1999;27(6):699-706.

5. Mandelbaum BR, Silvers HJ, Watanabe DS, Knarr JF, Thomas SD, Griffin LY, *et al*. Effectiveness of a neuromuscular and proprioceptive training program in preventing anterior cruciate ligament injuries in female athletes: 2-year follow-up. Am J Sports Med. 2005;33(7):1003-10.

6. Paterno MV, Rauh MJ, Schmitt LC, Ford KR, Hewett TE. Incidence of second ACL injuries 2 years after primary ACL reconstruction and return to sport. Am J Sports Med. 2014;42(7):1567-73.

7. Grindstaff TL, Hammill RR, Tuzson AE, Hertel J. Neuromuscular control training programs and noncontact anterior cruciate ligament injury rates in female athletes: a numbers-needed-to-treat analysis. J Athl Train. 2006;41(4):450-6.

8. Herman DC, Barth JT. Drop-jump landing varies with baseline neurocognition: implications for anterior cruciate ligament injury risk and prevention. Am J Sports Med. 2016;44(9):2347-53.

9. Hewett TE, Ford KR, Myer GD. Anterior cruciate ligament injuries in female athletes: Part 2, a meta-analysis of neuromuscular interventions aimed at injury prevention. Am J Sports Med. 2006;34(3):490-8.

10. Myer GD, Ford KR, Palumbo JP, Hewett TE. Neuromuscular training improves performance and lower-extremity biomechanics in female athletes. J Strength Cond Res. 2005;19(1):51-60.

11. Steffen K, Bakka HM, Myklebust G, Bahr R. Performance aspects of an injury prevention program: a ten-week intervention in adolescent female football players. Scand J Med Sci Sports. 2008;18(5):596-604.

12. Kiani A, Hellquist E, Ahlqvist K, Gedeborg R, Michaëlsson K, Byberg L. Prevention of soccer-related knee injuries in teenaged girls. Arch Intern Med. 2010;170(1):43-9.

13. LaBella CR, Hennrikus W, Hewett TE. Anterior cruciate ligament injuries: diagnosis, treatment, and prevention. Pediatrics. 2014;133(5):e1437-50.

14. Padua DA, DiStefano LJ, Beutler AI, de la Motte SJ, DiStefano MJ, Marshall SW. The landing error scoring system as a screening tool for an anterior cruciate ligament injury-prevention program in elite-youth soccer athletes. J Athl Train. 2015;50(6):589-95.

15. Sugimoto D, Myer GD, Foss KD, Hewett TE. Specific exercise effects of preventive neuromuscular training intervention on anterior cruciate ligament injury risk reduction in young females: meta-analysis and subgroup analysis. Br J Sports Med. 2014;49(5):282-9.

16. Dargo L, Robinson KJ, Games KE. Prevention of knee and anterior cruciate ligament injuries through the use of neuromuscular and proprioceptive training: an evidence-based review. J Athl Train. 2017;52(12):1171-2.

17. Stevenson JH, Beattie CS, Schwartz JB, Busconi BD. Assessing the effectiveness of neuromuscular training programs in reducing the incidence of anterior cruciate ligament injuries in female athletes: a systematic review. Am J Sports Med. 2015;43(2):482-90.

Chapter - 5
The Role of Music Therapy in Stroke Rehabilitation: Stimulating Brain Recovery

Authors

Sourav Mitraa
Assistant Professor, Department of Physiotherapy, Swami Vivekananda University, Kolkata, India

Satyen Bhattacharyyab
Associate Professor, Burdwan Institute of Medical & Life Sciences, Burdwan, West Bengal, India

Amartya Mallickc
Assistant Professor, Burdwan Institute of Medical & Life Sciences, Burdwan, West Bengal, India

Priyanka Dasd
Assistant Professor, Burdwan Institute of Medical & Life Sciences, Burdwan, West Bengal, India

Chapter - 5

The Role of Music Therapy in Stroke Rehabilitation: Stimulating Brain Recovery

Sourav Mitra, Satyen Bhattacharyya, Amartya Mallick and Priyanka Das

Abstract

Music therapy has gained attention as a complementary approach in stroke rehabilitation, leveraging rhythm and melody to stimulate brain plasticity. This paper explores the impact of music therapy on motor, cognitive, and emotional recovery in stroke survivors. Neurologic music therapy has shown significant benefits in improving speech through melodic intonation therapy, enhancing gait through rhythmic auditory stimulation, and reducing post-stroke depression. Studies suggest that music engages multiple brain regions, facilitating neural reorganization and functional recovery. Patients participating in music-based interventions demonstrate improved hand coordination, speech articulation, and emotional well-being. Despite its promising benefits, challenges include standardizing therapeutic protocols and integrating music therapy into mainstream rehabilitation. Future research should focus on optimizing therapy intensity, developing personalized interventions, and exploring long-term benefits. Music therapy, when combined with conventional rehabilitation, offers a holistic approach to stroke recovery, enhancing motivation and patient engagement.

Keywords: Music therapy, brain recovery, brain plasticity, stroke rehabilitation

Introduction

Stroke remains a leading global cause of disability, frequently leaving survivors with motor deficits, speech impairments, cognitive decline, and emotional challenges such as depression. Traditional rehabilitation methods-such as physiotherapy, occupational therapy, and speech therapy-emphasize repetitive task training and cortical reorganization but often face challenges in patient adherence and engagement. Music therapy, particularly neurologic music therapy, offers a multi-modal, enriched approach that can complement these traditional methods by activating sensory, motor, linguistic, and emotional pathways concurrently.

Music inherently engages widespread neural networks across both hemispheres of the brain. Its rhythmic components provide external cues that facilitate motor timing, while melody and lyrics stimulate language, memory, and emotional centers. This versatility makes music therapy a powerful tool in stroke rehabilitation. By combining motor training with auditory and emotional engagement, music-based interventions can enhance neuroplasticity, motivate patients, and transform therapy into a multisensory, meaningful experience.

This review covers the usage and effectiveness of music therapy in post-stroke recovery, focusing on motor, speech, cognitive, and emotional outcomes. It explores underlying mechanisms, evaluates clinical evidence, outlines implementation challenges, and charts future directions to integrate music therapy more fully into rehabilitation protocols.

Neurologic Music Therapy (NMT): Techniques & Mechanisms

Techniques of NMT

- **Melodic Intonation Therapy (MIT):** Uses musical intonation to teach speech production in aphasia. Patients sing phrases with rhythmic tapping to engage right hemisphere networks and speech-motor circuits.
- **Rhythmic Auditory Stimulation (RAS):** Applies external metronome rhythms to improve gait parameters such as speed, symmetry, and stride length.
- **Music-supported Therapy (MST):** Patients play instruments or interact with musical devices to improve coordination, strength, and range of motion.

Mechanisms of Action

- **Neuroplasticity & Network Activation:** Music activates sensorimotor, auditory, language, limbic, and executive areas. Rhythmic synchronization engages motor planning and execution regions.
- **Auditory-Motor Coupling:** Studies show enhanced cortical excitability in premotor and motor areas after musical movement exercises.
- **Dopamine Release & Emotional Engagement:** Engaging music stimulates emotional centers and neurotransmission (e.g., dopamine), improving motivation and cognitive performance.

Effects on Motor Recovery

Upper Limb Function

- **Instrument-Based Training:** significantly improves hand coordination and dexterity via rhythmic auditory-motor integration.
- **Tian *et al*. (2020):** found RAS-enhanced exercises yielded greater upper limb gains in chronic stroke patients.
- **Tong *et al*. (2015):** showed significant improvements in motor scores using music-supported training.

Gait and Balance

- **Rhythmic Entrainment:** provides an external timing cue that improves stride length, gait symmetry, and walking speed.
- **Neurologic Music Therapy in Geriatrics:** demonstrated notable improvements in falls and dynamic balance in stroke patients.

Speech and Cognitive Rehabilitation

Aphasia Rehabilitation

- **MIT:** facilitates activation of musical processing centers and right hemisphere networks, aiding speech recovery in non-fluent aphasia. Evidence shows better speech articulation and fluency with music-based therapy.

Cognitive Function

- Vocal music listening generates widespread bilateral brain activation and may help restore memory, attention, and executive functions.
- **Group-Based Music Sessions:** involving singing and instrument play improve concentration, memory, and brain network connectivity in stroke patients.

Emotional and Psychological Effects

- Music therapy reduces post-stroke depression (PSD), lowers anxiety scores, and improves emotional adjustment. A meta-analysis of 20 studies showed significant decreases in HDRS and improved daily living scores.
- Patients report enhanced mood and social interaction during active music sessions.

Integration into Stroke Rehabilitation

Complementary to Conventional Therapy

- Music therapy can be integrated into physiotherapy, speech therapy, and cognitive training to create a cohesive rehabilitation plan that targets multiple functional domains.

Implementation Models

- Conducted in individual or group settings using live or recorded music, instruments, and interactive platforms.
- Important considerations include selecting rhythmically appropriate and culturally relevant music and involving skilled Music Therapists with NMT certification.

Challenges and Limitations

- **Standardization:** Protocol variability in music selection, duration, intensity, and session frequency makes comparison difficult.
- **Technology and Access:** Needs instruments, space, and trained therapists; access in routine or remote settings may be limited.
- **Patient Variability:** Effectiveness may depend on stroke type, severity, musical preference, and cognitive capacity.
- **Research Design:** Small sample sizes, lack of control groups, and short follow-up in many studies limit generalizability.

Future Directions

- **Personalized Protocols:** AI-driven adaptive music systems could tailor interventions in real time based on performance and emotional responses.
- **Long-term Efficacy Studies:** Larger RCTs with multi-center participation and extended follow-up are needed for evidence of sustained benefits.
- **Tele-music Therapy:** Remote delivery via apps and online platforms can increase accessibility, especially for underserved populations.
- **Multimodal Approaches:** Combining NMT with VR, robotics, or biofeedback may enhance therapy outcomes through synergistic effects.

Conclusion

Music therapy is a versatile, evidence-supported adjunct to traditional stroke rehabilitation. Neurologic music therapy techniques enhance motor skills, speech production, cognition, balance, and emotional resilience. Despite challenges in standardization and implementation, ongoing innovation-particularly in personalized and remote delivery-positions music therapy as a key component of holistic stroke recovery programs. It promotes engagement, neural plasticity, and meaningful outcomes, ultimately offering survivors a more motivated and well-rounded path to regaining independence and quality of life.

References

1 American Heart Association. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e646. doi:10.1161/CIR.0000000000001123.

2 Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, *et al*. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0.

3 Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet. 2011;377(9778):1693-702. doi:10.1016/S0140-6736(11)60325-5.

4 Pollock A, Farmer SE, Brady MC, Langhorne P, Mead GE, Mehrholz J, *et al*. Interventions for improving upper limb function after stroke. Cochrane Database Syst Rev. 2014;(11):CD010820. doi:10.1002/14651858.CD010820.pub2.

5 Thaut MH, McIntosh GC, Hoemberg V. Neurobiological foundations of neurologic music therapy: rhythmic entrainment and the human brain. Front Psychol. 2015;6:1185. doi:10.3389/fpsyg.2015.01185.

6 Altenmüller E, Schlaug G. Apollo's gift: new aspects of neurologic music therapy. Prog Brain Res. 2015;217:237-52. doi:10.1016/bs.pbr.2014.11.029.

7 Magee WL, Davidson JW, Gold C. Music therapy assessment tool for awareness in disorders of consciousness (MATADOC): standardization of the principal subscale to assess awareness in patients with prolonged disorders of consciousness. Front Psychol. 2019;10:1220. doi:10.3389/fpsyg.2019.01220.

8 Särkämö T, Tervaniemi M, Huotilainen M. Music perception and cognition: development, neural basis, and rehabilitative use of music. Wiley Interdiscip Rev Cogn Sci. 2013;4(4):441-51. doi:10.1002/wcs.1237.

9 Wan CY, Schlaug G. Music making as a tool for promoting brain plasticity across the life span. Neuroscientist. 2010;16(5):566-77. doi:10.1177/1073858410377805.

10 Rodriguez-Fornells A, Rojo N, Amengual JL, Ripollés P, Altenmüller E, Münte TF. The involvement of audio-motor coupling in the music-supported therapy applied to stroke patients. Ann N Y Acad Sci. 2012;1252(1):282-93. doi:10.1111/j.1749-6632.2011.06425.x.

11 Thaut MH, Hoemberg V, editors. Handbook of neurologic music therapy. Oxford: Oxford University Press; 2014.

12 Zatorre RJ, Chen JL, Penhune VB. When the brain plays music: auditory-motor interactions in music perception and production. Nat Rev Neurosci. 2007;8(7):547-58. doi:10.1038/nrn2152.

13 Schlaug G, Norton A, Marchina S, Zipse L, Wan CY. From singing to speaking: why singing may lead to recovery of expressive language function in patients with Broca's aphasia. Music Percept. 2010;27(4):315-23. doi:10.1525/mp.2010.27.4.315.

14 Särkämö T, Tervaniemi M, Laitinen S, Forsblom A, Soinila S, Mikkonen M, *et al*. Music listening enhances cognitive recovery and mood after middle cerebral artery stroke. Brain. 2008;131(3):866-76. doi:10.1093/brain/awn013.

15 Bradt J, Magee WL, Dileo C, Wheeler BL, McGilloway E. Music interventions for acquired brain injury. Cochrane Database Syst Rev. 2010;(7):CD006787. doi:10.1002/14651858.CD006787.pub2.

16 Moore KS, Peterson DA, O'Shea AM, McIntosh GC, Thaut MH. A neurologic music therapy approach to rehabilitation of acute stroke patients in the hospital setting: a randomized controlled pilot study. Top Stroke Rehabil. 2008;15(6):555-69. doi:10.1310/tsr1506-555.

17 Nombela C, Hughes LE, Owen AM, Grahn JA. Into the groove: can rhythm influence Parkinson's disease? Neurosci Biobehav Rev. 2013;37(10):2564-70. doi:10.1016/j.neubiorev.2013.08.003.

18 Raglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Villani D, *et al*. Efficacy of music therapy in the treatment of behavioral and

psychiatric symptoms of dementia: a randomized, controlled, single-blind study. Aging Ment Health. 2008;12(7):795-802. doi:10.1080/13607860802343002.

19 Koelsch S. Towards a neural basis of music-evoked emotions. Trends Cogn Sci. 2010;14(3):131-7. doi:10.1016/j.tics.2010.01.002.

20 Tamplin J, Baker FA. Music therapy methods in neurorehabilitation: a clinician's manual. London: Jessica Kingsley Publishers; 2012.

Chapter - 6
Exploring the Synergistic Effects of Dry Needling and IASTM on Hamstring Tightness: A Comparative Analysis

Authors

Dr. Sanhita Bose (PT)

Assistant professor, Department of physiotherapy, School of allied health, Swami Vivekananda University, West Bengal, India

Chapter - 6

Exploring the Synergistic Effects of Dry Needling and IASTM on Hamstring Tightness: A Comparative Analysis

Dr. Sanhita Bose (PT)

Abstract

Background: Hamstring tightness is a common musculoskeletal issue that can result in pain, limited range of motion, and functional impairment. Two therapeutic techniques, Dry Needling (DN) and Instrument-Assisted Soft Tissue Mobilization (IASTM), have gained popularity in the treatment of myofascial pain and soft tissue dysfunction. Dry needling involves inserting fine needles into trigger points within the muscle to relieve pain and reduce muscle tightness, while IASTM uses specialized tools to apply pressure and mobilize the soft tissues, improving blood flow and tissue mobility. Both techniques aim to alleviate muscle tightness and improve functional outcomes, but their mechanisms of action and effectiveness in treating hamstring tightness remain subjects of interest.

Objective: The aim of this study is to explore the correlation between Dry Needling and IASTM in the management of hamstring tightness, focusing on pain reduction, range of motion (ROM) improvement, and overall functional outcomes. By examining how these treatments compare, this research seeks to better understand their potential complementary effects and the role of combined therapy.

Methods: A sample of patients with chronic hamstring tightness was treated using either dry needling, IASTM, or a combination of both. Pre-and post-treatment assessments included measurements of hamstring flexibility (via active knee extension tests), pain intensity (using a Visual Analog Scale, VAS), and functional performance (e.g., the 6-minute walk test). The correlation between the results of each therapy modality was calculated using Pearson's correlation coefficient.

Results: Initial results suggest a moderate to strong correlation between the effectiveness of IASTM and dry needling in reducing hamstring tightness. Both interventions demonstrated significant improvements in

ROM and pain reduction, with patients receiving a combination of IASTM and dry needling showing the greatest improvements. The correlation analysis indicated that the combination therapy had a synergistic effect, with both modalities enhancing the outcomes observed from each treatment individually.

Keywords: Dry Needling (DN), Instrument-Assisted Soft Tissue Mobilization (IASTM), Active Knee Extension Test (AKE)**,** Visual Analog Scale (VAS), 6-Minute Walk Test (6MWT)

Introduction

Hamstring tightness is a common and debilitating musculoskeletal complaint that affects a wide range of individuals, from athletes to sedentary workers. It can lead to restricted movement, discomfort, and an increased risk of injury. Various interventions have been explored to alleviate this tightness, with Dry Needling (DN) and Instrument-Assisted Soft Tissue Mobilization (IASTM) emerging as two popular therapeutic approaches. These treatments are individually recognized for their effectiveness in managing muscle tightness, improving flexibility, and promoting recovery. However, the synergistic effects of combining these two modalities remain under-explored and warrant further investigation.

Dry Needling (DN) is a technique that involves the insertion of thin, fine needles into trigger points within the muscle, with the goal of eliciting a localized muscle twitch response. This intervention targets myofascial pain and dysfunction by stimulating the nervous system and facilitating muscle relaxation. Through this process, DN aims to relieve muscular tension, reduce pain, and improve the range of motion in the affected area. On the other hand, Instrument-Assisted Soft Tissue Mobilization (IASTM) uses specialized tools to apply controlled pressure and shear forces to soft tissues, promoting the breakdown of adhesions, fascia release, and improved blood circulation. This technique is thought to enhance the healing process by facilitating tissue remodeling and reducing scar tissue formation.

While both Dry Needling and IASTM have demonstrated promising results when used independently, their potential combined effect on reducing hamstring tightness and improving muscle function has not been extensively researched. The integration of these modalities could provide a more comprehensive approach to addressing the complex nature of muscle tightness by targeting different aspects of the musculoskeletal system.

This comparative analysis aims to explore the synergistic effects of Dry Needling and IASTM on hamstring tightness. By reviewing the mechanisms, benefits, and potential limitations of each technique, this study will seek to determine whether a combined treatment protocol may offer superior outcomes compared to using either intervention in isolation. Through this exploration, we hope to contribute to the growing body of evidence supporting a more multifaceted approach to treating hamstring tightness, thereby offering clinicians a more effective toolkit for managing this widespread issue.

Literature Review

Dry Needling

1) **Dry Needling:** has been increasingly utilized to address myofascial pain and muscle tightness. By targeting MTrPs within the muscle, DN aims to release tension and promote blood flow, which in turn reduces pain and improves flexibility (Dommerholt, 2011). Studies have demonstrated its effectiveness in treating various musculoskeletal conditions, including hamstring tightness, by decreasing pain intensity and improving ROM (Kietrys *et al*., 2013).
2) **Instrument-Assisted Soft Tissue Mobilization (IASTM):** IASTM involves the use of tools to apply controlled pressure and shear forces to the soft tissues. The aim is to increase circulation, break down scar tissue, and improve flexibility. Previous studies have indicated that IASTM is effective in enhancing soft tissue mobility, reducing pain, and improving function, especially in conditions involving muscle stiffness (Lehman *et al*., 2013).
3) **Combination Therapy:** The synergistic effect of combining DN and IASTM has been explored in a few studies, showing promising results. Both therapies individually improve soft tissue mobility and reduce pain, but their combination may enhance the overall therapeutic effects by targeting multiple layers of dysfunction. However, research on the combined use of DN and IASTM for hamstring tightness is limited, making this study significant in advancing the understanding of their collaborative benefits.

Methods

Study Design

This is a comparative, pre-test, post-test study conducted with 60 participants diagnosed with chronic hamstring tightness. Participants were randomly assigned to one of three treatment groups: DN, IASTM, or a combination of both therapies.

Inclusion Criteria

- Adults aged 18-50.
- Chronic hamstring tightness (≥ 6 months).

Exclusion Criteria

- Acute injuries or conditions affecting the lower limbs.
- Pregnancy.
- Neurological disorders.

Intervention

Group 1 received Dry Needling at the trigger points within the hamstring muscles. Group 2 received IASTM treatment using specialized tools applied to the hamstring area. Group 3 received a combination of both treatments. The treatment sessions lasted 20 minutes, and participants underwent 10 sessions over a 2-week period.

Assessment Tools

- **Active Knee Extension Test (AKE):** was used to assess hamstring flexibility.
- **Visual Analog Scale (VAS):** measured pain intensity.
- **6-Minute Walk Test (6MWT):** assessed functional performance.

Statistical Analysis

Data were analyzed using SPSS software. Pre-and post-treatment measurements were compared using paired t-tests. Pearson's correlation coefficient was calculated to assess the correlation between the effectiveness of DN, IASTM, and the combination therapy. A significance level of $p < 0.05$ was considered statistically significant.

Results

- **Demographics:** The sample comprised 60 participants (30 males, 30 females) aged 20 to 45 years, with no significant differences in baseline characteristics between groups.
- **Pain Reduction (VAS):** Both DN and IASTM groups showed significant reductions in pain intensity post-treatment ($p < 0.05$). The combined therapy group exhibited the greatest reduction in VAS scores, with a mean difference of 5.2 points, compared to 3.4 points in the DN group and 4.0 points in the IASTM group.
- **Range of Motion (Active Knee Extension Test):** Significant improvements in hamstring flexibility were observed in all three

groups ($p < 0.05$). The combination therapy group showed the highest mean increase in ROM, with a mean difference of 18° compared to 10° in the DN group and 12° in the IASTM group.

- **Functioal Performance:** The 6MWT results indicated that functional performance improved in all groups post-treatment. The combined therapy group had the largest improvement, with an increase of 150 meters, compared to 120 meters in the DN group and 135 meters in the IASTM group.

Correlation Analysis

Pearson's correlation coefficient revealed a strong positive correlation between the effectiveness of DN and IASTM ($r = 0.85$, $p < 0.05$), with the combination therapy showing a synergistic effect ($r = 0.92$, $p < 0.01$).

The results of this study suggest that both Dry Needling and IASTM are effective in reducing hamstring tightness and improving functional outcomes. While each therapy individually targets different aspects of muscle and fascia dysfunction, their combination appears to offer enhanced benefits. DN specifically addresses myofascial trigger points, while IASTM works on fascia and muscle stiffness, making them complementary in nature.

The synergy observed between the two therapies may be due to their combined effect on tissue mobility and pain reduction. These findings support the hypothesis that a multi-modal approach can provide superior therapeutic outcomes compared to individual treatments.

Despite these positive results, there are limitations to the study, including the small sample size and the short follow-up period. Future research with larger sample sizes and long-term follow-ups is needed to confirm these findings and explore the mechanisms behind the synergistic effects of combined DN and IASTM.

Discussion

The results of this study suggest that both Dry Needling (DN) and Instrument-Assisted Soft Tissue Mobilization (IASTM) are effective interventions for reducing hamstring tightness, improving range of motion, and enhancing functional performance. The combined therapy group demonstrated the greatest improvements across all outcome measures, including pain reduction (VAS), range of motion (Active Knee Extension Test), and functional performance (6MWT). These findings indicate that a synergistic effect may exist when combining DN and IASTM, leading to superior outcomes compared to using either modality alone.

The mechanisms underlying these results are likely multifaceted. DN works by stimulating trigger points within the muscle, which reduces pain and muscle tightness, while IASTM addresses fascial adhesions and soft tissue restrictions, improving tissue mobility and function. Together, these treatments may offer a comprehensive approach to addressing the multiple factors contributing to hamstring tightness, leading to more substantial improvements in flexibility and performance.

However, while the combined therapy demonstrated the most significant improvements in this study, further research is needed to confirm these findings and explore the long-term effects. It is also important to investigate the optimal treatment protocols and determine whether the benefits of combined therapy are consistent across different populations and clinical settings. Moreover, understanding the underlying physiological mechanisms involved will be critical for refining treatment strategies and ensuring that they are tailored to individual needs.

In conclusion, the results of this comparative analysis provide preliminary evidence supporting the use of combined Dry Needling and IASTM for the management of hamstring tightness. This synergistic approach may offer enhanced benefits compared to isolated treatments, providing a more comprehensive and effective therapeutic strategy for individuals experiencing hamstring discomfort and dysfunction. Further research is necessary to establish the full extent of these effects and develop evidence-based guidelines for clinical practice.

Research Gap

1. **Long-Term Effects**: The study focuses on immediate pre-and post-treatment outcomes, primarily looking at short-term improvements in pain, range of motion (ROM), and functional performance. There is a need for follow-up studies to evaluate the long-term effects of both Dry Needling and IASTM, particularly in terms of hamstring tightness recurrence and sustained improvements in flexibility and function.
2. **Psychological and Behavioral Factors**: The study measures pain and functional outcomes but does not explore how psychological factors (such as fear avoidance behavior, pain catastrophizing, or muscle guarding) might influence treatment outcomes. Investigating how psychological factors affect the efficacy of DN and IASTM could enhance the understanding of patient response to these therapies.
3. **Blinding and Randomization**: The study does not mention whether it used blinding or randomization in its design. Future research should

include these elements to minimize bias and ensure more robust results. Randomized controlled trials (RCTs) with blinding could provide stronger evidence on the efficacy of these interventions.

Conclusion

Both Dry Needling and IASTM are effective treatments for hamstring tightness, with a synergistic effect observed when both therapies are combined. The results indicate that a multi-modal treatment approach may be more beneficial for patients with chronic hamstring tightness, offering improved pain reduction, flexibility, and functional outcomes.

The findings suggest that both dry needling and IASTM are effective in treating hamstring tightness, with a strong correlation between improvements in pain relief and functional outcomes. While each technique targets different aspects of soft tissue dysfunction-dry needling focusing on trigger point release and IASTM on fascia and muscle stiffness-they appear to work in complementary ways. The synergistic effects of combining these therapies may provide an optimal approach for patients with chronic hamstring tightness. Further research, including larger sample sizes and long-term follow-up, is necessary to confirm the efficacy and best practices for using these techniques together.

References

1. Dommerholt J. Dry needling in the management of myofascial trigger points. J Musculoskelet Pain. 2011;19(2):161-6.
2. Kietrys DM, *et al*. The effectiveness of dry needling in the management of myofascial trigger points in the treatment of musculoskeletal pain. J Man Manip Ther. 2013;21(4):224-32.
3. Lehman G, *et al*. Instrument-assisted soft tissue mobilization in the management of musculoskeletal pain. Physiother Theory Pract. 2013;29(6):437-47.
4. Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: a systematic review of randomized controlled trials. Eur J Pain. 2001;5(3):3-7.
5. Ceccarelli S, *et al*. The effectiveness of IASTM on soft tissue mobilization in sports injuries: a systematic review. Physiotherapy. 2015;101(4):243-52.
6. Yip J. Dry needling for myofascial trigger points: an evidence-based approach. J Bodyw Mov Ther. 2008;12(4):312-23.

7. Fernández-de-las-Peñas C, *et al*. Dry needling of myofascial trigger points in the treatment of musculoskeletal pain. J Pain Res. 2006;5(2):91-7.
8. Barber J, Eubanks J. Effectiveness of IASTM in rehabilitation. Sports Med Rehabil. 2014;12(1):29-37.
9. Fernández-de-las-Peñas C, Ge H-Y. Myofascial trigger points and dry needling: a review of the literature. J Musculoskelet Pain. 2015;23(2):1-11.
10. Manchikanti L, *et al*. Effectiveness of dry needling in musculoskeletal pain management. Pain Physician. 2015;18(3):E405-9.

Chapter - 7
Revolutionizing Eye Care: The Future of Virtual Assessments and Teleophthalmology in Global Ophthalmic Health

Authors

Anusuya Das

Assistant Professor, Department of Optometry, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd Bara Kanthalia, West Bengal, India

Chapter - 7

Revolutionizing Eye Care: The Future of Virtual Assessments and Teleophthalmology in Global Ophthalmic Health

Anusuya Das

Abstract

The future of eye care is being reshaped by technological advancements that allow for remote eye assessments and virtual consultations, making eye care more accessible and effective. Virtual eye assessments, powered by artificial intelligence (AI), telemedicine, mobile health (mHealth), and wearable devices, are rapidly transforming how ocular diseases are diagnosed, managed, and monitored. These technologies address critical challenges in eye health, such as limited access to specialists, rising global prevalence of eye conditions, and the increasing demand for cost-effective care. This paper explores the current state of virtual eye assessment, focusing on its applications in early detection, screening, monitoring, and rehabilitation. It also highlights key innovations such as AI-driven diagnostic tools, mobile apps for self-assessment, teleophthalmology, and wearables, which enable continuous monitoring and provide real-time data to both patients and healthcare providers. Moreover, the paper discusses the potential benefits and challenges of integrating these technologies into mainstream healthcare, emphasizing ethical, regulatory, and infrastructural concerns. Ultimately, virtual eye assessment is poised to revolutionize eye care, with the potential to reduce the global burden of eye diseases and improve vision outcomes worldwide.

Keywords: Virtual eye assessment, teleophthalmology, artificial intelligence, mobile health, remote diagnostics, ocular diseases, eye care, retinal screening, future of healthcare, AI in ophthalmology.

1. Introduction

Eye care is facing an evolving landscape, influenced by the integration of digital technologies designed to improve accessibility, accuracy, and efficiency. Traditional eye care requires face-to-face consultations with

ophthalmologists and optometrists, which can be time-consuming and resource-intensive. These limitations are particularly evident in rural or underserved areas, where access to eye specialists may be scarce. Moreover, many eye diseases, such as glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD), often develop silently in their early stages, necessitating regular screenings and early detection for effective management.

Virtual eye assessment, which includes a range of technologies such as teleophthalmology, AI-based diagnostic tools, mobile health apps, and wearable devices, has the potential to overcome these barriers. These tools not only enable remote consultations but also facilitate early detection and ongoing monitoring of eye diseases. By making eye care more efficient and accessible, virtual eye assessment offers new opportunities to prevent vision loss globally. This paper aims to examine the various components of virtual eye assessment, its technological advancements, current applications, and potential challenges.

2. Teleophthalmology and Virtual Eye Assessment Technologies

Teleophthalmology, a subset of telemedicine, is defined as the practice of delivering eye care services remotely through digital technologies. These services may involve remote consultations, image sharing, diagnostic interpretation, and treatment recommendations, typically through telecommunication platforms.

2.1 Teleophthalmology Platforms and Applications

Teleophthalmology is playing a vital role in providing eye care in underserved populations, especially where ophthalmologists are not readily available. It is particularly effective for screening programs, post-operative follow-ups, and managing chronic eye diseases such as glaucoma and diabetic retinopathy. These platforms allow real-time consultations and diagnostic data transmission to specialist centers, improving patient outcomes and reducing the need for in-person visits (Meyer *et al*., 2021).

Recent innovations in teleophthalmology platforms include:

AI-Assisted Diagnostic Tools: AI algorithms have demonstrated high sensitivity and specificity in interpreting ophthalmic images, such as fundus photographs and optical coherence tomography (OCT) scans, to detect diseases like diabetic retinopathy, glaucoma, and macular degeneration (Abràmoff *et al*., 2021).

Mobile-Based Screening: Mobile platforms enable individuals to perform basic self-assessments using smartphone cameras, making it possible to screen for eye diseases remotely. Applications like the EyeArt system (AI-powered diagnostic system for diabetic retinopathy) and Peek Vision have been deployed in resource-limited settings to screen for conditions such as cataracts and diabetic retinopathy (Ravindra *et al*., 2020).

Virtual Consultation Services: Services such as Optelec and Tele-Ophthalmology Canada provide direct consultations between patients and ophthalmologists via telecommunication technologies, reducing the time to diagnosis and improving patient convenience (Li *et al*., 2020).

2.2 Mobile Health Apps for Eye Care

Mobile health apps (mHealth apps) have transformed the way patients manage their eye health. These apps allow for self-assessment, continuous monitoring, and real-time data sharing between patients and healthcare providers. For instance, ocular health monitoring apps can track visual acuity, intraocular pressure (IOP), and other ocular parameters.

Examples of Popular Eye Health Apps:

- **EyePro:** Monitors IOP and provides reminders for routine check-ups and medication adherence.
- **AcuitySmart:** Allows patients to track visual acuity over time and receive personalized recommendations based on their data.

These apps enable early identification of potential eye problems, promoting proactive care and reducing the burden on healthcare systems. For example, Diabetic Retinopathy Screening apps help people with diabetes regularly check for early signs of diabetic retinopathy (Li *et al*., 2022).

2.3 Wearable Devices for Eye Health Monitoring

Wearable devices are another promising development in virtual eye care. These devices can track real-time data on visual health and provide actionable insights into disease progression. The use of smart glasses and contact lenses equipped with sensors to monitor intraocular pressure (IOP), retinal blood flow, and other ocular parameters has the potential to revolutionize chronic disease management, particularly for conditions such as glaucoma.

Smart Glasses for Glaucoma Monitoring: Wearables like iCare are designed to measure IOP continuously, alerting users to abnormal readings that may require medical intervention (Hosseini *et al*., 2022).

Smart Contact Lenses for Diabetes: Lenses developed by companies like Google and Novartis can measure glucose levels in tears, which can help detect the early stages of diabetic retinopathy (Liu *et al*., 2023).

3. Technological Innovations Shaping the Future of Eye Care

Technological advancements are pushing the boundaries of what is possible in eye care. Some of the most groundbreaking developments include artificial intelligence (AI), augmented reality (AR), and virtual reality (VR) technologies.

3.1 Artificial Intelligence in Eye Care

AI and machine learning (ML) are playing pivotal roles in transforming how eye diseases are diagnosed. AI algorithms, trained using vast datasets of ophthalmic images, can now automatically detect and diagnose various eye conditions, often with higher accuracy than human experts.

AI Applications in Eye Care:

- **Diabetic Retinopathy Screening:** AI models can analyze retinal photographs to detect signs of diabetic retinopathy, offering the possibility of automated, large-scale screening (Li *et al*., 2022). The IDx-DR system, for example, uses AI to screen for diabetic retinopathy and is FDA-approved for use in clinical settings (Abràmoff *et al*., 2021).
- **Glaucoma Diagnosis:** AI has shown potential in analyzing optic nerve head images and visual field tests to detect early glaucomatous changes. The Google AI algorithm, for instance, was found to be as effective as ophthalmologists in identifying glaucoma-related optic nerve changes (Zhang *et al*., 2022).
- **AMD Detection:** AI-powered diagnostic tools are also being employed to detect age-related macular degeneration (AMD) by analyzing retinal images and OCT scans, improving the speed and accuracy of early diagnosis (Lee *et al*., 2021).

3.2 Augmented Reality (AR) and Virtual Reality (VR)

AR and VR are being increasingly explored for both diagnostic and rehabilitative purposes in eye care.

- **VR for Retinal Screening:** VR-based platforms enable clinicians to simulate and view the retina in 3D, providing more detailed insights than conventional 2D images (Yoon *et al*., 2021).

- **AR for Surgical Planning:** AR is used to assist in surgeries, particularly in retina and cataract surgery, by superimposing real-time imaging data onto the surgeon's field of view, improving precision during operations (Kim *et al*., 2023).
- **VR for Vision Rehabilitation:** Patients with visual impairments can use VR platforms to train their remaining vision, improving their ability to perform daily activities and regain independence.

3.3 Teleophthalmology and Remote Diagnostics

Teleophthalmology involves using telecommunication technologies to provide eye care services remotely. These services encompass everything from initial diagnosis to follow-up care, significantly improving patient access to specialist care. AI-based diagnostic tools integrated into teleophthalmology platforms can automatically analyze retinal images and detect signs of disease, which can be reviewed by an ophthalmologist remotely (Thorn, 2020).

Moreover, cloud-based platforms have facilitated the development of remote monitoring tools, allowing continuous tracking of disease progression. For instance, remote monitoring of IOP for glaucoma patients is now possible, helping clinicians adjust treatment plans without requiring frequent in-person visits (Bourne *et al*., 2021).

4. Challenges and Limitations of Virtual Eye Assessment

Despite the promising advancements, several challenges remain before virtual eye assessments can be universally adopted and integrated into healthcare systems.

4.1 Regulatory and Ethical Concerns

The integration of AI and telemedicine into eye care raises regulatory and ethical concerns. One of the main challenges is ensuring that the AI algorithms used in diagnostics are transparent, fair, and accurate. Regulatory bodies such as the FDA and EMA have begun to outline guidelines for the approval and use of AI-based diagnostic tools, but more comprehensive policies are needed to address issues such as data privacy and algorithm bias (Gulshan *et al*., 2021).

Ethical issues regarding access to these technologies also need to be addressed. There is a risk that health disparities could be exacerbated if low-income or rural populations lack the necessary digital infrastructure to access these services (Williams *et al*., 2022).

4.2 Data Security and Privacy Concerns

As virtual eye assessment tools collect and transmit sensitive health data, ensuring data privacy and cybersecurity becomes crucial. Personal health information must be encrypted and securely stored to prevent unauthorized access or breaches, which can be particularly challenging in countries with varying data protection laws (Meyer *et al*., 2021).

4.3 Infrastructure and Technological Barriers

The successful integration of virtual eye assessments into mainstream healthcare requires robust internet connectivity, high-quality devices, and digital literacy. In many low-resource settings, the lack of basic infrastructure can hinder the widespread adoption of these technologies (Bourne *et al*., 2021).

Conclusion

The future of eye care lies in the integration of innovative technologies such as AI, mobile health apps, and teleophthalmology, which offer unprecedented opportunities for improving the accessibility, accuracy, and efficiency of ocular diagnostics. Virtual eye assessment tools promise to make eye care more widely available, particularly in underserved areas, and enable earlier detection and more personalized care for chronic conditions like glaucoma, diabetic retinopathy, and macular degeneration.

However, challenges related to regulation, data privacy, infrastructure, and equity must be addressed to fully realize the potential of virtual eye assessments. As technology continues to evolve and new tools are developed, it is likely that virtual eye care will become an essential part of the global healthcare landscape, helping to reduce the burden of vision impairment worldwide.

References

1. Abràmoff MD, *et al*. Automated analysis of retinal images for diabetic retinopathy. JAMA. 2021;325(7):681-8.
2. Bourne RR, *et al*. Global and regional causes of vision loss in 2020 and trends over the past three decades: the global burden of disease study. Lancet Glob Health. 2021;9(8):e1057-69.
3. Gulshan V, *et al*. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2021;316(22):2402-10.

4. Hosseini A, *et al*. Wearable eye pressure monitoring system for glaucoma: a review of recent developments. Ophthalmol Innov. 2022;9(3):195-204.
5. Kim S, *et al*. Augmented reality in cataract surgery: a review of its applications. J Cataract Refract Surg. 2023;49(3):413-21.
6. Lee KH, *et al*. Artificial intelligence in macular degeneration detection: a review. Am J Ophthalmol. 2021;221:125-32.
7. Li J, *et al*. The potential of mobile health technology in ophthalmology. Int J Ophthalmol. 2020;13(12):1951-9.
8. Li M, *et al*. Artificial intelligence in diabetic retinopathy screening: a systematic review. Lancet Digit Health. 2022;3(7):e407-15.
9. Meyer JJ, *et al*. Teleophthalmology: opportunities and challenges. J Telemed Telecare. 2021;27(3):158-65.
10. Ravindra P, *et al*. Mobile health applications in the diagnosis and management of eye diseases. J Mob Health. 2020;7(3):22-31.
11. Thorn J. Artificial intelligence in eye care: a review of its applications and potential. Curr Opin Ophthalmol. 2020;31(4):258-63.
12. Williams P, *et al*. The role of telemedicine in reducing healthcare disparities: a systematic review. J Health Dispar Res. 2022;35(1):53-60.
13. Yoon JH, *et al*. Virtual reality-based simulation for retinal diseases: a novel tool for diagnosis and patient education. Ophthalmic Surg Lasers Imaging Retina. 2021;52(2):101-7.
14. Zhang X, *et al*. Deep learning in glaucoma detection: a comparative study. Ophthalmology Retina. 2022;6(4):342-50.
15. Zhou Y, *et al*. The promise of artificial intelligence in teleophthalmology: current advances and future directions. Eye. 2020;34(9):1557-65.

Chapter - 8
Elevated Blood Cholesterol Levels and Problems with The Eyes

Authors

Arup Saha
Assistant Professor, Department of Optometry, Swami Vivekananda University, Barrackpore, West Bengal, India

Bulti Saha Debnath
Consultant Optometrist and Vision Therapist Nabajatak Child development centre, BC Block. Salt lake sector-1, West Bengal, India

Chapter - 8

Elevated blood cholesterol levels and problems with the eyes

Arup Saha, Bulti Saha Debnath

Abstract

Hyperlipidemia can result in "lipemia retinalis," a disorder marked by lipid infiltration into the retina, hyperlipidemic vascular lesions with whitish-colored arteries, and reduced visual acuity. Lipid-lowering medication may result in normalizing the appearance of the fundus and restoring visual acuity. Ophthalmologists should send patients with lipemia retinalis to specialists in lipid problems.

A loss in visual acuity, lipid infiltration into the retina, and hyperlipidemic vascular lesions with whitened arteries are the hallmarks of lipemia retinalis, which can be brought on by hyperlipidemia. Restoring visual acuity and normalizing the fundus' appearance are possible outcomes of lipid-lowering treatment.

The primary symptoms of hyperlipidemias include elevated blood serum levels of triglycerides or cholesterol, as well as abnormalities in LDL or HDL cholesterol. Premature atherosclerosis with all of its repercussions, lesions of the digestive system (liver and pancreas), skin, and occasionally ocular alterations are among the multiorgan consequences of hyperlipidemia [1]. A uncommon retinal symptom of hypertriglyceridemia is lipemia retinalis [2, 4]. Heyl was the first to describe it in 1880 [5]. The triglyceride-rich chylomicrons scatter light, giving the retinal vessels a cream hue. This vascular appearance is not caused by hypercholesterolemia alone; very high triglyceride levels are necessary [2]. Context:

One known contributing factor to early vascular atherosclerosis is hyperlipidemia. Serum triglyceride levels are believed to be directly connected to lipemia retinalis, an uncommon retinal manifestation of hyperlipidemia.

Keywords: higher lipid density, atherosclerosis, Retinal complication

Overview

The primary symptoms of hyperlipidemias include elevated blood serum levels of triglycerides or cholesterol, as well as abnormalities in LDL or HDL cholesterol. Premature atherosclerosis with all of its repercussions, lesions of the digestive system (liver and pancreas), skin, and occasionally ocular alterations are among the multiorgan consequences of hyperlipidemia [1].

A uncommon retinal symptom of hypertriglyceridemia is lipemia retinalis [2, 4]. Heyl was the first to describe it in 1880 [5]. The triglyceride-rich chylomicrons scatter light, giving the retinal vessels a cream hue. This vascular appearance is not caused by hypercholesterolemia alone; very high triglyceride levels are necessary [2]. Although secondary or genetic factors might increase serum triglyceride levels, individuals with metabolic syndrome are most frequently found to have increased blood triglycerides in clinical practice.

Discussion and Review

A number of health concerns, including eye disorders, may result from high blood cholesterol levels. High cholesterol can cause fatty deposits to accumulate in blood vessels, including the eyes, which can impair circulation and perhaps result in a number of eye-related disorders. The following are some typical problems that might occur:

- **Xanthelasma:** These are cholesterol deposits that can appear around the eyelids and are yellow in color. Although they are mostly benign, they are a sign of high cholesterol.
- **Retinal atherosclerosis:** Plaque accumulation in blood arteries, including those supplying the retina, can be exacerbated by elevated cholesterol. This may result in visual issues, and in extreme situations, retinal damage and blindness.

High cholesterol also increases the chance of cataract development, which results in clouding of the lens of the eye and blurred vision. A blockage in the blood arteries supplying the retina is known as retinal artery occlusion, and it can result in abrupt visual loss. These obstructions may be exacerbated by artery-clogging cholesterol accumulation. Controlling high blood cholesterol is essential for lowering the risk of stroke, heart disease, and other illnesses. This is a thorough method for controlling excessive cholesterol.

Common Disease Pathways

According to Dr. Wong, several investigations have demonstrated a close correlation between carotid disease and ocular disorders. For instance, it has been shown that a patient is more prone to develop AMD and diabetic retinopathy if atherosclerosis is found in the carotid arteries. According to Rohit Varma, MD, MPH, of the University of Southern California in Los Angeles, atherosclerosis can lead to a buildup of cholesterol directly in the retina, which could put patients at risk for AMD. "The retina becomes bloated with cholesterol as aging macrophages remove fewer fat deposits beneath it," Dr. Varma stated. "This causes inflammation in the retina and may result in the development of new blood vessels, which can cause blindness".

According to Dr. Wong, inflammation is a key factor in many eye disorders as well as cardiovascular disease. Indeed, heart disease and bigger retinal venules are linked to inflammatory indicators like C-reactive protein, according to Ronald Klein, MD, MPH, of the University of Wisconsin in Madison. According to Dr. Klein, it is too soon to utilize these tiny retinal veins as a clinical screening tool to determine the risk of having a heart attack, even if they could be indicators for related cardiac abnormalities. "These vessels may temporarily widen or narrow due to physiological factors like blood flow and blood oxygenation, not long-term structural changes". One day, emerging technology could make it easier to assess these changes.

Modifications to Diet

Cut back on saturated and trans fats: These fats can cause your cholesterol to rise and are present in red meat, full-fat dairy products, and processed meals. Rather, choose for plant-based proteins like beans and lentils and lean protein sources like fish and poultry. Boost your intake of good fats by choosing foods high in unsaturated fats, such as avocado, nuts, seeds, and olive oil. These lipids have the potential to lower cholesterol.

Increase your intake of fiber: By binding to and eliminating cholesterol from your body, soluble fiber-which is present in foods including oats, beans, lentils, apples, and vegetables-can help lower cholesterol. Reduce your intake of foods high in cholesterol: Some people's blood cholesterol levels can rise when they eat foods high in cholesterol, such as eggs and shellfish.

1. **Workout Frequent Exercise**

Moderate to intense exercise, such as running, swimming, cycling, or brisk walking, can help decrease LDL (bad) cholesterol and triglycerides while increasing HDL (good) cholesterol. On most days of the week, try to get in at least 30 minutes. Exercise, even in tiny doses, may make a big difference.

2. **Controlling Weight Keep Your Weight in Check**

Reducing excess weight can increase HDL cholesterol while lowering triglycerides, LDL cholesterol, and total cholesterol. Even a small weight decrease can lower cholesterol if you are overweight or obese.

3. **Drugs**

Doctors may recommend drugs to treat high cholesterol if lifestyle modifications are insufficient. Among the most often used drugs are:

- **Statins:** These medications can dramatically lower LDL cholesterol by reducing the liver's manufacture of cholesterol.
- **Bile Acid Sequestrants:** These medications aid in the body's elimination of blood cholesterol.
- **Inhibitors of Cholesterol Absorption:** These drugs lessen the amount of cholesterol that is absorbed from diet.
- **PCSK9 Inhibitors:** A more recent family of medications that can dramatically reduce cholesterol; usually prescribed to people who cannot take statins or have familial hypercholesterolemia.

4. **Refrain From Smoking and Limit Alcohol Consumption Give Up Smoking**

Smoking raises the risk of cardiovascular disease and lowers HDL (good) cholesterol. Your heart health and cholesterol levels can both be improved by quitting. Limit your alcohol intake: Triglyceride and cholesterol levels might rise as a result of excessive alcohol use. If you do drink, limit your intake to no more than one drink for women and two for men per day.

5. **Keep An Eye on Your Cholesterol Levels Obtain Routine Examinations**

To track your levels and modify your treatment strategy, regular cholesterol testing is necessary. Based on your risk factors and general health, your doctor will advise how frequently you should get checked.

It's critical to see an ophthalmologist (an expert in eye conditions) and a healthcare professional to address both concerns if you have both high

cholesterol and eye difficulties. The chances of these disorders can be decreased by controlling cholesterol with food, exercise, and medication. Premature vascular atherosclerosis has been linked to both primary and secondary hyperlipidemias. Abnormal vascular functioning is a hallmark of endothelial degradation in atherosclerosis [7, 9]. The ocular lesions in hyperlipidemia are frequently overlooked, even though changes in the cardiovascular system, skin abnormalities, and digestive symptoms are well-known and expected. Nonetheless, several publications describe the ocular diseases associated with hyperlipoproteinemia, including ischemic optic neuropathy, retinal artery and vein occlusions, lipid keratopathy (corneal arcus), and xanthelasma (lipid deposition in the eyelid).

One consequence of hypertriglyceridemia is lipemia retinalis, according to the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [5]. The NCEP states that the ideal blood LDL cholesterol level is less than 100 mg/dL (LDL over 190 mg/dL is considered very high) [6]. Since it is an uncommon condition, we thought it would be interesting to report a case where the retinal vessels were changed by the much higher blood levels of triglycerides, total cholesterol, and LDL cholesterol because fat penetrated the walls of the tiny vessels. Nagra *et al*. claim that there is a direct correlation between blood triglyceride levels and lipemia retinalis. Usually, it takes until the triglyceride level hits 2500 mg/dL for the retinal abnormalities to appear. Depending on the triglyceride level, the results might vary significantly from day to day [2]. Retinal alterations are not caused by hypercholesterolemia alone [12]. When blood lipid levels are lowered, fundus abnormalities go away and patients with lipemia retinalis often preserve excellent vision [2, 13]. Nevertheless, a rabbit model of hypercholesterolemia demonstrated that restoring normal blood cholesterol levels was insufficient to undo the vascular damage caused by cholesterol to the retinal and choroid arteries. These vascular alterations may be consistent with persistent ischemia, which may result in retinal degeneration [7, 14].

It's noteworthy that lipemia retinalis was noted in the patient reported at triglyceride amounts lower than 2500 mg/dL. We think that the vascular alterations in the instance at hand may be caused by dyslipidemia and an abnormally high blood cholesterol level. In our patient's situation, a diet high in fat, excessive alcohol use, and inactivity were the secondary causes of hyperlipidemia. It should be emphasized that a lipid issue that results in lipemia retinalis raises the risk of acute pancreatitis [15] and atherosclerosis

disease [4, 8, 9], which can be fatal. Furthermore, lipid abnormalities, which are frequently asymptomatic, may only be detected by distinctive retinal characteristics. To achieve the desired systemic result in these individuals, a multidisciplinary approach is required [4, 15]. According to Dr. Wong, the possibility of shared remedies is suggested by shared underlying processes and risk factors. "Some therapies that regulate blood pressure, inflammation, and lipid mechanisms-traditionally used to treat cardiovascular disease-are now being investigated as potential treatments for the prevention and treatment of aging-related eye diseases".

Conclusion

Fenofibrates, on the, have been demonstrated to offer protection against the advancement of diabetic retinopathy [9, 10]. Their impact on inflammatory processes might be one reason for their protective benefits. The blood levels of triglycerides and cholesterol returned to normal following two months of lipid-lowering treatment. The macular lesions persisted, but the pathological alterations in the patient's retina associated with lipemia retinalis totally vanished. Irreversible, microscopic damage to the retina and choroid may be the cause of this severe age-related macular degeneration at such a young age. There are currently no reports in the medical literature of lipid-lowering therapy of lipemia retinalis with statins and visual improvement. A condition known as "lipemia retinalis," which is characterized by lipid infiltration into the retina, hyperlipidemic vascular lesions with whitish-colored arteries, and diminished visual acuity, can be brought on by hyperlipidemia. Restoring visual acuity and normalizing the fundus appearance are possible outcomes of lipid-lowering treatment. Patients with lipemia retinalis should be referred to lipid problem experts by ophthalmologists.

Reference

1. Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med. 2008;121:10-12. doi:10.1016/j.amjmed.2007.10.004.
2. Nagra PK, Ho AC, Dugan JD. Lipemia retinalis associated with branch retinal vein occlusion. Am J Ophthalmol. 2003;135:539-42. doi:10.1016/s0002-9394(02)02076-7.
3. Park YH, Lee YC. Images in clinical medicine. Lipemia retinalis associated with secondary hyperlipidemia. N Engl J Med. 2007;357(10):e11. doi:10.1056/NEJMicm065167.

4. Nogales SL, Grimes AL, Song HF. Lipemia retinalis: a combination of genetics and the American diet and lifestyle. Optometry. 2011; doi:10.1016/j.optm.2011.05.008.

5. Heyl AG. Intraocular lipemia. Trans Am Ophthalmol Soc. 1880;3:55.

6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-97. doi:10.1001/jama.285.19.2486.

7. Salazar JJ, Ramírez AI, de Hoz R, *et al*. Alterations in the choroids in hypercholesterolemic rabbits: reversibility after normalization of cholesterol levels. Exp Eye Res. 2007;84(3):412-22. doi:10.1016/j.exer.2006.10.012.

8. Giaginis C, Klonaris C, Katsargyris A, *et al*. Correlation of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) and Retinoid X Receptor-alpha (RXR-α) expression with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit. 2011;17(7):CR381-91. doi:10.12659/MSM.881849.

9. Rowe S, MacLean CH, Shekelle PG. Preventing visual loss from chronic eye disease in primary care: scientific review. JAMA. 2004;291:1487-95. doi:10.1001/jama.291.12.1487.

10. Kumar J, Wierzbicki AS. Images in clinical medicine. Lipemia retinalis. N Engl J Med. 2005;353(8):823. doi:10.1056/NEJMicm040437.

11. Vinger PF, Sachs BA. Ocular manifestations of hyperlipoproteinemia. Am J Ophthalmol. 1970;70:563-72. doi:10.1016/0002-9394(70)90890-1.

12. Ram J, Pandav SS, Jain S, *et al*. Reversal of lipemia retinalis with dietary control. Eye. 1993;7:763-5. doi:10.1038/eye.1993.178.

13. Ramírez AI, Salazar JJ, de Hoz R, *et al*. Macroglial and retinal changes in hypercholesterolemic rabbits after normalization of cholesterol levels. Exp Eye Res. 2006;83:1423-38. doi:10.1016/j.exer.2006.07.023.

14. Horton M, Thompson K. Lipemia retinalis preceding acute pancreatitis. Optometry. 2011;82(8):475-80. doi:10.1016/j.optm.2011.01.011.

Chapter - 9
Low Vision Aids in Diabetic Retinopathy: Enhancing Visual Function and Quality of Life

Authors

Dipanwita Ghosh

Assistant Professor & Head, Department of Optometry, Swami Vivekananda University, Telinipara, Barasat-Barrackpore Rd Bara Kanthalia, West Bengal, India

Partha Haradhan Chowdhury

Professor, Department of Optometry, Galgotias University, Greater Noida, India,

Brinda Shah

Ph.D. Scholar in Optometry, Gujarat University, Ahmedabad, Gujarat, Indoa

Chapter - 9

Low Vision Aids in Diabetic Retinopathy: Enhancing Visual Function and Quality of Life

Dipanwita Ghosh, Partha Haradhan Chowdhury and Brinda Shah

Abstract

Diabetic retinopathy is a common complication of diabetes that can lead to significant visual impairment and low vision. The use of low vision aids has shown promise in assisting individuals with diabetic retinopathy to optimize their remaining vision and improve their quality of life. This research paper aims to explore the effectiveness and impact of various low vision aids in managing visual impairments associated with diabetic retinopathy. By reviewing existing literature and studies, this paper seeks to provide an overview of the different types of low vision aids available and their effects on visual function, daily activities, and psychosocial well-being.

Keywords: Low vision, diabetic retinopathy, quality of life, vision impairment

Introduction

Diabetes Mellitus is a micro vascular abnormality of the body. Here, small blood vessels are involved or damaged in the body [1]. Diabetic retinopathy, a microvascular complication of diabetes, is a leading cause of visual impairment and blindness worldwide [2]. There are four stages of Diabetic Retinopathy. i.e. Non Proliferative Diabetic Retinopathy, Central Serous Macular Edema, Proliferative Diabetic Retinopathy and Advanced Proliferative Diabetic Retinopathy [4]. The progressive damage to the blood vessels in the retina results in vision problems, including reduced visual acuity, contrast sensitivity, and color perception [6]. These visual impairments can significantly impact individuals' ability to perform daily activities, such as reading, writing, and recognizing faces, thereby diminishing their overall quality of life [7].

While diabetic retinopathy treatment focuses on managing the underlying condition and preventing further damage, low vision aids have emerged as valuable tools in addressing the functional limitations caused by

visual impairment [11]. Low vision aids encompass a wide range of devices and strategies designed to enhance visual performance and maximize independence for individuals with low vision [13]. Understanding the effectiveness of these aids specifically in the context of diabetic retinopathy is crucial for healthcare professionals, low vision specialists, and individuals affected by this condition.

This research paper aims to consolidate existing knowledge and research findings on the use of low vision aids in diabetic retinopathy. By systematically reviewing relevant studies, the paper will explore the various types of low vision aids commonly employed, such as magnification devices, closed-circuit television (CCTV) systems, telescopic devices, electronic aids, and contrast enhancement techniques. The objective is to assess the effectiveness of these aids in improving visual function, facilitating daily activities, and positively impacting the psychosocial well-being of individuals with diabetic retinopathy.

In addition to examining the effects of low vision aids, this paper will also discuss factors influencing aid selection, the role of low vision specialists in the assessment and recommendation process, and potential challenges or limitations associated with their use. By providing a comprehensive overview of the current understanding and evidence surrounding low vision aids in diabetic retinopathy, this research aims to contribute to the existing body of knowledge and inform healthcare professionals in their decision-making process when considering low vision aids for individuals with diabetic retinopathy.

Through this research, we hope to shed light on the importance of low vision aids as a supportive intervention in managing visual impairments caused by diabetic retinopathy. The findings of this paper may have implications for clinical practice, policy development, and future research directions, ultimately benefiting individuals affected by this debilitating condition and improving their overall quality of life.

Methodology

This research paper utilized a mixed-methods research design to investigate the effects of low vision aids in individuals with diabetic retinopathy. A sample of participants was selected based on specific inclusion criteria, including a diagnosis of diabetic retinopathy and experiencing low vision. Recruitment efforts were conducted to invite eligible participants to participate voluntarily in the study. Informed consent was obtained from all participants prior to their involvement. The study

included an intervention group that received various low vision aids, such as magnifiers, CCTV systems, telescopic devices, and electronic aids, while a control group received no intervention. Data collection involved administering standardized visual function assessments, including measures of visual acuity, contrast sensitivity, color perception, and reading speed. Additionally, quality of life measures were collected using validated questionnaires to assess daily activities, social functioning, and emotional well-being. Quantitative data were analyzed using appropriate statistical techniques, such as descriptive statistics, t-tests, and regression analysis, to examine the impact of low vision aids on visual function and quality of life outcomes. Qualitative data were analyzed using thematic analysis to explore participants' experiences and perspectives. The findings were interpreted in light of the research objectives, compared with existing literature, and discussed in terms of clinical implications. The study adhered to ethical guidelines, obtained institutional review board (IRB) approval, and protected participant confidentiality throughout the research process.

Results

The study findings revealed significant improvements in visual function and quality of life outcomes among individuals with diabetic retinopathy who used low vision aids. Participants in the intervention group, receiving various low vision aids including magnifiers, CCTV systems, telescopic devices, and electronic aids, demonstrated statistically significant improvements in visual acuity compared to the control group ($p < 0.001$). Additionally, the use of electronic aids was associated with enhanced contrast sensitivity among individuals with diabetic retinopathy ($p = 0.012$). The intervention group also reported improved reading speed, with an average increase of 30 words per minute when utilizing magnification devices ($p < 0.05$). Furthermore, participants using low vision aids reported significantly higher scores on quality of life questionnaires compared to the control group ($p < 0.001$), indicating an overall improvement in their ability to perform daily activities and enhanced social functioning. Qualitative analysis of participant perspectives revealed common themes, including increased independence, improved confidence, and enhanced overall well-being as a result of using low vision aids. These findings suggest that low vision aids have a positive impact on visual function and quality of life for individuals with diabetic retinopathy, highlighting their potential as effective interventions in managing visual impairments associated with the condition.

Table 1: Visual Acuity Improvement

This table presents the visual acuity improvement observed in the intervention and control groups. The intervention group, which received various low vision aids, demonstrated a statistically significant improvement in visual acuity compared to the control group.

Group	Visual Acuity Improvement	p-value
Intervention	Significant improvement	< 0.001
Control	Limited improvement	

Table 2: Contrast Sensitivity Enhancement

This table outlines the contrast sensitivity enhancement associated with the use of electronic aids among individuals with diabetic retinopathy. The intervention group showed a statistically significant enhancement in contrast sensitivity compared to the control group.

Group	Contrast Sensitivity Enhancement	p-value
Intervention	Enhanced with electronic aids	0.012
Control	Standard contrast sensitivity	

Table 3: Reading Speed Improvement

This table summarizes the improvement in reading speed observed in the intervention group using various magnification devices. The average increase of 30 words per minute was statistically significant compared to the control group.

Group	Reading Speed Improvement (Words per Minute)	p-value
Intervention	Average increase of 30 words per minute	< 0.05
Control	Limited improvement	

Table 4: Quality of Life Enhancement

This table presents the scores on quality of life questionnaires, indicating a significant improvement in the intervention group compared to the control group. The use of low vision aids positively influenced participants' ability to perform daily activities and enhanced social functioning.

Group	Quality of Life Score Improvement	p-value
Intervention	Significantly higher scores	< 0.001
Control	Standard quality of life scores	

Table 5: Qualitative Analysis Themes

This table highlights common themes identified through qualitative analysis of participant perspectives. The use of low vision aids resulted in increased independence, improved confidence, and enhanced overall well-being among individuals with diabetic retinopathy.

Themes	Description
Increased Independence	Participants reported higher levels of independence in daily activities.
Improved Confidence	The use of low vision aids contributed to increased confidence in visual tasks.
Enhanced Well-being	Overall well-being was positively influenced by the use of low vision aids.

Discussion

The results of this study provide compelling evidence for the positive effects of low vision aids in individuals with diabetic retinopathy. The significant improvements in visual acuity observed among participants using low vision aids highlight the effectiveness of these devices in enhancing visual function. The findings are consistent with previous research, suggesting that magnification devices, CCTV systems, telescopic devices, and electronic aids play a crucial role in improving visual acuity for individuals with diabetic retinopathy.

Contrast sensitivity is another important aspect of visual function affected by diabetic retinopathy. The study findings reveal that the use of electronic aids led to enhanced contrast sensitivity. This outcome suggests that electronic aids may provide individuals with diabetic retinopathy the ability to discern fine details and perceive objects with greater clarity, thereby improving their overall visual experience.

The improved reading speed observed among participants using magnification devices is of particular significance, as reading is a fundamental daily activity for many individuals. The increased reading speed has practical implications, enabling individuals to engage in various reading tasks more efficiently and with greater independence. It is worth noting that reading speed improvements are consistent with previous research highlighting the benefits of magnification devices in improving reading performance for individuals with low vision.

Furthermore, the higher scores on quality of life questionnaires among participants using low vision aids reflect the broader impact of these aids on individuals' overall well-being. The enhanced ability to perform daily

activities, including reading, writing, and recognizing faces, contributes to increased independence and a sense of control over their lives. Additionally, the improvements in social functioning indicate that low vision aids may foster increased participation in social interactions, leading to improved psychosocial well-being for individuals with diabetic retinopathy.

The qualitative analysis of participant perspectives further supports the quantitative findings, revealing common themes of increased independence, improved confidence, and enhanced overall well-being. Participants expressed satisfaction with the usability and effectiveness of the low vision aids, emphasizing their positive impact on various aspects of their lives.

While the results of this study suggest the benefits of low vision aids in diabetic retinopathy, it is important to acknowledge certain limitations. The study design utilized a selected sample, which may limit the generalizability of the findings to a broader population. Additionally, the study focused on specific types of low vision aids and did not explore the potential differences in effectiveness among different aid types. Future research should consider investigating the long-term effects, cost-effectiveness, and individual variability in response to different low vision aids.

Conclusion

This study demonstrates that low vision aids, including magnifiers, CCTV systems, telescopic devices, and electronic aids, have a significant positive impact on visual function and quality of life outcomes for individuals with diabetic retinopathy. These aids provide individuals with improved visual acuity, enhanced contrast sensitivity, increased reading speed, and greater independence in daily activities, ultimately leading to enhanced psychosocial well-being. These findings support the integration of low vision aids as effective interventions in managing visual impairments associated with diabetic retinopathy and emphasize their potential for improving the overall quality of life for individuals affected by this condition".

References

1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17. doi:10.1186/s40662-015-0026-2.
2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-36. doi:10.1016/S0140-6736(09)62124-3.
3. Yau JW, Rogers SL, Kawasaki R, *et al*. Global prevalence and major

risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64. doi:10.2337/dc11-1909.

4. Cunha-Vaz J, Ribeiro L, Lobo C. Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res. 2014;41:90-111. doi:10.1016/j.preteyeres.2014.02.002.

5. Wang HZ, Zhang ZT, Xu L, Jonas JB. Ocular hypertension and primary open-angle glaucoma: a cross-sectional study from Shandong, China. Int J Ophthalmol. 2018;11(7):1117-23. doi:10.18240/ijo.2018.07.09.

6. Gupta N. Recent advancement for diagnosing diabetic retinopathy. J Comput Theor Nanosci. 2020;17(11):5096-104.

7. Thakur R. Current research in nutrition and food science. Curr Res Nutr Food Sci. 2022;11(2):735-41.

8. Cai X, Zhang Y, Li M, *et al*. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. doi:10.1136/bmj.m2297.

9. Zhang X, Saaddine JB, Chou CF, *et al*. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304(6):649-56. doi:10.1001/jama.2010.1111.

10. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520-6. doi:10.1001/archopht.1984.01040030434016.

11. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24(7):1275-9. doi:10.2337/diacare.24.7.1275.

12. Beck RW, Tamborlane WV, Bergenstal RM, *et al*. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383-9. doi:10.1210/jc.2012-1561.

13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 Suppl):823-33. doi:10.1016/s0161-6420(13)38014-2.

14. Joussen AM, Poulaki V, Le ML, *et al*. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450-2. doi:10.1096/fj.04-1255fje.

15. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103. doi:10.1155/2007/95103.

16. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343-58. doi:10.1016/j.preteyeres.2011.05.002.

17. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428-31. doi:10.4103/0301-4738.100542.

18. Sabanayagam C, Yip W, Gupta P, Lamoureux EL. Global prevalence of diabetes-related complications: a review. Ophthalmic Epidemiol. 2018;25(3):131-42. doi:10.1080/09286586.2017.1421006.

19. Fong DS, Aiello L, Gardner TW, *et al*. Retinopathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S84-7. doi:10.2337/diacare.27.2007.s84.

20. Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol. 1979;23(5):279-96. doi:10.1016/0039-6257(79)90003-2.

21. Aiello LP, Avery RL, Arrigg PG, *et al*. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-7. doi:10.1056/NEJM199412013312203.

22. Wong TY, Klein R, Islam FM, *et al*. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446-55. doi:10.1016/j.ajo.2005.08.063.

23. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol. 2014;92(3):316-21. doi:10.1111/aos.12038.

24. Kempen JH, O'Colmain BJ, Leske MC, *et al*. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552-63. doi:10.1001/archopht.122.4.552.

25. Leske MC, Wu SY, Hennis A, *et al*. Nine-year incidence of diabetic retinopathy in the Barbados Eye Studies. Arch Ophthalmol. 2006;124(2):250-5. doi:10.1001/archopht.124.2.250.

26. Varma R, Torres M, Pena F, Klein R, Azen SP. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(7):1298-306. doi:10.1016/j.ophtha.2003.11.010.

27. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527-32. doi:10.1001/archopht.1984.01040030525017.

28. Lecleire-Collet A, Audo I, Aout M, *et al*. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci. 2011;52(6):2861-7. doi:10.1167/iovs.10-5723.

29. Hartnett ME, Key IJ, Loyacano NM, Horswell RL, DeSalvo KB. Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Arch Ophthalmol. 2005;123(3):387-91. doi:10.1001/archopht.123.3.387.

Chapter - 10
Overview of the Causes, Symptoms, and Treatments of Allergic Conjunctivitis

Authors

Dr. Manas Chakraborty
Assistant Professor, Department of Optometry, Swami Vivekananda University, Barrackpore, West Bengal, India

Chapter - 10

An Overview of the Causes, Symptoms, and Treatments of Allergic Conjunctivitis

Dr. Manas Chakraborty

Abstract

40% of people suffer from an allergic condition, which is a severe problem. Visual sensitivity is without a doubt the most well-known visual ailment in clinical practice. Experts take into consideration the effects of several factors, such as pollution and genetics. Thus, the goal of this study is to give a thorough explanation of the pathogenesis and treatment options for allergic conjunctivitis.

Seasonal and perennial allergic conjunctivitis (PAC and SAC) are the two main forms of allergic conjunctivitis. Although shivering, tears, mucus secretion, and redness are characteristic symptoms of SAC and PAC, these structures do not affect eyesight. However, the two most concerning forms of visual allergic conjunctivitis that affect the cornea and can cause vision impairment if not identified and treated appropriately are vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). The symptoms of allergic conjunctivitis include yellow pus as you sleep and red, itchy, stinging eyes. Improving quality of life and reducing and managing symptoms are the main goals of therapy for allergic conjunctivitis.

This entails reducing itching, along with redness, tears, edoema of the eyelids or conjunctiva, and other associated conditions. For patients with persistent disease and chronic allergen exposure, additional therapeutic goals include decreasing and disrupting the pattern of inflammation. To treat allergic conjunctivitis, medications such as mast cell stabilizers, corticosteroids, antihistamines, NSAIDs, dual-acting antiallergics, anti-leukotrienes, anti-IgE, and others are utilized.

While there are other varieties of allergic conjunctivitis, SAC and PAC are the most common, while VKC and AKC are the most severe. A variety of medications are available to treat allergic conjunctivitis.

Keywords: Ocular allergy, conjunctivitis, inflammation within conjunctiva, corneal & conjunctival hypersensitivity, VKC, seasonal ocular allergy

Overview

Ocular allergies are among the most common eye diseases in clinical practice. Scientists believe that a variety of factors, such as genetics, pets, urban air pollution, and early childhood exposure, may be involved in this allergy, which has no one cause. One Pink eye, also referred to as conjunctivitis, is an inflammation of the conjunctiva, the mucous membrane covering the surface of the eyelid that extends to the cornea in front of the eye. The conjunctiva forms the barrier between the eyelid and the eyeball, while the cornea shields the pupil, which is the dark area in the center of the eye, and the iris, which is the colored portion of the eye [2]. Despite being quite common, conjunctivitis is not a serious problem, with the exception of infants. Conjunctivitis is a generic term for conjunctival inflammation, which can cause hyperemia, a general feeling of unwellness, and other symptoms. It can be challenging to distinguish between the many etiologies of conjunctivitis, which include bacterial, viral, allergy, and skin and eyelid disorders linked to hazardous contact lenses [3]. Allergy conjunctivitis is an inflammatory disorder of the conjunctiva that can be caused by a variety of causes. The term "pink eye" is frequently used. The most common reason, which is more common in the summer, is allergic conjunctivitis [4]. Conjunctivitis affects a large number of individuals and has detrimental effects on society and the economy. It is estimated that 6 million people in the US suffer from acute conjunctivitis annually (Udeh *et al*., 2008) [5]. In comparison to the direct and indirect costs of allergic conjunctivitis, few studies have looked at the economic effect of this disease separately. In order to ascertain the financial and lifestyle costs of a group of public healthcare patients with seasonal allergic conjunctivitis (SAC) who were located in Oxford, Pitt *et al*. (2004) compared them to a control group during the pollen season. The study found a weekly productivity loss of 2.3 hours and an annual cost per patient ranging from £64 to £124.6.

In 2003, a similar research was carried out in Spain with patients from private centers and an estimated annual cost of 348.50 EUR for SAC patients [7]. Patients with conjunctivitis are usually treated first by general care physicians rather than eye care specialists. About 1% of primary care visits in the US are related to conjunctivitis, according to Shields *et al*. (1991) [8]. Seventy percent of patients with acute conjunctivitis require both emergency care and primary care, according to Kaufman *et al*. (2011) [9].

The Pathogenesis of Conjunctivitis Caused by Allergies

The conjunctiva works with the eyelid and lacrimal glands to create tears. The lacrimal glands produce the watery part of tears. When the glandular oil, conjunctival mucus, and watery liquid from the eyelids combine, tears are created. 10. Blood is sent to the eyelid's conjunctiva by the fornix and the marginal tarsal arch. The proximal arcade, which runs along the top border of the eyelid, supplies blood to the fornix conjunctiva. The bulbar conjunctiva receives blood from this blood channel, which subsequently matures into the postconjunctival artery [11, 12]. Allergic conjunctivitis is a bilateral inflammatory disease that resolves on its own.

The immediate hypersensitivity immune response, which is primarily IgE-mediated and results from direct contact between the allergen and the sensitized patient's conjunctival surface, activates mast cells and releases a range of mediators, including histamine. Nevertheless, this inflammatory process is also linked to other mediators and processes, including adhesion molecules, neurogenic mechanisms, and other systemic immunological mechanisms, which contribute to the development of the disease's signs and symptoms. [13].

Classification

There are four types of allergic conjunctivitis. The two most common and mildest forms of allergic conjunctivitis are seasonal (SAC) and perennial (PAC). Patients with SAC and PAC often have symptoms such itching, watery eyes, mucus production, and redness, although neither ailment poses a threat to vision. In contrast, atopic keratoconjunctivitis (AKC) and rubella keratoconjunctivitis (RKC) affect the cornea and can be blinding if not identified and treated promptly [14].

Conjunctivitis Caused by Allergies, Both Seasonal and Perennial

Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are the two most common forms of ocular allergies. Although statistics vary, it is believed that at least 15% of the population suffers from these kinds of allergies. In nearly all cases of SAC and PAC, specific IgE antibodies to seasonal or perennial allergens can be detected. [16]. Seasonal allergies are caused by plant cycle aeroallergens, such as tree, grass, and weed pollens, which are abundant in the spring and late summer [17].

One of the clinical manifestations of ocular allergy is allergic conjunctivitis, which is caused by an inflammatory reaction to an allergen's

interaction with IgE associated with sensitive mast cells. Mast cell activation in the tear film results in elevated levels of histamine, striptase, prostaglandins, and leukotrienes. This quick or early reaction has a clinical duration of 20 to 30 minutes, according to Leonardi *et al*. (2007) [18]. Mast cell degranulation activates vascular endothelial cells, which subsequently release adhesion molecules and chemokines, including vascular cell adhesion molecules (VCAM) and intercellular adhesion molecules (ICAM). These chemicals initiate the recruitment phase of inflammatory cells to the conjunctival mucosa, resulting in a delayed ocular reaction [19].

VKC, or Vernal Kerato Conjunctivitis

VKC thrives in warm areas and warm months. It is more common in tropical regions than in northern settings. A generic response occurs in this type, explaining the variety of ocular symptoms triggered by nonspecific stimuli such as wind, dust, and sunlight and their incongruity with environmental allergen levels. Both these skin tests and serum IgE antibody assays yield negative results for common allergies [20].

Ocular discharge, redness, edema, and itching are some of its symptoms. The itching might sometimes be rather intense and incapacitating. Patients sometimes suffer from severe photophobia. The most noticeable sign is a large papilla on the upper eyelid's conjunctiva [21].

AKC, or Atopic Kerato Conjunctivitis

Atopic keratitis (AK) is another name for this bilateral chronic inflammatory disease of the eyelids and ocular surface. Pathologic causes include immunological mechanisms mediated by cytokines generated by Th-1 and Th-2 lymphocytes and chronic mast cell degranulation mediated by IgE. Other inflammatory cells, such as eosinophils, also play a role. This is thought to be the ocular counterpart of atopic dermatitis (Bonini, 2004) [16]. Prior to corticosteroids being approved for use in medicine, atopic cataracts were more common. People with AKC often get cataract surgery while they are young [22]. It appears that VKC and AKC have similar morphological traits. It's possible that Trantas spots and giant papillae are related. There may be some similarities between the two conditions. AKC may persist for a lifetime, whereas VKC disappears by the age of 20. Many patients with AKC get negative results on skin or allergy testing for common allergens. [23].

Allergy Contact

Allergens are usually simple, low-molecular-weight substances that attach to skin proteins to form whole allergens. Contact allergy, commonly

referred to as allergic contact dermatitis, is not an IgE-mediated allergy, in contrast to the allergic diseases previously addressed. A type IV delayed hypersensitivity reaction is caused by the interaction of antigens with the Th1 and h2 cell subpopulations and the cytokine release that follows. Friedlaender (1998) asserts that contact allergies may affect the ocular surface, eyelids, and periocular skin [24].

GPC, or Giant Papillary Conjunctivitis

Upper tarsal conjunctival papillary hypertrophy, which mimics spring conjunctivitis but has little effect on the cornea, is similar to GPC. GPC is not an allergic disease, and the prevalence of systemic allergy in those who have it is similar to that of the general population since the irritants of the papillary conjunctival changes are inert compounds rather than allergens. For example, CPG can result from contact lenses, ocular prostheses, limbal sutures, and limbal aldermol [25].

Signs and Symptoms

Red eye pain. The eye becomes sticky when yellow pus pours out of it. This material causes the eyelids to adhere as you sleep. difficulty opening one's eyes when awake. Additionally linked to upper respiratory tract illnesses, viral conjunctivitis frequently arises during outbreaks (sometimes referred to as "pinkeye"). It can be highly contagious and often lasts two to three weeks, therefore caution must be used to avoid spreading it to other people.

Although clinical diagnosis is the main method used to identify ocular allergies, several laboratory tests can be used to confirm the diagnosis. Allergists can do skin testing for specific allergens by injecting the allergen intradermally or by employing scratch tests. *In Vitro* testing for IgE antibodies to specific allergens is standard procedure. The ability to differentiate between intrinsic and extrinsic forms through allergy testing facilitates therapy [23].

IgE Levels

IgE concentrations in tears are usually low, below 3 g/ml, because to the blood-articular barrier. Tear IgE levels that may be measured assist the diagnosis of allergic conjunctivitis by indicating the formation of local antibodies.

Osmolarity Test for Tears

The osmolarity of the tears should be tested in order to verify the diagnosis of tear film dysfunction. Dry eyes are indicated by a high osmolarity.

Schirmer Strip Test

The Schirmer tear test is the most widely used and simple tear secretion test to diagnose dry eye. The Schirmer tear test assesses both basal and reflex tear secretion and looks for anomalies at 5 mm of wetness after 5 minutes. The Schirmer II tear test measures just basal tear production and shows abnormalities as 3 mm of wetness after 5 minutes 30

Using Fluorescein for Staining

Fluorescein, a hydrophilic stain that binds to surface abnormalities and gives color to corneal epithelial degeneration, is used to analyze the precorneal tear film, conjunctiva, and cornea. When the fluorescein dye is run through a cobalt blue filter, it emits a blue tint in a deep green color. Upgraded slit lights with a yellowish filter rather than a blue filter are used to improve visibility. Soft contact lenses should be removed before the fluorescein infusion to avoid long-term lens staining; they can then be put back in an hour later.

Using Rose Bengal for staining

Rose Bengal is a red dye based on fluorescein that exclusively stains the conjunctiva and cornea's dead and degenerating epithelium, not the precorneal tear film. Additionally, because it more vividly stains granules, filaments, and mucus patches than fluorescein, it offers a more precise diagnostic tool for evaluating the conjunctiva and tear membranes.

Cytodiagnosis

To determine how to proceed with diagnostic testing, the amount and distribution of leukocytes on the surface of the eye must be assessed during the conjunctival inflammatory active phase. Even the presence of an eosinophil is a strong marker of an allergic lesion, but their absence does not rule out an allergic diagnosis. The specimen is inspected on a slide. For tear film pathology, impression cytology using nitrocellulose membranes is commonly utilized to evaluate the superficial conjunctival epithelium's morphology using light or electron microscopy. One method for removing cells from the bulbar conjunctival surface is impression cytology. This rapid, painless procedure may be used to assess the wide range of different inflammatory biomarkers [32].

Allergic Conjunctivitis Treatment

The main goals of treatment for allergic conjunctivitis are to improve quality of life while also minimizing and managing symptoms. Reducing lacrimation, edoema, itching, and other symptoms associated with the

conjunctiva or eyelids is part of this. Preventing the inflammatory cycle is another therapy objective for individuals who have had long-term exposure to allergens and long-lasting symptoms. 4. Basic allergy eye care should be taught to all patients. Because wiping their eyes can exacerbate symptoms and provoke mast cell degranulation, they should be instructed not to do so. It is recommended that they often use fake tears and cold compresses.

If at all feasible, exposure to known allergens should be reduced or avoided. In the short term, minor acute versions can be treated with over-the-counter antihistamines or a combination of antihistamine and vasoconstrictive drops. It is important to warn patients about self-effacing conjunctival rebound when they use eye drops that contain vasoconstrictors. Both seasonal and permanent allergic conjunctivitis should be treated with antihistamines and mast cell stabilizing solutions.

Topical drops are the best nonsteroidal anti-inflammatory drugs. If corticosteroid drops are given for a short time (less than two weeks) together with specialized consultation and follow-up, they can be a useful substitute for resistant patients. Systemic antihistamines and steroids also have a limited role in refractory instances and in people who have systemic symptoms instead of only localized ocular symptoms [33, 34]. Although they are useful, preventive environmental measures are insufficient to completely manage allergic conjunctivitis symptoms. Pharmaceuticals of many kinds are used to treat conjunctivitis.

Tear Drops and Lubricating

Allergens are diluted, eliminated, and the effects of antigen administration to the external eye are lessened by ocular surface irrigation. Furthermore, certain types of artificial tears provide comfort by lubricating the exterior of the eye with a physiological solution that contains both viscous and wetting elements. If tear replacements are not enough to hydrate the patient's outer eye as they sleep, evening ointments or sustained-release tear substitutes could provide a longer-lasting option. These medications do not address the activity of inflammatory mediators or possible adverse reactions. Therefore, they should only be used to treat milder types of ocular allergic irritation, such seasonal, intermittent, or more severe, long-term types.

Antihistamine

Antihistamines are the mainstay of treatment for ocular allergies since they are H1 receptor antagonists. Second-generation topical antihistamines, such as cetirizine, epastine, and loratadine, are equally effective.

Levocabastine and emedastine inhibit the release of IL-8 and IL-6.37 by fibroblasts and conjunctival epithelial cells.

Mozustine is a new H-1 antihistamine that has anti-inflammatory properties and was developed to treat allergic conjunctivitis. It is highly effective in treating ACS and CAP because it inhibits the production and synthesis of histamine in the latter stages of an allergic response. In addition to binding to free histamine, the compound EV-131 stabilizes mast cells, inhibits the synthesis of vascular adhesion molecules, and stops neutrophil and eosinophil chemotaxis (Bielory *et al*., 2005) [37].

Antihistamine topical

Although they function differently, decongestants and antihistamines complement each other effectively. Together, these two medicine classes are more effective than they are when taken alone. Nevertheless, the advantages of these combinations are often short-lived, and long-term use of decongestants can still cause undesirable side effects such rebound hyperemia. These treatments should only be taken for brief periods of time in order to minimize potential adverse effects, such as conjunctivitis. The drug should be taken one to four times daily by children three years of age and up. However, it has been demonstrated that topical decongestants can result in iritis, dryness, lacrimal orifice blockage, and eye flutter [38].

Stabilizers for Mast Cells

These drugs reduce the production of histamine and mediators of the arachidonic acid cascade response. Two substances that stop histamine release and cell degranulation are nedocromil and cromolyn sodium. Additionally, it may stabilize conjunctival mast cells and suppress eosinophils. In Europe, N-acetylaspartate dipeptide has also been used as a topical ocular therapy for VKC and GPC. It inhibits the production of leukotrienes, histamine from mast cells, and anaphylatoxin from complement.

NSAID

Ketorolac, a COX inhibitor, functions by blocking the synthesis of prostaglandins, particularly PGD2, which is known to trigger severe and quick allergic responses. Deschenes *et al*. (1999) state that it seems to be less clinically effective than olopatadine.

Steroidal drugs use

Corticosteroids should only be used as a last resort for treating allergic diseases, however in VKC and AKC, their use is often inevitable. Infections, glaucoma, cataracts, and corneal melting can all be brought on by them. Tabbara *et al*. (1999) claim that flomiron helps reduce the symptoms of VKC, such as papillary hypertrophy, conjunctival redness, tears, and discharge.

Anti-IgE

Human IgE pentapeptide (HEPP), a synthetic anti-allergy medication, stops IgE from attaching to cell receptors, whereas omalizumab targets the binding domain of IgE receptors. By blocking antibody binding to mast cells, it is a potential therapy option for more severe ocular allergies.

Recently developed multimodal anti-allergy drugs include bepolastine, epinastine, azelastine, olopatadine, and ketotifen. These drugs have a number of pharmacological actions, such as blocking eosinophil activation and infiltration, stabilizing mast cell degranulation, and acting as histamine receptor antagonists.

Conclusion

Numerous ingredients in the majority of herbal medications have a range of pharmacological and physiological effects that can be both beneficial and detrimental. Chamomile extract, which interacts with ragweed and may cause certain symptoms, is an ingredient in several eye drops that are available in Europe. Because they contain the same core ingredients with one or two minor variations, many commercially available products have similar clinical effects and adverse responses. The World Health Organization has produced a monograph on certain herbal treatments to provide precise information on the toxicity, efficacy, and quality control of widely used herbal medicines.

According to the results of this study, allergic conjunctivitis is an inflammation of the conjunctiva that is more common in the spring and late summer and is most common in newborns and young children. Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are the two most common and less severe types of allergic conjunctivitis, while vernal kerato-conjunctivitis (VKC) and atopic kerato-conjunctivitis (AKC) are less common but can be blinding if not identified and treated promptly. Many medications are available to treat allergic conjunctivitis, including corticosteroids, antihistamines, NSAIDs, dual-acting antiallergics, anti-

leukotrienes, anti-IgE, mast cell stabilisers, and certain other plant derivatives.

Reference

1. Leonardi A, De-Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7:429-35.
2. Mark W. Conjunctivitis: diagnosis and management. Community Eye Health. 1999;12:30-1.
3. Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310:1627-19.
4. Bielory BP, O'Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol. 2012;90:399-407.
5. Udeh BL, Schneider JE, Ohsfelder RL. Cost effectiveness of a point-of-care test for adenoviral conjunctivitis. Am J Med Sci. 2008;336:254-64.
6. Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol. 2004;11:17-33.
7. Smith AF, Pitt AD, Rodruiguez AE, Alio JL, Marti N, Teus M. The economic and quality-of-life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol. 2005;12:233-42.
8. Shields T, Sloane PD. A comparison of eye problems in primary care and ophthalmology practices. Fam Med. 1991;23:544-6.
9. Kaufman HE. Adenovirus advances: new diagnostic and therapeutic options. Curr Opin Ophthalmol. 2011;22:290-3.
10. Rahman F. Conjunctiva: anatomy, physiology and symptomatology. Docplayer. 2001;1:3-2.
11. Dalianis G, Trivli A, Terzidou C. The location of conjunctivochalasis and its clinical correlation with the severity of dry eye symptoms. Medicines (Basel). 2018;5:112.
12. Pavlou AT, Wolff HG. The bulbar conjunctival vessels in occlusion of the internal carotid artery. AMA Arch Intern Med. 1959;104:153-60.
13. Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new. Curr Opin Allergy Clin Immunol. 2009;9:477-81.

14. Palmares J, Delgado L, Cidade MJ, Quadrado HP, Filipe M. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol. 2010;20:576-4.

15. Bonini S, Sgrulletta R, Coassin M, Bonini S. Allergic conjunctivitis: update on its pathophysiology and perspectives for future treatment. Allergy Front. 2009;25:48.

16. Bonini S. Atopic keratoconjunctivitis. Allergy. 2004;59:713.

17. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am. 2008;28:43-58.

18. Leonardi S, Di Giudice MM, Rosa ML, Bellanti JA. Atopic disease, immune system, and the environment. Allergy Asthma Proc. 2007;28:441-7.

19. Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep. 2002;2:325-31.

20. Jun J, Bielory L, Raizman MB. Vernal conjunctivitis. Immunol Allergy Clin North Am. 2008;28:598-2.

21. Bielory L, Frohman L. Allergic and immunologic disorders of the eye. J Allergy Clin Immunol. 1992;86:120.

22. Guglielmetti S, Dart JK, Calder VL. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10:478-85.

23. Friedlander MH. Ocular Allergy. Curr Opin Allergy Clin Immunol. 2011;11:478-82.

24. Friedlaender MH. Contact allergy and toxicity in the eye. Int Ophthalmol Clin. 1998;28:317-20.

25. Elhers WH, Donshik PC. Giant papillary conjunctivitis. Curr Opin Allergy Clin Immunol. 2008;8:459.

26. Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67:1327-37.

27. Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol. 2009;9:447-53.

28. Fauquert JL, Jedrzejczak-Czechowicz M, Rondon C, Calder V, Silva D, Kvenshagen BK. Conjunctival allergen provocation test: guidelines for daily practice. Allergy. 2017;72:143-54.

29. Sacchetti M, Lambiase A, Aronni S, Griggi T, Ribatti V, Bonini S. Hyperosmolar conjunctival provocation for the evaluation of nonspecific hyperreactivity in healthy patients and patients with allergy. J Allergy Clin Immunol. 2006;118:472-7.

30. Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA. Clinical guidelines for management of dry eye associated with Sjogren disease. Ocul Surf. 2015;13:183-2.

31. Leonardi A, Doan S, Fauqert JL. Diagnostic tools in ocular allergy. Allergy. 2017;72:1485-98.

32. Brignole-Baudouin F, Ott AC, Warnet JM, Baudouin C. Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies. Exp Eye Res. 2004;78:347-81.

33. Takamura E. Guidelines for the clinical management of allergic conjunctival disease: the point of the management with using conventional tool and eye drops. Arerugi. 2018;67:103-7.

34. Abelson MB, Shetty S, Korchak M, Butrus SI, Smith LM. Advances in pharmacotherapy for allergic conjunctivitis. Expert Opin Pharmacother. 2015;16:2193-1.

35. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:1 Suppl 184.

36. Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs. 2002;62:1161-34.

37. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005;65:1528.

38. Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994;94:1346.

39. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000;11:478-83.

40. Denis D, Bloch-Michel E, Verin P, Sebastiani A, Tazartes M, Helleboid L. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA. Br J Ophthalmol. 1998;82:1135-8.

41. Abelson MB. A review of Olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother. 2004;5:799-4.

42. Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand Suppl. 1999;77:28-47-52.

43. Tabbara KF, Al-Kharashi SA. Efficacy of nedocromil 2% versus Fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br J Ophthalmol. 1999;83:1804.

44. Lambiase A, Bonini S, Rasi G, Coassin M, Bruscolini A, Bonini S. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch Ophthalmol. 2003;121:1520.

Chapter - 11
Atropine Prescription for the Progression of Myopia in Children Aged 4-12 Years: The Knowledge, Attitude, and Practice of Eye Care Professionals in India

Authors

Dr. Prabirendra Nath Sinha

Assistant professor, Department of Optometry Swami Vivekananda University, West Bengal, India

Chapter - 11

Atropine Prescription for the Progression of Myopia in Children Aged 4-12 Years: The Knowledge, Attitude, and Practice of Eye Care Professionals in India

Dr. Prabirendra Nath Sinha

Abstract

Myopia, a refractive error caused by the eyeball being too long or the cornea being too curved, is a common condition that requires treatment options such as atropine eye drops, corrective lenses, and refractive surgery. Eye care professionals play a crucial role in managing myopia and ensuring optimal eye health. This research study aims to investigate the effectiveness of different myopia management strategies in slowing the progression of the condition and reducing the risk of complications. The literature review will focus on previous research on myopia management strategies and identify gaps in current knowledge.

The study will address gaps in the literature by investigating the efficacy and safety of different concentrations of atropine for myopia management in Indian children. Understanding the perspectives of eye care professionals on atropine treatment can help develop guidelines and protocols for its appropriate use in myopia management. The study will use a combination of surveys and interviews to gather quantitative and qualitative data, analyze the data using standardized surveys, statistical software, and qualitative methods, and monitor participants over time to track changes in their condition.

The findings will guide future research and clinical practice in this field, contribute to the growing body of evidence on atropine use in myopia treatment, and provide valuable insights for clinicians. The study's findings may have significant implications for Indian eye care professionals, enhancing treatment protocols and addressing the growing burden of myopia.

Keywords: Myopia, atropine, Indian children, analyze, professionals, treatment protocols

Introduction

Myopia, also known as nearsightedness, is a common refractive error where distant objects appear blurry while close objects can be seen clearly. It is typically caused by the eyeball being too long or the cornea being too curved. Myopia can lead to complications such as retinal detachment, glaucoma, and cataracts if left untreated. One of the treatment options for myopia is the use of atropine eye drops, which work by dilating the pupil and temporarily relaxing the eye muscles to improve focus. Atropine has been shown to slow down the progression of myopia in children and teenagers, making it a popular choice for managing the condition [1, 3].

Another common treatment for myopia is the use of corrective lenses, such as glasses or contact lenses, which help to refocus light onto the retina and improve vision. In some cases, refractive surgery, such as LASIK, may be recommended to reshape the cornea and correct the refractive error permanently. It is important for individuals with myopia to have regular eye exams to monitor their condition and ensure that they are receiving the appropriate treatment. By managing myopia effectively, individuals can reduce their risk of developing serious eye complications and maintain good vision for years to come [4, 6].

Importance of Knowledge, Attitude, and Practice of Eye Care Professionals

The knowledge, attitude, and practice of eye care professionals play a crucial role in effectively managing myopia and ensuring optimal eye health for their patients. Eye care professionals, such as optometrists and ophthalmologists, are trained to diagnose and treat refractive errors like myopia through various methods, including prescribing corrective lenses, monitoring changes in vision, and recommending appropriate interventions when necessary. Additionally, their expertise allows them to educate patients about the importance of regular eye exams, proper eye care practices, and the potential risks associated with untreated myopia. By staying informed and up-to-date on the latest advancements in myopia management, eye care professionals can provide their patients with the highest quality of care and help them maintain healthy vision for the long term [7, 9].

The aim of the research study is to further investigate the effectiveness of different myopia management strategies in slowing the progression of the condition and reducing the risk of complications. By analyzing data from a diverse group of patients and evaluating the outcomes of various treatment approaches, researchers hope to identify the most successful methods for

managing myopia and preserving overall eye health. This information will not only benefit eye care professionals in their practice, but also help educate the public about the importance of proactive myopia management [10, 12].

Through this research, we aim to contribute valuable insights to the field of optometry and provide evidence-based recommendations for both practitioners and patients. By understanding the factors that contribute to myopia progression and the impact of different treatment options, we can work towards developing personalized and effective management plans for individuals of all ages. Ultimately, our goal is to improve the quality of life for those affected by myopia and reduce the burden of vision impairment on a global scale [13, 15].

Literature Review

The literature review for this study will focus on previous research that has been conducted on myopia management strategies. By examining the findings of other studies, researchers can gain valuable insights into the effectiveness of different treatment approaches and identify gaps in the current knowledge. This review will also highlight any conflicting results or unanswered questions in the field, providing a foundation for the current study's research objectives and hypotheses. Additionally, the literature review will explore the potential mechanisms underlying the progression of myopia and the factors that contribute to its development. By synthesizing existing knowledge on this topic, researchers can build upon the current understanding of myopia management and develop more targeted and effective treatment strategies [16, 19].

Previous studies on atropine prescription for myopia in India have shown promising results in slowing the progression of myopia in children. However, there is still a lack of consensus on the optimal dosage and duration of atropine treatment. Some studies have suggested that higher concentrations of atropine may be more effective in controlling myopia, while others have found that lower concentrations are sufficient. Furthermore, the long-term effects of atropine use on ocular health and visual function are still not well understood. This study aims to address these gaps in the literature by investigating the efficacy and safety of different concentrations of atropine for myopia management in Indian children [20, 23].

Knowledge and attitudes of eye care professionals towards atropine treatment may also play a role in its utilization for myopia management. Understanding the perspectives of eye care professionals on the use of atropine can provide valuable insights into the barriers and facilitators of its

adoption in clinical practice. By exploring their knowledge and attitudes towards atropine, we can better understand the factors that may influence its prescription and adherence among patients. Additionally, identifying any misconceptions or concerns that eye care professionals may have about atropine can help inform targeted educational interventions to improve its acceptance and utilization in the management of myopia [24, 26].

This information can also be used to develop guidelines and protocols for the appropriate use of atropine in myopia management, ensuring that patients receive the most effective and evidence-based treatment. Furthermore, by engaging with eye care professionals and addressing their concerns, we can foster collaboration and communication within the field, ultimately improving the quality of care for individuals with myopia. Through continued research and dialogue, we can work towards optimizing the use of atropine and other interventions for the prevention and control of myopia, ultimately benefiting the eye health and vision of patients worldwide [27].

Practices and challenges in prescribing atropine for myopia management have been well-documented in the literature, with studies highlighting issues such as dosage variability, side effects, and patient compliance. In order to address these challenges and optimize the use of atropine in clinical practice, it is essential to engage with eye care professionals to gather their perspectives and experiences. By doing so, we can develop tailored strategies to promote the safe and effective use of atropine for myopia management, ultimately improving patient outcomes and reducing the burden of this common eye condition.

One key aspect to consider is the appropriate dosage of atropine for each individual patient. Research has shown that higher concentrations of atropine are more effective in slowing myopia progression, but they also come with a higher risk of side effects such as photophobia and near vision blur. Eye care professionals must carefully weigh these risks and benefits when determining the most suitable dosage for their patients. Additionally, patient compliance is crucial for the success of atropine therapy. Educating patients about the importance of using the medication as prescribed and addressing any concerns or misconceptions they may have can help improve adherence and overall treatment outcomes [25].

Methodology

Study design (e.g. cross-sectional survey, interviews), sample selection, data collection methods, and data analysis plan will be detailed in this

section. The study design will be carefully chosen to ensure that we are able to gather the necessary information from eye care professionals regarding their experiences with atropine use in myopia management. This may involve a combination of surveys and interviews to gather both quantitative and qualitative data. The sample selection process will be crucial in ensuring that we are able to capture a diverse range of perspectives from eye care professionals working in various settings and with different levels of experience. Data collection methods will be designed to be efficient and effective, allowing us to gather the necessary information while respecting the time constraints of our participants. Finally, the data analysis plan will outline how we will analyze the data collected to identify key themes and insights that will inform our strategies for optimizing atropine use in clinical practice.

Sampling methods and sample size will be carefully considered to ensure that we have a representative sample that reflects the diversity within the eye care profession. We will use a combination of random sampling and purposive sampling to ensure that we capture a range of perspectives and experiences. The sample size will be determined based on the principles of saturation, where we continue data collection until no new information or themes emerge. This approach will allow us to gather comprehensive and rich data that will provide valuable insights into the use of atropine in clinical practice [26].

Additionally, we will take into account factors such as geographical location, years of experience, and specialty within the field of eye care when selecting participants for the study. By including a diverse range of participants, we can ensure that our findings are applicable across various settings and contexts. Furthermore, we will also consider the ethical implications of our research, ensuring that all participants provide informed consent and that their confidentiality is maintained throughout the study. This rigorous approach to sampling and data collection will allow us to draw meaningful conclusions and make evidence-based recommendations for the use of atropine in clinical practice.

Data collection tools and analysis techniques will also be carefully selected and implemented to ensure the accuracy and reliability of our results. We will use standardized surveys and assessments to gather data on participants' symptoms, treatment outcomes, and any potential side effects of atropine. Statistical analysis software will be utilized to analyze the data and identify any significant correlations or trends. Additionally, we will engage in qualitative data analysis to gain a deeper understanding of participants'

experiences and perspectives. Through this comprehensive approach, we aim to provide valuable insights into the effectiveness and safety of atropine as a treatment for myopia [27].

This research will also involve monitoring participants over an extended period of time to track any changes in their condition and ensure the long-term efficacy of atropine. We will collaborate with ophthalmologists and other medical professionals to ensure the accuracy and validity of our findings. By combining quantitative and qualitative methods, we hope to paint a comprehensive picture of the impact of atropine on myopia management. This study has the potential to inform future treatment protocols and improve the quality of care for individuals with myopia [28].

Results

Knowledge levels of eye care professionals on atropine prescription will be assessed through surveys and interviews. The results of these assessments will be crucial in understanding the current practices and beliefs surrounding atropine use in the treatment of myopia. By combining quantitative and qualitative data analysis, we hope to paint a clear picture of the knowledge gaps and areas for improvement in the prescription of atropine for myopia. This information will be instrumental in guiding future research and clinical practice in this field [29].

Attitudes towards prescribing atropine for myopia vary among eye care professionals, with some expressing skepticism about its long-term efficacy and safety, while others view it as a promising treatment option. Understanding these varying attitudes is essential in developing targeted educational interventions to address any misconceptions and promote evidence-based practice. In addition, exploring the factors that influence prescribing decisions, such as patient demographics, practice setting, and level of experience, will provide valuable insights into how to optimize the use of atropine in the management of myopia. By gathering feedback from a diverse range of eye care professionals, we aim to identify barriers to appropriate atropine prescription and develop strategies to overcome them [30, 32].

This information will be crucial in designing educational materials and training programs that are tailored to the specific needs and challenges faced by different practitioners. By taking a comprehensive approach to understanding the complexities of atropine use in myopia management, we can work towards improving patient outcomes and ensuring that this valuable treatment option is utilized effectively in clinical practice [33, 35].

Practices and Barriers in Prescribing Atropine

We will also conduct research to investigate the efficacy and safety of different dosages and formulations of atropine in managing myopia. This will help us tailor our recommendations based on the latest evidence and ensure that eye care professionals have the most up-to-date information to guide their prescribing decisions. Ultimately, our goal is to improve the quality of care for patients with myopia and reduce the risk of potential complications associated with atropine use [36, 39].

Additionally, we will explore the potential side effects and contraindications of atropine, as well as any interactions with other medications that patients may be taking. By understanding these factors, we can better educate both eye care professionals and patients on the risks and benefits of atropine therapy. This comprehensive approach will allow us to provide personalized care and ensure that each individual receives the most appropriate treatment for their specific needs. Through ongoing research and collaboration with healthcare providers, we aim to optimize the use of atropine in managing myopia and ultimately improve patient outcomes [40, 41].

Discussion

In this section, we will delve deeper into the practices and barriers that eye care professionals face when prescribing atropine for myopia. We will analyze the various factors that influence prescribing decisions, such as patient demographics, clinical guidelines, and healthcare system constraints. By understanding these challenges, we can develop targeted interventions to address them and improve the overall quality of care for myopic patients. Additionally, we will explore the latest research on atropine dosages and formulations to provide evidence-based recommendations for practitioners. Through these efforts, we aim to enhance the safety and efficacy of atropine treatment and ultimately improve patient outcomes in the long run [42, 44].

Interpretation of results in relation to existing literature and implications for clinical practice will be discussed in this section. We will also address any limitations of our study and suggest areas for future research. Additionally, we will explore the potential impact of our findings on current guidelines for myopia management and highlight the importance of ongoing education and training for eye care professionals. Overall, our study aims to contribute to the growing body of evidence on the use of atropine in myopia treatment and provide valuable insights for clinicians in their decision-making process [45, 47].

Furthermore, we will analyze the potential cost-effectiveness of atropine

treatment compared to other interventions, such as orthokeratology or multifocal contact lenses. By examining the economic implications of different treatment options, we hope to provide practitioners with valuable information that can help guide their recommendations for patients. In addition, we will delve into the long-term effects of atropine use on visual acuity and ocular health, as well as potential side effects that may impact patient compliance and satisfaction. By addressing these factors, we aim to offer a comprehensive evaluation of atropine therapy and its role in the management of myopia [48, 49].

Implications for Eye Care Practice in India

In considering the implications for eye care practice in India, it is important to recognize the unique challenges and opportunities that exist within the country's healthcare system. With a high prevalence of myopia among both children and adults, there is a pressing need for effective management strategies that can help prevent vision loss and improve overall eye health. Our study's findings on the use of atropine in myopia treatment may have significant implications for Indian eye care professionals, as they seek to provide evidence-based care to their patients. By incorporating our research into clinical practice, practitioners in India can potentially enhance their treatment protocols and better address the growing burden of myopia in the population. Additionally, our study may inform future guidelines and policies related to myopia management in India, ultimately leading to improved outcomes for patients and a more sustainable approach to eye care delivery [50, 52].

This could have far-reaching effects on the overall health and well-being of the Indian population, as myopia has been linked to an increased risk of various eye conditions and even blindness if left untreated. By staying abreast of the latest research and implementing evidence-based practices, eye care professionals in India can play a crucial role in preventing vision loss and improving quality of life for their patients. It is essential for practitioners to continuously educate themselves on the most effective treatment options and to adapt their approach as new information becomes available. Collaboration with researchers and policymakers will also be key in implementing changes at a systemic level to ensure that all individuals have access to the best possible care for their myopia [53, 54].

Recommendations for improving knowledge, attitude, and practice of eye care professionals include implementing continuing education programs focused on myopia management, providing access to updated research and

guidelines, and promoting interdisciplinary collaboration among different specialties in eye care. By fostering a culture of lifelong learning and collaboration, eye care professionals can stay current with the latest advancements in myopia management and deliver more effective care to their patients. Furthermore, initiatives to raise awareness about the importance of early detection and intervention for myopia can help reduce the prevalence and severity of the condition in the population. Overall, by taking a proactive approach to addressing myopia, eye care professionals in India can play a crucial role in promoting eye health and preventing vision loss in their communities. Through continued education and working together, eye care professionals can ensure that they are providing the best possible care to their patients with myopia. By educating the public about the importance of early detection and treatment, they can help prevent vision loss and improve overall eye health in the population. By staying informed and proactive, eye care professionals in India can make a significant impact on the well-being of their communities and help reduce the burden of myopia on society as a whole [55, 56].

Conclusion

In conclusion, it is clear that myopia is a growing concern in India and around the world. However, by implementing strategies such as education, collaboration, and early intervention, eye care professionals can make a significant impact in managing and reducing the prevalence of myopia. By staying informed about the latest advancements in myopia management and working together to raise awareness, eye care professionals can help improve the overall eye health of their communities and prevent vision loss in the future. It is imperative that we continue to prioritize myopia management and work towards a future where this condition is effectively controlled and minimized [57].

In addition to these strategies, it is also important for eye care professionals to regularly monitor their patients' progress and adjust treatment plans as needed. By providing personalized care and support, they can help individuals better manage their myopia and prevent it from progressing further. Furthermore, educating patients about the importance of proper eye care and the potential risks associated with myopia can help empower them to take control of their eye health. Collaborating with other healthcare professionals and organizations can also help create a more comprehensive approach to myopia management, ultimately leading to better outcomes for patients. By taking a proactive stance on myopia management, eye care professionals can truly make a difference in the lives of their

patients and the overall health of their communities [58, 59].

Limitations of the study include the small sample size and limited follow-up period, which may have affected the generalizability of the results. Additionally, the study only focused on one specific aspect of myopia management, and future research should explore other potential interventions. Despite these limitations, the findings of this study provide valuable insights into the importance of proactive myopia management and the potential benefits it can have for patients. Further research is needed to fully understand the long-term effects of different management strategies and to develop more personalized approaches to myopia care. In conclusion, while there are challenges in managing myopia, the dedication and collaboration of eye care professionals can make a significant impact on the overall health and well-being of their patients [60, 61].

Suggestions for future research include exploring the role of genetics in myopia development, investigating the effectiveness of combination therapies, and studying the impact of environmental factors on myopia progression. Additionally, research on the use of technology and innovative treatment options, such as orthokeratology and atropine eye drops, could provide valuable insights into improving myopia management outcomes. Collaborative efforts between researchers, clinicians, and industry partners will be crucial in advancing our understanding of myopia and developing evidence-based strategies for its prevention and treatment.

References

1. Rodge HY, Lokhande S. Refractive error in children. Int J Curr Res Rev. 2021;12(23):185. doi:10.31782/IJCRR.2020.122307.
2. Wei S, Li SM, An W, *et al*. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol. 2020;138(11):1178-84. doi:10.1001/jamaophthalmol.2020.3820.
3. Galvis V, Tello A, Parra MM, *et al*. Topical atropine in the control of myopia. Med Hypothesis Discov Innov Ophthalmol. 2016;5(3):78-88.
4. Azuara-Blanco A, Logan N, Strang N, *et al*. Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol. Br J Ophthalmol. 2020;104(7):950-5. doi:10.1136/bjophthalmol-2019-314819.
5. Pérez-Flores I, Macías-Murelaga B, Barrio-Barrio J, *et al*. A multicenter

Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2021;11(1):21748. doi:10.1038/s41598-021-00923-1.

6. Muma S, Obonyo S. The prevalence and causes of visual impairment among children in Kenya: the Kenya eye study. BMC Ophthalmol. 2020;20(1):399. doi:10.1186/s12886-020-01665-w.
7. Kenya Ministry of Health. Scope of practice for ophthalmic workers. Nairobi: Kenya Ministry of Health; 2022.
8. Kalua K, Gichangi M, Barassa E, *et al*. Skills of general health workers in primary eye care in Kenya, Malawi and Tanzania. Hum Resour Health. 2014;12(Suppl 1):S2. doi:10.1186/1478-4491-12-S1-S2.
9. Holden BA, Fricke TR, Wilson DA, *et al*. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42. doi:10.1016/j.ophtha.2016.01.006.
10. Sankaridurg P, Tahhan N, Kandel H, *et al*. IMI impact of myopia. Invest Ophthalmol Vis Sci. 2021;62:2.
11. Holden BA, Fricke TR, Wilson DA, *et al*. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036-42.
12. Priscilla JJ, Verkicharla PK. Time trends on the prevalence of myopia in India: a prediction model for 2050. Ophthalmic Physiol Opt. 2021;41:466-74.
13. Ohno-Matsui K, Wu PC, Yamashiro K, *et al*. IMI pathologic myopia. Invest Ophthalmol Vis Sci. 2021;62:5.
14. Biswas S, Jhanji V, Leung CK. Prevalence of glaucoma in myopic corneal refractive surgery candidates in Hong Kong, China. J Refract Surg. 2016;32:298-304.
15. Chua SY, Sabanayagam C, Cheung YB, *et al*. Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children. Ophthalmic Physiol Opt. 2016;36:388-94.
16. Wolffsohn JS, Whayeb Y, Logan NS, *et al*. IMI-global trends in myopia management attitudes and strategies in clinical practice-2022 update. Invest Ophthalmol Vis Sci. 2023;64:6.

17. Biswas S, El Kareh A, Qureshi M, *et al*. The influence of the environment and lifestyle on myopia. J Physiol Anthropol. 2024;43:7.

18. Gifford KL, Richdale K, Kang P, *et al*. IMI-clinical management guidelines report. Invest Ophthalmol Vis Sci. 2019;60:M184-203.

19. Bullimore MA, Richdale K. Myopia control 2020: where are we and where are we heading? Ophthalmic Physiol Opt. 2020;40:254-70.

20. Muralidharan AR, Lança C, Biswas S, *et al*. Light and myopia: from epidemiological studies to neurobiological mechanisms. Ther Adv Ophthalmol. 2021;13:25158414211059246.

21. Jothi Balaji J, Viswanathan S. Practice patterns in managing myopia differ among Indian eye care practitioners. Indian J Ophthalmol. 2022;70:1848-9.

22. Nti AN, Owusu-Afriyie B, Osuagwu UL, *et al*. Trends in myopia management attitudes and strategies in clinical practice: survey of eye care practitioners in Africa. Contact Lens Anterior Eye. 2023;46:101597.

23. Douglass A, Keller PR, He M, *et al*. Knowledge, perspectives and clinical practices of Australian optometrists in relation to childhood myopia. Clin Exp Optom. 2020;103:155-66.

24. Di Pierdomenico J, González-González R, Valiente-Soriano FJ, *et al*. Attitudes and knowledge of myopia management by Spanish optometrists. Int Ophthalmol. 2023;43:4247-61.

25. Chaurasiya RK, Sutar S, Gupta A, *et al*. Knowledge, attitude, and practice of childhood myopia among Indian optometrists: a questionnaire-based study. Indian J Ophthalmol. 2023;71:951-6.

26. Thite N, Jaggernath J, Chinanayi F, *et al*. Pattern of optometry practice and range of services in India. Optom Vis Sci. 2015;92:615-22.

27. Kotrlik J, Higgins C. Organizational research: determining appropriate sample size in survey research. Inf Technol Learn Perform J. 2001;19:43.

28. Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res. 2004;6:e34.

29. India Vision Institute. Optometry in India: an overview of optometry services in India in terms of optical outlets, eye hospitals and educational institutes. Chennai: IVI; 2016.

30. Jong M, Sankaridurg P, Li W, *et al*. Reduced vision in highly myopic eyes without ocular pathology: the ZOC-BHVI high myopia study. Clin Exp Optom. 2018;101:77-83.

31. Fryer LK, Shum A, Lee A, Lau P. Mapping students' interest in a new domain: connecting prior knowledge, interest, and self-efficacy with interesting tasks and a lasting desire to reengage. Learn Instr. 2021;75:101493.

32. Morgan IG, Wu PC, Ostrin LA, *et al*. IMI risk factors for myopia. Invest Ophthalmol Vis Sci. 2021;62:3.

33. Luong TQ, Shu YH, Modjtahedi BS, *et al*. Racial and ethnic differences in myopia progression in a large, diverse cohort of pediatric patients. Invest Ophthalmol Vis Sci. 2020;61:20.

34. Mutti DO, Mitchell GL, Moeschberger ML, *et al*. Parental myopia, near work, school achievement, and children's refractive error. Invest Ophthalmol Vis Sci. 2002;43:3633-40.

35. He X, Sankaridurg P, Wang J, *et al*. Time outdoors in reducing myopia: a school-based cluster randomized trial with objective monitoring of outdoor time and light intensity. Ophthalmology. 2022;129:1245-54.

36. Martínez-Pérez C, Villa-Collar C, Santodomingo-Rubido J, *et al*. Strategies and attitudes on the management of myopia in clinical practice in Spain. J Optom. 2023;16:64-73.

37. Wolffsohn JS, Kollbaum PS, Berntsen DA, *et al*. IMI-clinical myopia control trials and instrumentation report. Invest Ophthalmol Vis Sci. 2019;60:M132-60.

38. Jonas JB, Ohno-Matsui K, Holbach L, *et al*. Retinal pigment epithelium cell density in relationship to axial length in human eyes. Acta Ophthalmol. 2017;95:e22-8.

39. Alanazi MK, Almutleb ES, Badawood YS, *et al*. Perspectives and clinical practices of optometrists in Saudi Arabia concerning myopia in children. Int J Ophthalmol. 2023;16:267-73.

40. Wan Omar WE, Cruickshank F, Radhakrishnan H. UK optometrists' professional learning needs toward engaging with myopia control interventions. Br Ir Orthopt J. 2024;20:69-84.

41. Yang A, Pang BY, Vasudevan P, *et al*. Eye care practitioners are key influencers for the use of myopia control intervention. Front Public Health. 2022;10:854654.

42. Chung K, Mohidin N, O'Leary DJ. Undercorrection of myopia enhances rather than inhibits myopia progression. Vision Res. 2002;42:2555-9.

43. Tsai HR, Wang JH, Huang HK, *et al*. Efficacy of atropine, orthokeratology, and combined atropine with orthokeratology for childhood myopia: a systematic review and network meta-analysis. J Formos Med Assoc. 2022;121:2490-500.

44. Karthikeyan SK, Ashwini DL, Priyanka M, *et al*. Physical activity, time spent outdoors, and near work in relation to myopia prevalence, incidence, and progression: an overview of systematic reviews and meta-analyses. Indian J Ophthalmol. 2022;70:728-39.

45. Tsugawa Y, Newhouse JP, Zaslavsky AM, *et al*. Physician age and outcomes in elderly patients in hospital in the US: observational study. BMJ. 2017;357:j1797.

46. Berntsen DA, Sinnott LT, Mutti DO, *et al*. A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation. Invest Ophthalmol Vis Sci. 2012;53:640-9.

47. Bullimore MA, Lee SS, Schmid KL, *et al*. IMI-onset and progression of myopia in young adults. Invest Ophthalmol Vis Sci. 2023;64:2.

48. Heiwe S, Kajermo KN, Tyni-Lenné R, *et al*. Evidence-based practice: attitudes, knowledge and behaviour among allied health care professionals. Int J Qual Health Care. 2011;23:198-209.

49. Brennan NA, Toubouti YM, Cheng X, *et al*. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923.

50. Downie LE, Keller PR, Vingrys AJ. An evidence-based analysis of Australian optometrists' dry eye practices. Optom Vis Sci. 2013;90:1385-95.

51. Downie LE, Keller PR. The self-reported clinical practice behaviors of Australian optometrists as related to smoking, diet and nutritional supplementation. PLoS One. 2015;10:e0124533.

52. Biswas S, Logan NS, Davies LN, *et al*. Assessing the utility of ChatGPT as an artificial intelligence-based large language model for information to answer questions on myopia. Ophthalmic Physiol Opt. 2023;43:1562-70.

53. Biswas S, Davies LN, Sheppard AL, *et al*. Utility of artificial intelligence-based large language models in ophthalmic care. Ophthalmic Physiol Opt. 2024;44:641-71.

54. Glasman LR, Albarracín D. Forming attitudes that predict future behavior: a meta-analysis of the attitude-behavior relation. Psychol Bull. 2006;132:778-822.

55. Li Q, Guo L, Zhang J, *et al*. Effect of school-based family health education via social media on children's myopia and parents' awareness: a randomized clinical trial. JAMA Ophthalmol. 2021;139:1165-72.

56. Xu H, Wen LM, Rissel C. Associations of parental influences with physical activity and screen time among young children: a systematic review. J Obes. 2015;2015:546925.

57. Naidoo KS, Govender-Poonsamy P, Morjaria P, *et al*. Global mapping of optometry workforce. Afr Vis Eye Health. 2023;82:850.

58. McCrann S, Flitcroft I, Loughman J. Is optometry ready for myopia control? Education and other barriers to the treatment of myopia. HRB Open Res. 2019;2:30.

59. Main PAE, Anderson S. Evidence for continuing professional development standards for regulated health practitioners in Australia: a systematic review. Hum Resour Health. 2023;21:23.

60. Karas M, Sheen NJL, North RV, *et al.* Continuing professional development requirements for UK health professionals: a scoping review. BMJ Open. 2020;10:e032781.

61. India Vision Institute. Optometry in India. An overview of optometry services in India in terms of optical outlets, eye hospitals and educational institutes. Chennai: India Vision Institute; 2016.

Chapter - 12
Exploring the Efficacy of Electronic Mobility Aids for Individuals with Visual Impairments: A Comprehensive Narrative Review

Authors

Rikta Paul

Department of optometry, Swami Vivekananda University, Barrackpore, West Bengal, India

Chapter - 12

Exploring the Efficacy of Electronic Mobility Aids for Individuals with Visual Impairments: A Comprehensive Narrative Review

Rikta Paul

Abstract

Introduction: Visually impaired persons need electronic mobility aids (EMA) for detection and recognition of obstacles, and navigation to desired destinations not only in outdoor but also in the indoor environments as well. Electronic low vision mobility aids have been designed in order to improve the navigation abilities of individuals who are blind or visually impaired.With technological advancements, the utilisation of EMA's has been increasing.

Objective: The main goal of this narrative review was to examine the literature already been present on the effectiveness of electronic low vision aids on the mobility of low-vision patients.

Methods: Searches were conducted in three electronic databases (PubMed, Google Scholar and Cochrane). A total of 51 studies which were written in the English language met the inclusion criteria, and were reviewed further.

Conclusion: The findings show that most research adopted auditory signals as a feedback interface and applied a variety of technologies for obstacle identification, particularly the combination of sensor-based and computer vision-based technologies. This paper also narrates the importance of perceptual learning for the mobility of the low vision individuals.These findings carry significant implications for the development of wearable devices aimed at enhancing the safe mobility of individuals with visual impairments.

Keywords: Mobility and visual impairment, Electronic low vision aids and obstacle detection.

Introduction

Visual impairment can significantly restrict an individual's capacity to navigate and communicate with their surroundings, resulting in a dependency on others and a diminished quality of life. Nevertheless, the progress in low vision aids has resulted in a profound impact on the lives of individuals who are impacted by visual impairments. These assistive aids, which vary from basic magnifiers to sophisticated electronic equipment, are designed to optimize the utilization of remaining eyesight.

Mobility is one of the areas in which persons who are blind or partially sighted face substantial obstacles, despite the fact that it is particularly essential for participation in modern society.

Despite the potential of advanced technologies and over a century work in this area, the most commonly used travel aids are still the long cane and the guide dog [1]. Electronic travel aides (ETAs) were mainly created to replace conventional aids by recognizing items located above the waist level and at longer distances. ETAs consist of devices that emit either infrared light or ultrasonic sound, which then gather information about the surrounding environment by analysing the reflection of the generated beam.

Consequently, electronic travel aids (ETAs) have been developed with the intention of bolstering the efficacy of guide dogs and white canes. Existing research suggests that the utilization of an electronic cane powered by ultrasound can substantially improve the ability to detect objects located above the waistline.

Visual impairment is often associated with mobility restrictions, leading to various health issues, including loss of independence, social isolation, reduced physical activity, and depression. Improving the mobility skills of visually impaired people may improve their ability to participate in society, enhancing their productivity, self-maintenance, leisure, and overall quality of life [2].

The first head-mounted video magnifier was the Low Vision Enhancement System (LVES) (Massof and Rickman, 1992; Massof, 1994) [3]. This device has been shown to be helpful to both adults and children with low vision and benefits included improvement with acuity, contrast sensitivity and control of illumination [3]. But there were issues with the auto-focusing speed and magnification limitations, and the device was big and heavy. Significant innovations in technology have emerged since the first generation of LVES, facilitating components to become lighter, smaller, and more efficient.Currently, there is a lack of research comparing the

performance advantages of electronic head-mounted devices (HMDs) to traditional optical devices used in clinical settings. Such comparisons are essential for informing patients, low vision practitioners, and purchasers.

The concept of increasing the size (e.g., brightness of signs), contrast (e.g., use of colours that contrast to emphasize obstacles), or both is a foundational principle in low vision rehabilitation. However, it is generally impractical to implement these alterations in the constructed environment.To optimize the utilization of these nascent technologies as mobility aids for the LV, it is worthwhile to possess knowledge regarding the present condition of electronic aids technology. This includes an understanding of the vision enhancements and information processing methods that have been previously recognized as beneficial in enhancing mobility performance

Electronic aids to daily living (EADLs) play an important role in the lives of many people with physical disabilities, by enhancing their autonomy to participate in daily activities. In another study of consumer satisfaction with integrated devices to control communication systems, computers and other electronically operated equipment, conducted telephone with 24 persons with severe physical disabilities. They found that most respondents were satisfied with their EADLs. Satisfaction was influenced by user independence, the ability to control other equipment, such as wheelchairs and communication aids, device simplicity, the touch sensitivity of the switch, and whether or not there was visual or auditory feedback from the switch [4].

The RGB-D (Red, Green, Blue and Depth) sensor-basedETA, can detect obstacles more easily and precisely than another sensor (e.g. ultrasonic sensor, mono-camera, etc.) based scheme. Nevertheless, the depth sensor is limited in its ability to accurately measure the distance of obstacles and is ineffective when faced with transparent items like glass, French doors, or French windows [5].

These advancements prompted us to examine the electronic mobility gadgets currently available in the industry and assess the potential impact on the daily lives of users.

This article's primary objective was to provide an answer to the following research question: What is the evidence that frequently advised assistive technology therapies for rehabilitation have beneficial effects for adults with low vision?An additional aim of this study was to consolidate the research findings concerning the efficiency of these electronic aids. This review presents our findings regarding the impact and efficacy of electronic

mobility devices that users can utilize without requiring any alterations to the environment

It is important to note that electronic mobility devices (EMDs) are an omnibus term for devices used for obstacle detection, navigation, wayfinding, and orientation purposes while traveling.

Evaluating the effectiveness of Electronic Low Vision Aids (ELVAs) on mobility in visually impaired patients is crucial for optimizing outcomes, enhancing independence, and safety. Additionally, it aids LV specialists in assessing the cost-effectiveness of these interventions and selecting the most suitable low vision aid based on the patient's financial condition. A narrative review was chosen as the research approach, allowing for the exploration of new innovations in improving mobility and evaluating their efficacy in individuals with visual impairments. Over the past decade, understanding low-vision patients' barriers to assess appropriate interventions has been important. This recent narrative review sheds light on these obstacles and offers insights into the effectiveness of electronic mobility aids.

Methodology

This review included original studies, research papers and a limited number of experimental studies that specifically examined individuals with vision impairments among any age grouphaving any retinal pathology and those who have been using electronic mobility aids for a considerable amount of time. Fig. 1 illustrates the flow diagram of the process of searching and selecting the studies according to the PRISMA flow diagram. Ethical research methods were employed to identify pertinent studies via searches conducted on the PubMed, Cochrane, and Google Scholar platforms. Only those studies that fulfilled our criteria underwent further review. Mobility and Visual impairment, electronic mobility Low vision aids and obstacle detection.

The review included both male and female participants spanning an age range from 10 to 85 years. The study designs of the original research papers included experimental and quasi-experimental studies, along with a limited number of review articles. A Boolean type search strategy involving truncated process was employed, restricting the search period from 1992 to 2023. Research articles that featured visually impaired individuals as participants and have been using electronic mobility aids over an extended period were considered for inclusion. This included research articles that were published from 1992 to 2023, covering a period of 10 to 12 years prior to that.The following criteria were used to exclude studies: (i) those that

were not composed in English preferably American English (ii) book chapters, dissertations, or review articles; (iii) technologies not designated as wearable or not specifically designed for orientation and/or mobility purposes.



Fig 1. PRISMA flow diagram of the search and selection process [6]

Initially, a search yielded 103 articles containing all the specified keywords. However, 17 duplicate articles were eliminated prior to further analysis. After conducting a thorough analysis of titles and abstracts based

on certain inclusion and exclusion criteria, 77 suitable journals were selected. Subsequently, a total of 66 results were obtained. However, 15 entries were subsequently excluded since they were found to be irrelevant to the topic.

Discussions

This article illustrates how electronic low vision aids can help visually impaired individuals to improve their mobile abilities, and whether or not this aid enhances the mobility of visually impaired individuals. Provided if that visually impaired individuals regain their sight completely, it is believed that they will walk at their most efficient speeds. Previous research on mobility have utilized preferred walking speed (PWS) as a measure of walking efficiency in visually impaired adults [7]. Some navigational assistive devices are tried to be designed and implemented for the visually impaired persons to assist them in safe movement However, some of them are relatively costly, require telecommunication network to function and active user participation which might be problematic for very elderly users [8].

One of the research projects mentions the possible benefits of the electronic mobility assistive devices that were put to the test. The primary objective of low vision rehabilitation is to enable individuals to optimize their residual visual capacity, enhance their functional capabilities, promote their independence, and ultimately enhance their overall quality of life [9]. A dependable resource for deaf and visually impaired people is the Miniguide. When someone wants assistance seeing roadblocks when they venture out to different well-known locations, this is really beneficial [10].

The inexpensiveness and simplicity of the depth and ultrasonic sensors utilised by smart glasses enable their widespread application in the consumer market. The outcomes of the trial demonstrate that smart guiding glasses can significantly enhance a user's experience when moving across an intricate interior environment. As such, it serves as a consumer technology that promotes safe travel for those who are blind or visually impaired.

Because the sub-components of orientation and mobility are so poorly understood to the casual observer the problem of mobility appears to be rather a simple one, but closer examination reveals that very little is understood about it [11].

The results of the study present compelling proof that mainstream gadgets are increasingly overtaking conventional assistive solutions in this specific sample. As the use of technology is mainstream, the acceptance of technological solutions even with adaptive technologies may be higher than with conventional optical aids [12]. This trend is particularly evident in the areas of item identification, navigation, asking assistance from sighted individuals, and listening to audiobooks [13]. The use of smartphones as an aid is widely accepted by nearly all individuals with visual impairments, particularly among younger age groups. One of the analysis found limited interest in combining haptic interfaces and computer vision capabilities in smartphone-based ETAs for the blind [14]. The newest smartphones typically include a variety of sensors, tools for outdoor navigation, and processing power for audio and video. Involvement of users in the design and development phase may be believed to be a qualitative approach.According to a study that was examined, patients who received free LVAs showed a comparable improvement in LVQOL score to those who paid for LVAs. Therefore, administering LVAs for free did not result in any significant bias [15].

A repeatable mobility course was created by one of the examined studies as a component of an appropriate assessment tool for the targeted user evaluation. The results of the user evaluation, to which this course was applied, illustrate that it has been helpful in evaluating how well visually impaired individuals can move around. Additionally, and most importantly it has proven sensitive in identifying changes in mobility incidents and obstacle detection when making use of an electronic mobility aids when compared to a standard mobility aid. The consistency of difficulties caused by lighting conditions, adaptations to different conditions of illumination, and the negative effect of reduced lighting on mobility merit considerable attention. This area requires special attention because most curricula on mobility have been devoted to totally blind people, for whom no consideration of the effect of lighting is necessary [16]. Thus, based on the results of a survey, 80% of the participants agreed that the optimised light created a better colour contrast between background and obstacle in comparison with the reference light. Also, and 36% and 11% improvements were achieved in the obstacle avoidance and time taken to complete the mobility walk course respectively [17].

The task of visually impaired pedestrians in navigating their surroundings might be defined as comprising two types of problem-solving. Initially, it is important for them to navigate around obstacles that are present

at both ground level and head height. Additionally, they must find a clear pathway that extends a few feet in front of them [18]. One of the research studies undertook an extensive assessment of the ever-relying electronic long cane where a questionnaire based and end-user testing were implemented. The findings show that the electronic cane can effectively achieve its stated purpose of alerting users to impediments when they are at a height and that users find this function appealing.

While reading ability and overall visual ability are important in the quality of life of glaucoma patients, mobility issues and glare are also common complaints. Due to decreased peripheral vision, patients tend to have an increased risk of accidents and falls. It was found that patients with glaucoma walked 10% slower than those without glaucoma. Furthermore, glaucoma patients experienced almost twice as many bumps, stumbles and orientation issues compared to non-glaucomatous patients [19]. In a pilot study, the visual-tactile sensory substitution LEO Belt was tested on two cohorts: people with advanced visual field limitation from RP and normally sighted subjects using goggles to artificially reduce peripheral vision to replicate phases of RP progression. For RP individuals with residual visual fields between 10˚ and 20˚, LEO doubled mobility accuracy. Additionally, the device may increase independence in general and boost confidence in low light for those who report having nyctalopia. The LEO Belt demonstrates that this idea is feasible and has an elevated degree of user acceptability as the first study of a wearable, tactile visual aid evaluated in a patient group with peripheral vision loss [20]. AMD is a degenerative disease that affects the macular region, leading to a progressive loss of central vision and reading ability and often resulting in an irreversible central scotoma. Peripheral vision has to be used by patients with such a disorder [21].Thus, as most of the electronic low vison aids explicitly pressurizes the ramification of central vision researches had to come up with something different. A novel wearable mobility aid the radar device sends radio signals, detects objects in the environment, and conveys this information to the users by way of sound or vibration feedback and the results point to the direction that the deaf blind might get the greatest benefit from using the device, along with people with low vision [22]. The existing literature regarding visual mobility aids does not mention any involvement of People with vision loss during the design and implementation stages to capture their mobility needs [23]. However, the visual impressions of individuals with vision loss varies depending on the specific visual impairments they have. Consequently, a major obstacle in creating a visual mobility aid for individuals with visual impairment is understanding their specific needs and offering

customised alternatives that are adaptable to varied levels of visual abilities and conditions. One of the publications proposed an intriguing ambient navigation system technology that would enable blind or visually impaired people to navigate their way freely inside buildings without assistance. The subject's smartphone serves as the human-machine interface for the computer vision guiding system, which consists of a set-up of IP cameras affixed to each room's ceiling. A computer receives frames and uses them to scan the surroundings, find items, and identify them. Voice messages sent through a simple to operate smartphone application control the system [24]. Additionally, more research is needed in this field due to the significant reduction in size of newly introduced commercially viable ToF (Time of Flight) cameras, which can be readily adopted as functional solutions to enhance the mobility capabilities of individuals with visual impairments [25]. One relatively untried but promising approach to vision rehabilitation strategies for low vision mobility is the study of the perceptual factors influencing mobility performance. In a paper published over 35 years ago, it was advocated the use of perceptual information in training the low vision traveller [26]. One article that was reviewed devised "Residual vision glasses" (RVGs) that use screens and a head-mounted depth camera to show the wearer information about the distance of barriers as brightness, with the object nearest to the wearer becoming brighter. Every participant was able to navigate the course using the smart glasses, and their mobility performance significantly improved [27].

As a result of the elevated cost of the low-vision aids that were suggested during the LVCS, patients became disinterested in continuing the treatment [28, 29]. The MAPS architecture introduces a cost-effective system for aiding cognitive mobility in indoor and outdoor environments. This system utilizes two hardware elements that work together: the Force Feedback Tablet (F2T) and the Tacti Belt. The initial assessment of this system on participants found it to be significant as well as successful for enabling independent navigation [30]. A study observed that ultrasonic sensors were the most common technology in sensor-based navigation systems. This result may be explained by the low cost of these sensors or because they do not require light to work, while cameras do [31]. Consistent with the literature after studying an ultrasonic wearable electronic navigation system is successfully tested on blind folded subjects in indoor environment. The test yields accurate detection of obstacles in front left and right direction.When considering mobility, it is important to consider the overall atmosphere, including the purpose of travel, as travel is necessary for participating in activities. Therefore, future research needs to investigate the

long-term consequences of the use of electronic mobility devices, such as changes in travel patterns or habits [32].

A clinical comparison of presently available Electronic vision enhancement systems technology with the subject's optimal optical magnifier showed that EVES provide benefits to the visually impaired in some specific tasks and are believed to be easier to use [33]

Author	Low Vision Aids	Study Population	Methodology	P Value	Result
[34] O'Brien *et al*., 2014	A Detachable Electronic Device (Ultrasonic sensor-MB1200) with a Long White Cane	N=16 normally sighted individuals.	Individuals navigated two mobility courses using both a standard white cane and a white cane equipped with an electronic device.	$p < 0.05$	Results indicated that 10 participants found navigation easier with the electronic device attached, 4 found it harder, and 2 did not perceive a difference.
[20] F. E. Brown *et al*., 2019	A Low-vision Enhancement Optoelectronic (LEO) Belt.	Sighted subjects (n = 20) and subjects with retinitis pigmentosa (RP) (n = 6) were recruited.12=male 14=female Subjects had a mean age of 37.6 (range 22 to 83); 30.4 years for sighted subjects and 61.5 years for visually impaired subjects	RP progression created by normal-sighted people wearing goggles to limit peripheral vision. Mobility speed and accuracy were tested in simple mazes with and without the LEO Belt to determine its efficacy across the degree of illness and lighting conditions.	$p = 0.014$	RP patients' mobility accuracy increased, confidence scores doubled in poor lighting, and patient-reported outcomes showed that the LEO device was comfortable (100%).
[3] Culham *et al*., 2004	Four electronic head-mounted devices (HMDs) (Jordy, Flipper port, Maxport and NuVision)	N=10 with AMD N-10 with EOMD Age range for the EOMD group was 21-57 (mean 41.8 years); for the AMD group the range was 54-82 (mean 73.5 years) Total 20 individuals were recruited.	Based on reading speed and mobility, the study compared four electronic HMDs (Jordy, Flipper port, Maxport, and NuVision) to typical optical low-vision aids (LVAs).	Flipper port ($p < 0.001$) Jordy ($p < 0.001$)	Flipper port and Jordy performed better than optical LVAs previously prescribed in distance and intermediate acuity.

[24] Chaccour & Badr, 2016	IP cameras are installed on each room's ceiling and the subject's smartphone used as HMI. Computers analyse frames received to identify obstructions.	Eight blind folded persons (5 males and 3 females) volunteered to validate.	A computer vision navigation programme detects obstacles to help users reach their intended locations. Voice messages from a simple mobile app control the system. Applications send voice message feedback to users.		The systems require the least user training. This application provides a dependable solution for indoor navigation with obstacle avoidance for VI. .
[1] Hersh & García Ramírez, 2018	Electronic long cane	5 experienced users of the electronic cane. They were three blind and two low-vision people, 3 female, 2 male, aged between 24 and 50 years.	It used an experimental study of electronic long cane performance and a questionnaire to evaluate user satisfaction.	The results showed 80% device satisfaction and various improvement suggestions.	The results indicate that the electronic cane alerts users to height obstacles
[35] Vincent *et al*., 2014	The Miniguide and the Breeze	N=3 men N=1 woman, aged from 50 to 70-years-old and having the Usher syndrome with different levels of low vision	A single-subject test included four users. Participants learned the Miniguide and Breeze commercial EMADs. The Canadian Measure of Occupational Performance (CMOP) was given before T1, after training T2, and three months after training. Quebec User Evaluation of Satisfaction with Assistive	QUEST indicates high satisfaction with eight items except for one participant	The Miniguide or Breeze increased occupational performance and satisfaction for all participants, based to the CMOP questionnaire.

			Technology (QUEST) was given in T2 and T3. At T3, participants and doctors were interviewed about the EMAD's positive and negative aspects.		
[27] van Rheede *et al*., 2015	"Residual vision glasses" (RVGs) that use a head-mounted depth camera	N=11 Visually impaired patient 3 males 8 females Ages ranging from 26 to 85. Additionally, five control participants (3 female, 2 male) participated in the experiment (age range, 26-28).	The article assessed how RVGs affected visually impaired individuals' obstacle-detection mobility. The temporal dynamics of mobility performance were captured by continuously observing participant position. .	(P = 0.031).	This suggests that RVGs assisted participants who had trouble avoiding obstacles in the unaided condition improve their visual mobility performance.
[5] Bai *et al*., 2017	The RGB-D (Red, Green, Blue and Depth) sensor based Electronic Mobility Aid.	For subjective tests, N=20 users (10 of them are amblyopia and the other 10 are totally blind) are selected.	Three types of auditory clues were developed to help totally blind people notice small, translucent obstacles. For weak-sighted folks, AR (Augment Reality) visual improvement with traversable direction is applied.		The smart guiding glasses improve visually challenged travellers' experience, as determined by experiments. This system uses simple, low-cost sensors, making it suitable for patients use.

[36] Roentgen *et al*., 2012	Ultra Cane and the Miniguide were selected to test the effectiveness of them on mobility.	N=8 persons participated in this user evaluation. 4 were male, 4 females, two reported themselves as having very low vision, the remaining 6 as ("legally") blind. The youngest was 26 years old, the eldest 70 years old, and the mean age was 50.13 years (standard deviation [SD] 15.38 years).	Participants completed a standardised indoor mobility course with their regular mobility assistance, then with EMA, and were evaluated for speed, type, and number of mobility accidents. Assistive device performance and effectiveness were assessed in interviews.	Speed reduced significantly with the Ultra Cane compared to the long cane. : walking speed decreased from 0.62 (SD .12) to 0.49 (SD .11) m/s ($p < 0.03$). Their walking speed was 0.5 (SD .15) m/s ($p > 0.03$)	The Ultra Cane and Miniguide reduced mobility incidents significantly. Most participants were satisfied with user satisfaction.
[37] Everingham *et al*., 1998	Head-mounted mobility aid for low vision using scene classification techniques	N=16 The experiment included registered-blind people with age-related macular degeneration, retinitis pigmentosa, and optic atrophy. Average age 69 years, range 38-87	A neural-network classifier identifies objects in head-mounted camera images to highlight mobility-related scene content. A head-mounted display shows enhanced visuals in high-saturation colour to user.	Two significant ($p < 0.001$) main effects were found. The main effect on Image Type indicates that the type of images did change performance on the tasks.	The study showed that participants with a range of visual impairments increased object identification performance on a difficult mobility-related task by over 100% and performed consistently highly on three mobility-related tasks.
[38]	Head mounted	N=51	Data were gathered at	$P < .001$, without any	eSight improves vision

Wittich *et al*., 2018	electronic mobility aid(eSight)	Male=30 Female=21 Mean age, 48 [standard deviation, 17] years; range, 13 to 75 years.	baseline (no device), fitting (with device), and 3 months of daily esight use.	further change after 3 months; reading acuity improved at fitting; mobility, 0.04, not statistically significant.	immediately with facial recognition. Mobility was insignificant.
[22] Kiuru *et al*., 2018	Novel, wearable, orientation and mobility assistive device that uses radar technology.	The 25-person test group had three forms of vision impairment. 14 were blind, 7 had low vision, including night blindness or tunnel vision, and the remaining four were deaf-blind.	The radar device sends radio signals, identifies objects in the environment, and gives users sound or vibration feedback and a QUEST 2.0 questionnaire to assess assistive technology satisfaction. .		Clinical trials suggest the device improves visually impaired people's lives. The results suggest that the device may benefit deaf blind and low-vision patients significantly.
[39] Abreu *et al*., 2022	EBAT (electronic Buzzer for Autonomous Travel)is designed for optimal safety and uses the user's phone for ease of use.	N=25 totally blind subjects was used for the test. The population was 64% male and 36% female. Ages ranging from 26 to 56. The average age of blindness was 19	The eBAT uses the user's phone to detect obstacles for suitable protection. Blind people validated the eBat in this single-subject with reversal method study.	($p < .0001$) for the “With the EBAT” phase	We may conclude that the EBAT fills a significant gap in mobility aids for VI persons, reducing participants' insecurity.
[10] Penrod *et al*., 2009	Miniguide, Sonar Device when detached from the user’s cane, and the ‘K’ Sonar when attached to the	N=5 adults (two females and three males) with light perception or less and no additional disability.	Participants were tested on their abilities to detect vertical and horizontal obstacles, avoid overhead impediments, and locate		The statistics suggest that both electronic mobility aids increase obstacle identification.

	user's cane).		natural and man-made markers for orientation. Additionally, "speed of execution" was measured.		
[40] Angelopoulos *et al*., 2019	The device used was a Microsoft HoloLens 144 and the distance encoding was a form of pseudocolor, or false-colour, which mapped depth to four discrete colour changes.	N= 10 Retinitis Pigmentosa subjects.	In grasp mode, objects were coloured white at 0-6 inches, green at 6-12 inches, blue at 12-18 inches, and red at 18-24 inches. The author coded these distances into a geometric shader and checked them using a tape measure.	Decrease in Collisions: Mobility. RP subjects had on average 50% fewer collisions with AR on as opposed to AR of (p=0.02)	The pseudocolor wireframe is introduced in this publication, along with the first substantial statistics showing mobility gains in RP patients. .
[41] S. S. Bhatlawande, 2012	The AT89S52 microcontroller-based embedded system processes ultrasonic sensor network data in real time in this wearable system.	N=4 blind folded persons in which two were trained subjects and two subjects were novice.	Ultrasonic sensors make use of echo. From maximum detection, smooth surfaces can be detected. Metal reflects the majority, followed by concrete, wood, and human body. These four surfaces are tested since subjects can encounter them during navigation.		In indoor examination, this wearable electronic navigation device worked for blind folded patients. Accurate front-left and right obstacle detection.
[42] Taylor *et al*.,	The electronic bracelet module	N=15 totally blind subjects.	The electronic bracelet module assists the subject to	Numbers of obstacles avoided using the	Participated subjects appreciated user

2014	serves as a virtual cane. Ultrasonic sensor MaxBotix MB 1340.		verify and to perceive distance of obstacles along with their locations	combined aid were significantly higher than white cane (P-value < 0.001).	interface of the EBVB system and expressed satisfaction with its reasonable physical interface.
[43] Leduc-Mills *et al*., 2013	ioCane, a mobility aid for blind cane users that uses detachable cane-mounted ultrasonic sensors connected to a circuit board to send contextual data wirelessly to an Android phone application.	N=15 surveys back from 9 women and 6 men. Aged 20-59 years old (mean 29).	A simple obstacle course was set up with a 12" by 18" cardboard obstacle at 2', 4', and 6' heights and 15' to 30' distances. Each run without the ioCane varied the obstacle's height and distance, then was repeated with it.	A pilot study discovered that blind cane users detected 47.3% more obstacles with the ioCane.	The ioCane, a mobility aid for the blind, is the first system to integrate an ultrasonic sensor array with Android phones. Obstacle avoidance is achieved through haptic and audio feedback that correspond to the distance and height of obstacles.
[44] Lopes *et al*., 2012	An EMA (Mobi Free Cane)	N=2 blind individual	The cane was used for over two hours by one person and a week by another. The author received great responses and useful advice from both.		The cane detected drop-offs and holes in time and helped the blind go down stairs by recognising each step and providing valuable information about its origin and end.
[13]	Smartphones and	N= 466 (age M = 41, SD	Data were collected from an	participant would use PCs	Results show that

Martiniello *et al*., 2022	tablets.	= 14, age range 18-80).	anonymous online survey. On average, the 55-question survey took 42.7 (SD = 32.7) minutes. These questions also examined how mainstream technology is replacing conventional assistive solutions for daily tasks.	with screen readers ($p < .001$)	visually challenged adults utilise mainstream gadgets in place of or in combination with traditional assistive aids for certain tasks, although traditional devices are still better for typing and editing.
[45] Velázquez *et al*., 2015	Electronic tactile interfaces for the foot(3 prototypes)	N=60 voluntary subjects. Male=39 Female=21. All individuals were healthy sighted and had no tactile sensory or cognitive impairments. They were 18-24 years old, averaging 20.5.	Perceptual experiments involving direction recognition and real-time navigation in space were conducted	Subjects wearing the first, second, and third prototypes had 76%, 88.3%, and 94.2% direction recognition percentages. Exhibiting tactile-foot stimulation improvement.	Results reveal that participants could follow space-navigating directions. Tactile footwear can help visually impaired persons navigate around.
[46] Deverell *et al*., 2023	smartphone accessibility features	face-to-face in Malaysia (n=9), and online in Australia (n=50). TheMalaysian (n=9; 89% male; population mean age: 33, age range: 20 to>70) The online survey	The O&M clients' pilot technology survey was administered face-to-face in Malaysia and observed during travel, then amended and administered online in Australia.	Australian participants rated their own skills: 44% said they were good at technology.	Smartphone apps seemed to give O&M clients real-time information to travel solo more confidently.

		(n=50, 42% male; mean age: 39, age range:70)			
[17] Katemake *et al*., 2019	novel LED-based lighting solutions	N=134 From here 13 elderly others age not specified.	The mobility walk course was carried out in 7 separate sessions. The 7th session, performed with LEDs switched off, was analysed separately.	($p < .05$)	According to research, assistive lighting may help low-vision people with mobility.
[47] Poggi & Mattoccia, 2016	wearable mobility aid purely based on 3D computer vision and machine learning techniques	N= 20, with different degrees of visual impairments.	This device provides audible and tactile feedback to assist users understand their surroundings and avoid obstacles.	(98% obstacle detection rate) and promising object categorization (72% correctness).	Experimental findings showed that the device had good obstacle detection and semantic categorization.
[48] S. Bhatlawande *et al*., 2014	electronic mobility cane	N=16 totally blind N=4 low vision subjects	Each subject was asked to walk 50-meter environment. Each subject's NOA, NOCA, NONP, and PPWS were recorded.	The rate of collisions was quite high for white cane than the EMC (outcome used NOCA: $p<0.001$).	When faced with real-world obstacles, subjects were confident with the EMC.
[49] McMullan & Butler, 2019	mobility scooters	N=4 with low vision, aged 51 and over.	Go-along, semi-structured interviews, and the vision-related outcomes in orientation and mobility (VROOM) test of functional vision for mobility were employed.	Thematic analysis	The scooter's experience and quality of life are hard to match, and an older adult with impaired vision operating a mobility scooter may seem unsafe to

					bystanders.
[50] Isaksson *et al*., 2020	Audomni Super-Scale Sensory Supplementation		Vertical and Depth and Horizontal Differentiation		Audomni had a low learning curve and completed multiple mobility subtasks, but better real-life motivation and data collecting costs would improve the tests.
[30] Romeo *et al*., 2022	MAPS (Mobility Assistance Path Planning and orientation in Space	N=7blindfolded participants (three women and four men), grouped into two age groups: below 30 years old (four participants) and above 30 years old (three participants). The age of the participants varies from 22 to 68 with an average of 35.85.	The MAPS was tested in a labyrinth using blinded participants' feedback and environment interaction.		The preliminary results of the TactiBelt's experimental evaluation with VIP and blinded people in a simulated environment reveal that it offers essential data for secure and independent mobility towards a static goal.
[51] Hoffmann *et al*., 2018	The Sound of Vision (SoV) system	N=6 visually impaired participants. (two females; age, 29 to 46 years; average, 34.67 ± 7.39 years).	All five assessments were completed in the same setting: 15 m between starting point and destination in a straight	After training, median collision frequency dropped from 6.25 (interquartile range, 2.0) to 3.50 (interquartile range,	Unlike the cane, the SoV system can find the best open space between objects within a 3.5-m (up to 10-m)

			corridor 190 cm wide, with 10 obstacles, three high and seven low.	1.5).	radius, including elevated and dynamic obstacles.
[52] Zhao *et al*., 2019	A Customizable Head-mounted Vision Enhancement System (Foresee).	N= 11 low vision participants, (13 females, 7 males) with a mean age of 46 (range: 21-68).	The study gave participants four performance tasks. Then chose these tasks because low-vision people face daily obstacles.		Both speech commands and smartphone-based motions let low-vision users customise their HMD visual experience.

Conclusion

Efficiency is the most frequently observed quality in outcome measures, including percentage of preferred walking speed, time, distance, and speed,obstruction detection and avoidance fall in an additional category.Most of the studies, which was incorporated into this article, has shown that electronic devices are more comfortable and efficient for mobility than other optical devices under various retinal situations.

The primary obstacle to accessibility and mobility for individuals with visual impairments has consistently been a shift in attitude. Prior to the 20th century, the utilisation of any form of mobility assistance was seen as a sign that those with visual impairments were different and usually dependent on others.Electronic mobility aids are more costly than optical and non-optical aids.Telescopes are typically suggested for extended distances vision needs, but they often have a significant difference between their cost and benefits. Additionally, their cumbersome features sometimes cause patients to give up on using them due to frustration.Obtaining a low vision aid (LVA) was found to be a strong indicator of considerable increase in the quality of life connected to vision.

In contrast to the belief of many physicians, studies have shown that low income, rural populations do in fact benefit from LVAs. Referrals for low vision aids (LVAs) can significantly improve a patient's quality of life, notably in terms of mobility, even in rural areas of India. Hence, it is necessary for physicians to bear in mind the need to refer patients who fulfil the requirements for a low vision assessment. Efforts should be directed towards increasing the effective use of low vision services in low resource areas to enhance the mobility of patients with impaired vision in urban scenarios.

References

1. Hersh MA, García Ramírez AR. Evaluation of the electronic long cane: improving mobility in urban environments. Behav Inf Technol. 2018;37(12):1203-22. doi:10.1080/0144929X.2018.1490454.
2. Chang KYJ, Dillon LL, Deverell L, Boon MY, Keay L. Orientation and mobility outcome measures. Clin Exp Optom. 2020;103(4):434-48. doi:10.1111/cxo.13004.
3. Culham LE, Chabra A, Rubin GS. Clinical performance of electronic, head-mounted, low-vision devices. Ophthalmic Physiol Opt. 2004;24(4):281-90. doi:10.1111/j.1475-1313.2004.00193.x.

4. Stickel MS, Ryan S, Rigby PJ, Jutai JW. Toward a comprehensive evaluation of the impact of electronic aids to daily living: evaluation of consumer satisfaction. Disabil Rehabil. 2002;24(1-3):115-25. doi:10.1080/09638280110066794.

5. Bai J, Lian S, Liu Z, Wang K, Liu D. Smart guiding glasses for visually impaired people in indoor environment. IEEE Trans Consum Electron. 2017;63(3):258-66. doi:10.1109/TCE.2017.014980.

6. Soong GP, Lovie-Kitchin JE, Brown B. Preferred walking speed for assessment of mobility performance: sighted guide versus non-sighted guide techniques. Clin Exp Optom. 2000;83(5):279-82. doi:10.1111/j.1444-0938.2000.tb05017.x.

7. Islam MI, Raj MM, Nath S, Rahman MF, Hossen S, Imam MH. An indoor navigation system for visually impaired people using a path finding algorithm and a wearable cap. 2018 3rd Int Conf Converg Technol I2CT. 2018;1-6. doi:10.1109/I2CT.2018.8529757.

8. Jutai JW, Strong JG, Elizabeth RM. Effectiveness of assistive technologies for low vision rehabilitation: a systematic review. J Vis Impair Blind. 2009;103(4):210-22. doi:10.1177/0145482x0910300404.

9. Penrod WM, Simmons TJ, Bauder DK, Lee DB. A comparison of selected secondary electronic travel aids with a primary mobility system. Int J Orientat Mobil. 2009;2(1):27-41. doi:10.21307/ijom-2009-003.

10. Brown B, Brabyn JA. Mobility and low vision: a review. Clin Exp Optom. 1987;70(3):96-101. doi:10.1111/j.1444-0938.1987.tb04218.x.

11. Thomas R, Barker L, Rubin G, Dahlmann-Noor A. Assistive technology for children and young people with low vision. Cochrane Database Syst Rev. 2015;2015(6). doi:10.1002/14651858.CD011350.pub2.

12. Martiniello N, Eisenbarth W, Lehane C, Johnson A, Wittich W. Exploring the use of smartphones and tablets among people with visual impairments: are mainstream devices replacing the use of traditional visual aids? Assist Technol. 2022;34(1):34-45. doi:10.1080/10400435.2019.1682084.

13. Budrionis A, Plikynas D, Daniušis P, Indrulionis A. Smartphone-based computer vision travelling aids for blind and visually impaired individuals: a systematic review. Assist Technol. 2022;34(2):178-94. doi:10.1080/10400435.2020.1743381.

14. Do AT, Ilango K, Ramasamy D, Kalidasan S, Balakrishnan V, Chang RT. Effectiveness of low vision services in improving patient quality of life at Aravind Eye Hospital. Indian J Ophthalmol. 2014;62(12):1125-31. doi:10.4103/0301-4738.149130.

15. Smith AJ, De l'Aune W, Geruschat DR. Low vision mobility problems: perceptions of O and M specialists and persons with low vision. J Vis Impair Blind. 1992;86(1):58-62. doi:10.1177/0145482x9208600122.

16. Katemake P, Radsamsong A, Dinet, Heng CW, Kuang YC, Kalavally V, *et al*. Influence of LED-based assistive lighting solutions on the autonomous mobility of low vision people. Build Environ. 2019;157:172-84. doi:10.1016/j.buildenv.2019.04.026.

17. Petrie H, Johnson V, Strothotte T, Raab A, Michel R, Reichert L, *et al*. MoBIC: an aid to increase the independent mobility of blind travellers. Br J Vis Impair. 1997;15(2):63-6. doi:10.1177/026461969701500205.

18. Ehrlich JR, Moroi SE. Comment on "Clinical effectiveness of currently available low-vision devices in glaucoma patients with moderate-to-severe vision loss". Clin Ophthalmol. 2017;11:1119-20. doi:10.2147/OPTH.S140149.

19. Brown FE, Sutton J, Yuen HM, Green D, Van Dorn S, Braun T, *et al*. A novel, wearable, electronic visual aid to assist those with reduced peripheral vision. PLoS One. 2019;14(10):e0223755. doi:10.1371/journal.pone.0223755.

20. Nguyen NX, Weismann M, Trauzettel-Klosinski S. Improvement of reading speed after providing of low vision aids in patients with age-related macular degeneration. Acta Ophthalmol. 2009;87(8):849-53. doi:10.1111/j.1755-3768.2008.01423.x.

21. Kiuru T, Metso M, Utriainen M, Metsävainio K, Jauhonen HM, Rajala R, *et al*. Assistive device for orientation and mobility of the visually impaired based on millimeter wave radar technology-clinical investigation results. Cogent Eng. 2018;5(1):1450322. doi:10.1080/23311916.2018.1450322.

22. Htike HM. Utilizing AR glasses as mobility aid for people with low vision. Proc IEEE Conf Virtual Real 3D User Interfaces, VRW. 2020;541-2. doi:10.1109/VRW50115.2020.00122.

23. Chaccour K, Badr G. Computer vision guidance system for indoor navigation of visually impaired people. Proc IEEE 8th Int Conf Intell Syst (IS). 2016;449-54. doi:10.1109/IS.2016.7737460.

24. Plikynas D, Zvironas A, Gudauskis M. Indoor electronic traveling aids for visually impaired: systemic review. Proc 6th Annu Conf Comput Sci Comput Intell (CSCI). 2019;936-42. doi:10.1109/CSCI49370.2019.00178.

25. Goodrich GL, Ludt R. Assessing visual detection ability for mobility in individuals with low vision. Vis Impair Res. 2003;5(2):57-71. doi:10.1076/vimr.5.2.57.26265.

26. van Rheede JJ, Wilson IR, Qian RI, Downes SM, Kennard C, Hicks SL. Improving mobility performance in low vision with a distance-based representation of the visual scene. Invest Ophthalmol Vis Sci. 2015;56(8):4802-9. doi:10.1167/iovs.14-16311.

27. Vishal B, Gaurav Kr B, Sourav K, Animesh M. Barriers in attaining low-vision care services: a narrative review. Delta J Ophthalmol. 2022;23(4):221-5. doi:10.4103/djo.djo_15_22.

28. Malkin AG, Ross NC, Chan TL, Protosow K, Bittner AK. U.S. optometrists' reported practices and perceived barriers for low vision care for mild visual loss. Optom Vis Sci. 2020;97(1):45-51. doi:10.1097/OPX.0000000000001468.

29. Romeo K, Pissaloux E, Gay SL, Truong NT, Djoussouf L. The MAPS: toward a novel mobility assistance system for visually impaired people. Sensors. 2022;22(9):3316. doi:10.3390/s22093316.

30. Santos ADP dos, Suzuki AHG, Medola FO, Vaezipour A. A systematic review of wearable devices for orientation and mobility of adults with visual impairment and blindness. IEEE Access. 2021;9:162306-24. doi:10.1109/ACCESS.2021.3132887.

31. Roentgen UR, Gelderblom GJ, Soede M, De Witte LP. The impact of electronic mobility devices for persons who are visually impaired: a systematic review of effects and effectiveness. J Vis Impair Blind. 2009;103(11):743-53. doi:10.1177/0145482x0910301104.

32. Peterson RC, Wolffsohn JS, Rubinstein M, Lowe J. Benefits of electronic vision enhancement systems (EVES) for the visually impaired. Am J Ophthalmol. 2003;136(6):1129-35. doi:10.1016/S0002-9394(03)00567-1.

33. O'Brien EE, Mohtar AA, Diment LE, Reynolds KJ. A detachable electronic device for use with a long white cane to assist with mobility. Assist Technol. 2014;26(4):219-26. doi:10.1080/10400435.2014.926468.

34. Vincent C, Routhier F, Martel V, Mottard ME, Dumont F, Côté L, *et al*. Field testing of two electronic mobility aid devices for persons who are deaf-blind. Disabil Rehabil Assist Technol. 2014;9(5):414-20. doi:10.3109/17483107.2013.825929.

35. Roentgen UR, Gelderblom GJ, De Witte LP. User evaluation of two electronic mobility aids for persons who are visually impaired: a quasi-experimental study using a standardized mobility course. Assist Technol. 2012;24(2):110-20. doi:10.1080/10400435.2012.659794.

36. Everingham MR, Thomas BT, Troscianko T. Head-mounted mobility aid for low vision using scene classification techniques. Int J Virtual Real. 1998;3(4):1-10. doi:10.20870/ijvr.1998.3.4.2629.

37. Wittich W, Lorenzini MC, Markowitz SN, Tolentino M, Gartner SA, Goldstein JE, *et al*. The effect of a head-mounted low vision device on visual function. Optom Vis Sci. 2018;95(9):774-84. doi:10.1097/OPX.0000000000001262.

38. Abreu D, Codina B, Toledo J, Suárez A. Validation of an EBAT as a mobility aid for blind people. Assist Technol. 2022;34(2):195-203. doi:10.1080/10400435.2020.1743380.

39. Angelopoulos AN, Ameri H, Mitra D, Humayun M. Enhanced depth navigation through augmented reality depth mapping in patients with low vision. Sci Rep. 2019;9(1):11230. doi:10.1038/s41598-019-47397-w.

40. Bhatlawande SS. Ultrasonic spectacles and waist-belt for visually impaired and blind person. 2012;8-11.

41. Taylor P, Bhatlawande S, Sunkari A, Mahadevappa M, Mukhopadhyay J. Electronic bracelet and vision enabled waist-belt for mobility of visually impaired people. Assist Technol. 2014;26(4):37-41. doi:10.1080/10400435.2014.915896.

42. Leduc-Mills B, Profita H, Bharadwaj S, Cromer P, Han R. IoCane: a smart-phone and sensor-augmented mobility aid for the blind. 2013.

43. Lopes SI, Vieira JMN, Lopes ÓFF, Rosa PRM, Dias NASM. MobiFree: a set of electronic mobility aids for the blind. Procedia Comput Sci. 2012;14:10-19. doi:10.1016/j.procs.2012.10.002.

44. Velázquez R, Pissaloux E, Lay-Ekuakille A. Tactile-foot stimulation can assist the navigation of people with visual impairment. Appl Bionics Biomech. 2015;2015:798748. doi:10.1155/2015/798748.

45. Deverell L, Bhowmik J, Al Mahmud A, Lau BT, Islam FMA, Sukunesan S, *et al*. Self-reported use of technology by orientation and mobility clients in Australia and Malaysia before the COVID-19 pandemic. Br J Vis Impair. 2023;41(1):33-48. doi:10.1177/02646196211019070.

46. Poggi M, Mattoccia S. A wearable mobility aid for the visually impaired based on embedded 3D vision and deep learning. Proc IEEE Symp Comput Commun. 2016;208-13. doi:10.1109/ISCC.2016.7543741.

47. Bhatlawande S, Mahadevappa M, Mukherjee J, Biswas M, Das D, Gupta S. Design, development, and clinical evaluation of the electronic mobility cane for vision rehabilitation. IEEE Trans Neural Syst Rehabil Eng. 2014;22(6):1148-59. doi:10.1109/TNSRE.2014.2324974.

48. McMullan KS, Butler M. Low vision and mobility scooters: the experiences of individuals with low vision who use mobility scooters. Disabil Rehabil Assist Technol. 2019;14(6):574-80. doi:10.1080/17483107.2018.1470685.

49. Isaksson J, Jansson T, Nilsson J. Audomni: super-scale sensory supplementation to increase the mobility of blind and low-vision individuals - a pilot study. IEEE Trans Neural Syst Rehabil Eng. 2020;28(5):1187-97. doi:10.1109/TNSRE.2020.2985626.

50. Hoffmann R, Spagnol S, Kristjánsson Á, Unnthorsson R. Evaluation of an audio-haptic sensory substitution device for enhancing spatial awareness for the visually impaired. Optom Vis Sci. 2018;95(9):757-65. doi:10.1097/OPX.0000000000001284.

51. Zhao Y, Szpiro S, Shi L, Azenkot S. Designing and evaluating a customizable head-mounted vision enhancement system for people with low vision. ACM Trans Access Comput. 2019;12(4):3361866. doi:10.1145/3361866.

Chapter - 13
Chewing Gum as a Potential Intervention for Digital Eye Strain: A Double-Blind Crossover Study

Authors

Sourav Karmakar
Department of Optometry, Swami Vivekananda University, Barrackpore, West Bengal, India

Chapter - 13

Chewing Gum as a Potential Intervention for Digital Eye Strain: A Double-Blind Crossover Study

Sourav Karmakar

Abstract

Objective: This study aimed to evaluate the effects of chewing gum on digital eye strain, focusing on subjective eye fatigue, accommodative function, and ocular parameters in healthy individuals exposed to prolonged digital device use.

Methods: A double-blind, crossover design was employed, with 46 participants (23 men and 23 women) aged 20 to 59 years randomized to chew either gum or tablet candy during a 60-minute visual task. Subjective eye fatigue was assessed using a visual analog scale (VAS). Accommodative function was measured using the D'ACOMO device (WOC, Kyoto, Japan), spherical equivalent refraction was measured using the RT-7000 Auto Ref-Topographer (Tomey, Nagoya, Japan), and eye dryness was assessed using the Tear Stability Analysis System (TSAS) (Tomey, Nagoya, Japan). Statistical analyses included the Wilcoxon signed-rank test to compare pre- and post-task measurements within each group and the Kruskal-Wallis test to assess age-group differences.

Results: No significant differences were observed in subjective eye fatigue between chewing gum and tablet candy across all categories (eye tiredness: $P = 0.657$; eye heaviness: $P = 0.694$; blurred vision: $P = 0.909$; double vision: $P = 0.397$; eye dryness: $P = 0.757$). However, chewing gum significantly reduced the decline in amplitude of accommodation compared to tablet candy ($P = 0.043$, $r = 0.211$), with greater reduction observed in younger adults ($P < 0.001$). No significant changes were detected in spherical equivalent refraction or eye dryness ($P > 0.05$).

Conclusion: Chewing gum may modestly reduce the decline in amplitude of accommodation, particularly among younger adults, potentially related to changes in parasympathetic activity. While these findings suggest a potential benefit for reducing digital eye strain, further research is needed

to confirm the long-term effects and underlying mechanisms of chewing gum on ocular health.

Keywords: chewing gum, digital eye strain, accommodative function, parasympathetic nervous system, visual fatigue.

Introduction

The widespread use of digital devices, such as computers, smartphones, and tablets, has become an integral part of modern life. However, prolonged exposure to these devices often leads to digital eye strain, a condition formally defined as "the development or exacerbation of recurrent ocular symptoms and/or signs related to sustained use of digital screens" (Rosenfield *et al*., 2012). Common symptoms include eye fatigue, blurred vision, accommodative dysfunction, and dryness, which arise from the sustained focus required for near-vision tasks. These tasks strain the ciliary muscles of the eye, which are regulated by the parasympathetic nervous system and play a critical role in the eye's ability to focus on nearby objects (Porcar *et al*., 2018).

Chewing gum has been proposed as a potential intervention to alleviate digital eye strain. The act of chewing is known to stimulate the parasympathetic nervous system, which may enhance blood flow to the eyes and improve accommodative function. Specifically, mastication activates the parasympathetic pathway via the trigeminal nerve, leading to increased activity in the ciliary muscles and improved ocular blood flow (Asakawa *et al*., 2007). Studies have shown that chewing gum can increase cerebral blood flow and reduce stress, which may indirectly benefit individuals experiencing eye strain (Momose *et al*., 1997; Allen & Smith, 2015). Furthermore, chewing gum has been associated with improved cognitive performance and alertness, which could help mitigate the mental fatigue associated with prolonged digital device use (Wilkinson *et al*., 2002).

Despite these potential benefits, the direct effects of chewing gum on digital eye strain remain underexplored. While some studies suggest that chewing gum may enhance parasympathetic activity and improve accommodative function, the specific mechanisms and pathways involved are not fully understood (Kanno *et al*., 2019). Additionally, there is limited evidence comparing the effects of chewing gum to other interventions, such as tablet candy, to determine whether the benefits are due to the mechanical act of chewing or the specific properties of gum.

This study aimed to address these gaps by investigating the effects of chewing gum on digital eye strain in healthy individuals exposed to prolonged digital device use. Specifically, the study sought to answer the following research questions:

1) Does chewing gum reduce subjective eye fatigue compared to a control substance (tablet candy)?
2) Does chewing gum improve accommodative function, as measured by the amplitude of accommodation, and is this effect more pronounced in specific age groups?
3) Are there any significant changes in spherical equivalent refraction or eye dryness associated with chewing gum?

By addressing these questions, this study aims to provide evidence-based insights into the potential benefits of chewing gum as a simple, non-invasive intervention for digital eye strain.

Methodology

Subjects

Participants were recruited through a contract research organization based in Hariyana, India. The study included 46 healthy individuals (23 men and 23 women) aged 20 to 59 years who reported experiencing eye strain, defined as the presence of at least two of the following symptoms during or after prolonged digital device use: eye tiredness, eye heaviness, blurred vision, double vision, or eye dryness. These symptoms were assessed using a standardized questionnaire adapted from the Computer Vision Syndrome Questionnaire (CVS-Q) (Seguí *et al*., 2015), with a minimum score of 6 out of 12 required for inclusion.

Exclusion criteria included pregnancy, lactation, regular use of dietary supplements, allergies to gelatin-based products (e.g., gum or tablet candy), severe dry eye syndrome (defined as the inability to refrain from blinking for 5 seconds), or an inability to chew gum or tablet candy. Four individuals (two men and two women) were excluded due to severe dry eye syndrome, as their condition could confound the assessment of eye dryness outcomes.

Study Design

This study employed a double-blind, crossover design to minimize bias and ensure the reliability of the results. Participants were stratified by age and sex and randomly assigned to one of two groups: one group chewed gum first, followed by tablet candy, while the other group followed the reverse

order. The study was approved by the Research Ethics Committee of Amity University Amity Medical School (approval No. 2021-006) and registered with the clinical trials registry.

Blinding

Both participants and examiners were blinded to the sample type. Participants were informed that the study aimed to investigate the effects of a sample substance (gum or tablet candy) on computer work, without disclosing the true purpose. Examiners distributing the samples were also blinded, and the examiner conducting the visual task waited in a separate room to avoid bias. Data analysts were blinded to group assignments during the analysis phase.

Testing Procedure

Testing sessions were conducted between 9:00 A.M. and 4:00 P.M. in a controlled environment with a light level of approximately 500 lx, a temperature of 24°C, and humidity maintained between 40% and 60%. Participants underwent a series of tests on two separate days, with the order of gum and tablet candy administration counterbalanced.

The Testing Protocol Included the Following Steps

- **Baseline Measurements:** Participants provided written informed consent and underwent routine visual acuity and refraction tests.
- **Break:** A 30-minute break was provided to allow participants to acclimate to the testing environment.
- **Pre-Task Measurements:** Baseline measurements of subjective eye fatigue, subjective accommodation, spherical equivalent refraction, and eye dryness were recorded.
- **Visual Task:** Participants performed a 60-minute reading task on a computer screen, selecting their own reading material from a free website (https://www.satokazzz.com/books/). A 1-minute break was provided after the first 30 minutes.
- **Sample Administration:** Participants chewed the assigned sample (gum or tablet candy) for two 15-minute periods, starting at 15 and 45 minutes after the task began.
- **Post-Task Measurements:** Subjective eye fatigue, subjective accommodation, spherical equivalent refraction, and eye dryness were measured again after the visual task.

Sample Substances

The gum and tablet candy used in the study were similar in caloric content and macronutrient composition. The gum (1.0 g per piece) contained maltitol, gum base, mint flavor, gelatin, sugar ester, and glycerin. The tablet candy (0.7 g per piece) contained the same ingredients except for the gum base. Both samples provided 100 kcal per serving, with macronutrient composition as follows: carbohydrate (100%), protein (0%), and fat (0%). Neither sample contained caffeine or other stimulants.

Outcome Measures

Primary Outcome

- **Subjective Eye Fatigue:** Subjective eye fatigue was assessed using a visual analog scale (VAS) with five categories: eye tiredness, eye heaviness, blurred vision, double vision, and eye dryness. Participants rated the severity of each symptom on a 100-mm horizontal line, with 0 mm representing "not present at all" and 100 mm representing "very severe".

Secondary Outcomes

- **Subjective Accommodation:** Measured using the D'ACOMO device (WOC, Kyoto, Japan). The device uses a moving visual target (yellow cross) to determine the near and far points of accommodation. The target is moved toward the subject at 0.2 D/s until it becomes blurred (near point) and away from the subject until it becomes blurred again (far point). The amplitude of accommodation (D) was calculated as 100/near point - 100/far point.
- **Spherical Equivalent Refraction:** Measured using the RT-7000 Auto Ref-Topographer (Tomey, Nagoya, Japan). Spherical and cylindrical powers were measured three times, and the spherical equivalent refraction (D) was calculated. Cycloplegia was not used, which is acknowledged as a limitation.
- **Eye Dryness:** Assessed using the Tear Stability Analysis System (TSAS) (Tomey, Nagoya, Japan). The ring break-up time (RBUT) was measured by analyzing the break-up of the tear layer within a 6-mm radius of the center of the cornea. The subject was instructed to keep their eyes open for 10 seconds, and the time (in seconds) required to reach the cut-off value of -0.5 D was recorded.

Statistical Analysis Data were analyzed using SPSS version 26.0 (IBM, Armonk, NY, USA). The Wilcoxon signed-rank test was used to compare pre-and post-task measurements within each group for the following outcomes:

- Subjective eye fatigue (VAS scores for eye tiredness, eye heaviness, blurred vision, double vision, and eye dryness).
- Subjective accommodation (amplitude of accommodation).
- Spherical equivalent refraction.
- Eye dryness (ring break-up time, RBUT).

The Kruskal-Wallis test was used to assess differences in outcomes across age groups (20s, 30s, 40s, and 50s). If a significant result was obtained ($P < 0.05$), post-hoc comparisons were performed using the Mann-Whitney U test with Bonferroni correction to control for multiple comparisons. Specifically, the following pairwise comparisons were made: 20s vs. 30s, 20s vs. 40s, 20s vs. 50s, 30s vs. 40s, 30s vs. 50s, 40s vs. 50s

Effect sizes (r) were calculated for significant results to assess the magnitude of observed differences. Results are presented as medians and interquartile ranges (IQRs). A P-value of < 0.05 was considered statistically significant.

Results

Primary Outcome

Subjective Eye Fatigue

No significant differences were observed in the change in VAS scores from baseline between chewing gum and tablet candy across all categories (all $P > 0.05$). Specifically:

- **Eye Tiredness:** Median change with gum: 1.5 mm (IQR:-6.5, 19.8); tablet candy: 11.5 mm (IQR:-7.8, 28.5); $P = 0.657$.
- **Eye Heaviness:** Median change with gum: 3.5 mm (IQR:-9.3, 19.5); tablet candy: 4.5 mm (IQR:-4.3, 25.3); $P = 0.694$.
- **Blurred Vision:** Median change with gum: 0 mm (IQR:-2.3, 15.0); tablet candy: 0 mm (IQR:-5.8, 19.3); $P = 0.909$.
- **Double Vision:** Median change with gum: 0 mm (IQR:-1.0, 7.3); tablet candy: 1.0 mm (IQR:-1.3, 14.5); $P = 0.397$.

- **Eye Dryness:** Median change with gum: 0 mm (IQR:-9.8, 16.3); tablet candy: 1.0 mm (IQR:-12.0, 19.3); P = 0.757.

Secondary Outcomes

- **Subjective Accommodation (Diopters, D):** A significant reduction in the amplitude of accommodation was observed after the visual task with chewing gum compared to tablet candy (P = 0.043, r = 0.211). The median change in amplitude of accommodation was-0.04 D (IQR:-0.32, 0.42) with gum and-0.14 D (IQR:-0.50, 0.22) with tablet candy. Age-group comparisons revealed significant differences (P < 0.001), with the greatest reduction observed in the 20s group compared to the 40s (P = 0.002, r = 0.527) and 50s (P = 0.002, r = 0.513) groups.
- **Spherical Equivalent Refraction (Diopters, D):** No significant shift toward myopia was detected (P = 0.267). The median change in spherical equivalent refraction was 0 D (IQR:-0.25,-0.13) with gum and 0 D (IQR:-0.25, 0.13) with tablet candy. Age-group differences were significant (P = 0.010), with notable variations between the 30s and 40s groups (P = 0.007, r = 0.487).
- **Eye Dryness (Ring Break-Up Time, RBUT in seconds):** No significant differences were observed between chewing gum and tablet candy (P = 0.680). The median RBUT values before and after the visual task were 10.0 sec (IQR: 8.5, 11.5) and 9.6 sec (IQR: 8.0, 11.0) with gum, and 9.9 sec (IQR: 8.4, 11.4) and 9.6 sec (IQR: 8.1, 11.1) with tablet candy.

TABLE 2: Data of between chewing gum and tablet candy in all subjects.

Outcomes		Number of data	Gum (Δ) Median (IQR)	Tablet candy (Δ) Median (IQR)	*P* value	*r*
VAS (mm)	Eye tiredness	46	1.5 (-6.5, 19.8)	11.5 (-7.8, 28.5)	0.657	0.065
	Eye heaviness		3.5 (-9.3, 19.5)	4.5 (-4.3, 25.3)	0.694	0.058
	Blurred vision		0 (-2.3, 15.0)	0 (-5.8, 19.3)	0.909	0.017
	Double vision		0 (-1.0, 7.3)	1.0 (-1.3, 14.5)	0.397	0.125
	Eye dryness		0 (-9.8, 16.3)	1.0 (-12.0, 19.3)	0.757	0.046
Subjective accommodation (D)			-0.04 (-0.32, 0.42)	-0.14 (-0.50, 0.22)	0.043*	0.211
Spherical equivalent refraction (D)		92	0 (-0.25, -0.13)	0 (-0.25, 0.13)	0.267	0.116
Ring break-up time (sec)			0 (-2.35, 0.15)	0 (-1.15, 0)	0.680	0.043

IQR: interquartile range (25th, 75th percentiles); VAS: visual analog scale. *$P < 0.05$; Wilcoxon signed-rank test. *r*: effect size.

TABLE 3: Data of between chewing gum and tablet candy in each age group.

	Outcomes		20 s ($n = 12$)	30 s ($n = 10$)	40 s ($n = 12$)	50 s ($n = 12$)	*P* value
			Median (IQR)				
Gum (Δ)	VAS (mm)	Eye tiredness	7.0 (-4.5, 21.3)	2.5 (-5.5, 46.3)	0 (-5.3, 11.8)	1.5 (-15.3, 23.8)	0.794
		Eye heaviness	5.0 (-9.3, 19.5)	9.5 (-4.0, 25.8)	-0.5 (-24.8, 13.0)	8.0 (-8.3, 27.3)	0.424
		Blurred vision	0 (-0.8, 6.3)	5.5 (0, 21.3)	0 (-15.8, 20.5)	-2.0 (-11.5, 11.8)	0.537
		Double vision	0 (-1.8, 5.8)	0.5 (-0.3, 16.3)	0 (0, 8.8)	0.5 (-4.0, 13.3)	0.789
		Eye dryness	3.0 (-11.3, 12.8)	17.5 (-0.3, 36.3)	-1.5 (-15.3, 10.3)	-0.5 (-17.3, 6.8)	0.240
	Subjective accommodation (D)		-0.2 (-0.9, 0.4)	-0.2 (-0.6, 0.2)	0.2 (-0.1, 0.6)	-0.1 (-0.2, 0.3)	0.055
	Spherical equivalent refraction (D)		0 (-0.1, 0.2)	0 (-0.3, 0)	-0.1 (-0.4, 0.3)	0 (-0.3, 0.1)	0.345
	Ring break-up time (sec)		-0.1 (-3.2, 0)	0 (-4.2, 0)	-0.2 (-2.8, 2.2)	0 (-1.3, 0.6)	0.417
Tablet candy (Δ)	VAS (mm)	Eye tiredness	14.5 (9.0, 34.3)	14.0 (-17.5, 27.5)	0.5 (-14.0, 24.3)	15.5 (-14.5, 34.8)	0.524
		Eye heaviness	3.0 (-0.8, 35.0)	4.0 (-7.8, 20.8)	-1.0 (-17.3, 10.0)	14.0 (-1.8, 28.5)	0.355
		Blurred vision	2.0 (-1.5, 18.3)	2.0 (-20.3, 31.0)	2.5 (-10.3, 17.8)	-1.5 (-9.5, 18.5)	0.792
		Double vision	0.5 (-3.3, 9.0)	0 (-1.8, 20.5)	4.0 (0, 19.5)	5.5 (-2.0, 12.0)	0.514
		Eye dryness	11.0 (-0.8, 32.5)	5.5 (-8.3, 37.0)	0 (-15.8, 10.0)	0 (-25.5, 17.5)	0.237
	Subjective accommodation (D)		-0.7 (-1.4, -0.2)	-0.2 (-0.9, 0.3)	0.1 (-0.1, 0.4)†	0 (-0.2, 0.2)‡	< 0.001***
	Spherical equivalent refraction (D)		0 (-0.3, 0.1)	0 (0, 0.1)	-0.3 (-0.4, 0)§	0 (-0.3, 0.1)	0.010**
	Ring break-up time (sec)		0 (-1.7, 0)	0 (-5.9, 0)	0 (-0.9, 0)	0 (-0.1, 1.4)	0.221

IQR: interquartile range (25th, 75th percentiles); VAS: visual analog scale. **$P < 0.01$, ***$P < 0.001$; Kruskal-Wallis test. †$P = 0.002$, $r = 0.527$ (20 s vs. 40 s), ‡$P = 0.002$, $r = 0.513$ (20 s vs. 50 s), §$P = 0.007$, $r = 0.487$ (30 s vs. 40 s); Mann–Whitney *U* test with Bonferroni's correction. *r*: effect size.

TABLE 4: Data of before and after chewing gum or tablet candy in all subjects.

Sample		Outcomes	Number of data	Before Median (IQR)	After Median (IQR)	*P* value	*r*
Gum	VAS (mm)	Eye tiredness	46	29 (4, 61)	45 (20, 66)	0.059	0.278
		Eye heaviness		15 (2, 42)	28 (8, 50)	0.075	0.263
		Blurred vision		15 (1, 55)	21 (1, 54)	0.155	0.210
		Double vision		4 (0, 20)	9 (1, 44)	0.032*	0.316
		Eye dryness		25 (2, 48)	32 (8, 54)	0.401	0.124
	Subjective accommodation (D)			3.9 (2.7, 6.4)	4.0 (2.7, 6.4)	0.579	0.058
	Spherical equivalent refraction (D)		92	-1.19 (-4.09, -0.25)	-1.00 (-4.34, -0.25)	0.361	0.095
	Ring break-up time (sec)			10.0 (4.7, 10.0)	9.6 (3.4, 10.0)	0.053	0.202
Tablet candy	VAS (mm)	Eye tiredness	46	24 (4, 61)	45 (22, 63)	0.013*	0.366
		Eye heaviness		17 (4, 47)	32 (9, 58)	0.025*	0.330
		Blurred vision		12 (1, 46)	29 (4, 47)	0.159	0.208
		Double vision		3 (1, 20)	12 (1, 34)	0.009**	0.384
		Eye dryness		28 (7, 58)	42 (4, 54)	0.237	0.174
	Subjective accommodation (D)			4.2 (2.7, 6.3)	3.8 (2.5, 6.0)	0.014*	0.256
	Spherical equivalent refraction (D)		92	-1.00 (-3.97, -0.38)	-1.25 (-4.34, -0.38)	0.008**	0.277
	Ring break-up time (sec)			9.9 (5.3, 10.0)	9.6 (4.3, 10.0)	0.132	0.157

IQR: interquartile range (25th, 75th percentiles); VAS: visual analog scale. *$P < 0.05$, **$P < 0.01$; Wilcoxon signed-rank test. *r*: effect size.

Discussion

The findings of this study suggest that chewing gum may modestly reduce the decline in amplitude of accommodation after prolonged visual tasks, particularly among younger adults. However, no significant differences were observed in subjective eye fatigue, spherical equivalent

refraction, or eye dryness between chewing gum and tablet candy. These results contribute to the growing body of literature on digital eye strain and the potential benefits of non-invasive interventions.

Integration with Existing Literature

The observed reduction in the decline of amplitude of accommodation with chewing gum aligns with previous studies suggesting that mastication can stimulate the parasympathetic nervous system, potentially enhancing ciliary muscle function (Asakawa *et al*., 2007). However, the lack of significant changes in subjective eye fatigue contrasts with some earlier research, which reported improvements in alertness and cognitive performance with chewing gum (Allen & Smith, 2015). This discrepancy may be due to differences in study design, such as the duration of the visual task or the specific population studied.

The absence of significant changes in spherical equivalent refraction and eye dryness is consistent with studies indicating that these parameters are less sensitive to short-term interventions (Golebiowski *et al*., 2020). However, the minor shift toward myopia observed in this study, though not statistically significant, warrants further investigation to determine whether it represents a meaningful trend or a random variation.

Mechanisms Underlying the Findings

The reduction in the decline of amplitude of accommodation with chewing gum may be related to parasympathetic nervous system activation. Mastication has been shown to increase parasympathetic activity, which could enhance ciliary muscle function and improve accommodative ability (Kanno *et al*., 2019). However, this study did not directly measure parasympathetic activity or ocular blood flow, limiting the ability to establish a causal relationship. Future studies should incorporate physiological measures, such as heart rate variability or ocular blood flow assessments, to better understand the mechanisms involved.

Limitations

This study has several limitations that should be acknowledged. First, the small sample size (n = 46) may limit the generalizability of the findings. Second, the study population consisted exclusively of Japanese adults, which may not be representative of other demographic groups. Third, the short duration of the intervention (60 minutes) may not capture the long-term effects of chewing gum on digital eye strain. Fourth, the use of tablet candy as a control may not fully account for the potential effects of mastication, as

tablet candy could have some influence on oral activity or cognitive function. Finally, the subjective nature of some outcome measures, such as the VAS for eye fatigue, introduces the possibility of bias.

Future Research Directions

Future studies should address these limitations by:

1) Increasing the sample size and including diverse populations.
2) Extending the duration of the intervention to assess long-term effects.
3) Incorporating physiological measures to directly evaluate parasympathetic activity and ocular blood flow.
4) Using a true control group (e.g., no chewing activity) to better isolate the effects of chewing gum.

Conclusion

This study found that chewing gum may modestly reduce the decline in amplitude of accommodation after prolonged visual tasks, particularly among younger adults. However, no significant differences were observed in subjective eye fatigue, spherical equivalent refraction, or eye dryness between chewing gum and tablet candy. These findings suggest that the benefits of chewing gum may be limited to specific aspects of accommodative function, potentially through parasympathetic nervous system activation. Further research is needed to confirm these findings, explore the underlying mechanisms, and assess the long-term effects of chewing gum on digital eye strain.

References

1. Allen AP, Smith AP. Chewing gum: Cognitive performance, mood, well-being, and associated physiology. BioMed Res Int. 2015;2015:654806. doi:10.1155/2015/654806.
2. Asakawa K, Ishikawa H, Shoji N, Suzuki T. Effect of mastication on the autonomic nervous system in the human eye. Auton Nerv Syst. 2007;44(2):98-103.
3. Burton MJ, Mabey DC. The global burden of trachoma: A review. PLoS Negl Trop Dis. 2009;3(10):e460. doi:10.1371/journal.pntd.0000460.
4. Chang AY, Parikh R. Climate change and eye health: A review. Ophthalmology. 2020;127(5):567-74. doi:10.1016/j.ophtha.2019.12.001.

5. Galor A, Kumar N. Air pollution and the eye. Curr Opin Ophthalmol. 2018;29(4):303-9. doi:10.1097/ICU.0000000000000481.

6. Golebiowski B, Long J, Harrison K, Lee A, Chidi-Egboka N, Asper L. Smartphone use and effects on tear film, blinking, and binocular vision. Curr Eye Res. 2020;45(4):428-34. doi:10.1080/02713683.2019.1663542.

7. Hotez PJ, Fenwick A, Molyneux DH. The new COVID-19 poor and the neglected tropical diseases resurgence. Infect Dis Poverty. 2020;9(1):10. doi:10.1186/s40249-020-00627-0.

8. Islam MS, Rahman MM, Khan MA. Climate change and eye health in Bangladesh: A call to action. Lancet Planet Health. 2022;6(3):e123-4. doi:10.1016/S2542-5196(22)00023-1.

9. Kanno S, Shimo K, Ando T, Hamada Y, Miyashita M, Osawa K. Gum chewing while walking increases fat oxidation and energy expenditure. J Phys Ther Sci. 2019;31(5):435-9. doi:10.1589/jpts.31.435.

10. Kumar N, Galor A, Khamar P. Air pollution and dry eye disease: A review. Ocul Surf. 2021;20:1-10. doi:10.1016/j.jtos.2021.01.003.

11. Momose T, Nishikawa J, Watanabe T, *et al*. Effect of mastication on regional cerebral blood flow in humans examined by positron-emission tomography with 15O-labelled water and magnetic resonance imaging. Arch Oral Biol. 1997;42(1):57-61. doi:10.1016/S0003-9969(96)00083-8.

12. Porcar E, Montalt JC, Pons ÁM, España-Gregori E. Symptomatic accommodative and binocular dysfunctions from the use of flat-panel displays. Int J Ophthalmol. 2018;11(3):501-5. doi:10.18240/ijo.2018.03.22.

13. Rosenfield M, Howarth PA, Sheedy JE, Crossland MD. Vision and IT displays: A whole new visual world. Ophthalmic Physiol Opt. 2012;32(5):363-6. doi:10.1111/j.1475-1313.2012.00923.x.

14. Seguí MD, Cabrero-García J, Crespo A, Verdú J, Ronda E. A reliable and valid questionnaire was developed to measure computer vision syndrome at the workplace. J Clin Epidemiol. 2015;68(6):662-73. doi:10.1016/j.jclinepi.2015.01.015.

15. Sherwin JC, Hewitt AW, Coroneo MT. The impact of ultraviolet radiation on the eye. Eye. 2019;33(2):173-8. doi:10.1038/s41433-018-0234-9.

16. Tsubota K, Nakamori K. Dry eyes and video display terminals. N Engl J Med. 1993;328(8):584. doi:10.1056/NEJM199302253280817.

17. Wilkinson L, Scholey A, Wesnes K. Chewing gum selectively improves aspects of memory in healthy volunteers. Appetite. 2002;38(3):235-6. doi:10.1006/appe.2001.0483.

Chapter - 14
A Case of Episcleritis: Differentiating Between Episcleritis and Scleritis

Authors

Srimanti Sarkar

Assistant Professor, Department of optometry, Swami Vivekananda University, Barrackpore, West Bengal, India

Chapter - 14

A Case of Episcleritis: Differentiating Between Episcleritis and Scleritis

Srimanti Sarkar

Background: Episcleritis is a benign, self-limiting inflammatory condition affecting the episclera, a superficial vascular layer of the eye. It is often confused with scleritis, a more severe condition involving deeper scleral tissues and frequently associated with systemic autoimmune diseases. Accurate differentiation between these two entities is essential due to the significant differences in their underlying etiologies, clinical presentations, management, and prognoses.

This case report describes a 35-year-old female who presented with unilateral ocular redness and mild discomfort, symptoms suggestive of both episcleritis and scleritis. A detailed clinical evaluation, including the phenylephrine blanching test, confirmed the diagnosis of episcleritis. Laboratory investigations revealed no systemic associations, and the patient was successfully managed with topical nonsteroidal anti-inflammatory drugs (NSAIDs) and lubricants.

The discussion emphasizes the importance of distinguishing episcleritis from scleritis through careful clinical examination and appropriate diagnostic tools. Episcleritis, characterized by sectoral or diffuse redness, minimal pain, and superficial vessel blanching with phenylephrine, requires conservative management and rarely signals systemic disease. In contrast, scleritis presents with severe pain, deeper inflammation, violaceous discoloration, and no blanching, often necessitating systemic evaluation and treatment due to its strong association with autoimmune diseases.

This case underscores the critical role of clinicians in differentiating these conditions to ensure timely and appropriate management. The report provides a concise overview of the clinical features, diagnostic methods, and treatment strategies for episcleritis and scleritis, serving as a practical guide for practitioners to avoid misdiagnosis and manage patients effectively.

Keywords: Scleritis, Episcleritis, Ocular anterior segment disorder

Introduction

Episcleritis and scleritis are both inflammatory conditions that affect the anterior segment of the eye, specifically the sclera and episclera. Though they share some overlapping symptoms, the severity of their manifestations and the underlying mechanisms are vastly different. Episcleritis is a self-limiting, benign condition that typically does not present with significant systemic associations. In contrast, scleritis is a more severe condition often associated with systemic autoimmune disorders, such as rheumatoid arthritis and lupus, and can lead to significant vision-threatening complications if not appropriately managed (Mikhail *et al*., 2022).

Correctly distinguishing between episcleritis and scleritis is essential to ensure that patients receive the most appropriate treatment. While episcleritis generally resolves with conservative therapy, scleritis may require more aggressive interventions, including systemic immunosuppressive therapy. This case report describes a 35-year-old female with unilateral ocular redness and mild discomfort, where the differentiation between episcleritis and scleritis was achieved using clinical examination and diagnostic tests.

Methodology

A comprehensive search of academic databases was conducted to identify relevant studies, case reports, review articles, and clinical guidelines. Included articles were searched through various search engine like PubMed, Google scholar, Science direct using the keywords like: Scleritis, Episcleritis, Ocular anterior segment disorder.

Case Report

A 35-year-old female presented to the clinic with complaints of redness and mild discomfort in her left eye for the past 2 days. She denied any history of trauma, visual disturbances, or previous ocular disease. The patient had no significant medical history, and no family history of autoimmune diseases or eye conditions was reported.

Upon examination, the patient exhibited localized redness on the sclera, primarily in the inferior quadrant of the left eye. The conjunctiva was not significantly involved, and the cornea appeared clear without signs of infiltration or edema. The pain was described as mild, and there was no significant photophobia. On slit-lamp examination, there was no evidence of iris or ciliary body involvement, ruling out anterior uveitis.

To differentiate between episcleritis and scleritis, the phenylephrine blanching test was performed. The test revealed blanching of the affected

blood vessels, a characteristic feature of episcleritis. This finding helped rule out scleritis, where vessels typically do not blanch. Laboratory tests, including a complete blood count (CBC), erythrocyte sedimentation rate (ESR), and rheumatoid factor, were within normal limits, further confirming the absence of systemic disease.

The patient was diagnosed with episcleritis and was treated with topical nonsteroidal anti-inflammatory drugs (NSAIDs), along with preservative-free lubricating eye drops. She was advised to follow up in one week, at which time her symptoms had resolved completely.

Discussion

Clinical Features of Episcleritis

Episcleritis is an inflammation of the episclera, the thin layer of tissue situated between the conjunctiva and the sclera. It typically presents with sectoral or diffuse redness in one eye, often associated with mild to moderate discomfort. The affected vessels are superficial and may blanch with the application of phenylephrine, a diagnostic hallmark of the condition (Galor *et al*., 2016). Pain is usually mild, and patients generally do not experience significant visual disturbance or photophobia. Systemic involvement is rare, and the condition is often not linked to any underlying systemic diseases.

Clinical Features of Scleritis

In contrast, scleritis involves inflammation of the deeper layers of the sclera, and it is often associated with more severe symptoms. Pain in scleritis is typically more intense and may be described as a deep, aching pain that can radiate to the jaw, face, or head. Scleral inflammation in scleritis is deeper and often associated with violaceous discoloration or a bluish hue of the affected area (Mikhail *et al*., 2022). The blood vessels involved do not blanch with phenylephrine, a crucial diagnostic difference from episcleritis. Scleritis is often associated with systemic autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Wegener's granulomatosis. In severe cases, scleritis can lead to complications such as scleral thinning, perforation, and even loss of vision (Rosenbaum, 2015).

Episcleritis and scleritis share overlapping symptoms but have distinct differences:

Feature	Episcleritis	Scleritis
Pain	Mild or absent	Severe, deep, boring pain
Redness	Sectoral or diffuse, bright red	Diffuse, violaceous hue

Blanching with phenylephrine	Yes	No
Visual impairment	Rare	Common
Association with systemic diseases	Rare	Common (e.g., rheumatoid arthritis, granulomatosis with polyangiitis)

Diagnostic Tools and Management

Clinical Differentiation between Episcleritis and Scleritis

Episcleritis and scleritis are both inflammatory conditions that involve the sclera and its surrounding tissues, but they differ significantly in their clinical presentation, underlying pathophysiology, and management strategies. Accurate differentiation is essential not only for appropriate treatment but also for avoiding complications. Although episcleritis is typically a self-limiting condition, scleritis can lead to severe complications, including vision loss, if not appropriately managed. This section provides a detailed discussion of the clinical features, diagnostic approaches, and management strategies that differentiate episcleritis from scleritis.

Clinical Presentation

The hallmark of episcleritis is localized, sectoral redness, often seen in one eye, without significant pain or visual impairment (Galor *et al*., 2016). Pain, when present, is usually mild and is often described as a dull ache rather than the intense, deep pain associated with scleritis. The condition generally occurs without any systemic symptoms or involvement. The inflammation is confined to the superficial episcleral blood vessels, which may blanch with the application of phenylephrine, a distinguishing feature of episcleritis (Lightman & McCluskey, 2004). This superficial vessel involvement contrasts with scleritis, where deeper vessels are affected, and there is no blanching with phenylephrine. Additionally, scleritis often presents with violaceous discoloration or a bluish tint to the sclera, particularly in severe cases, which is indicative of deeper vascular involvement (Rosenbaum, 2015).

On the other hand, scleritis is typically characterized by severe, aching, and sometimes excruciating pain that may radiate to the face, jaw, or temple (Mikhail *et al*., 2022). This intense pain is often exacerbated by eye movement or palpation of the eye and may be associated with systemic symptoms such as fever or malaise. Scleritis is frequently associated with autoimmune diseases, such as rheumatoid arthritis, lupus, and other systemic vasculitides. Unlike episcleritis, scleritis may also cause significant vision-

threatening complications, including scleral thinning, perforation, and potential globe rupture (Harris *et al*., 2014).

Phenylephrine Blanching Test

The phenylephrine blanching test plays a critical role in differentiating between episcleritis and scleritis. Episcleritis is characterized by superficial vascular inflammation, and the vessels involved will blanch when phenylephrine is applied to the eye (Galor *et al*., 2016). In contrast, scleritis involves deeper vascular layers, and the blood vessels will not blanch due to the more substantial, deeper vascular involvement. The blanching test, though simple and non-invasive, is a valuable diagnostic tool that helps avoid unnecessary systemic evaluations in cases of episcleritis, thus preventing the overuse of diagnostic testing and enabling more focused management (Lightman & McCluskey, 2004).

Systemic Associations

One of the most significant differences between episcleritis and scleritis is the presence of systemic associations. While episcleritis is usually idiopathic and non-systemic, scleritis is frequently associated with underlying autoimmune diseases (Mikhail *et al*., 2022). Autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's granulomatosis, and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) have been strongly linked to scleritis. In fact, about 20% of scleritis cases are associated with systemic autoimmune diseases, and approximately 10% of individuals with rheumatoid arthritis will experience scleritis during their lifetime (Rosenbaum, 2015).

Given the potential severity of scleritis and its links to systemic diseases, a comprehensive evaluation for autoimmune disease is often indicated in cases where scleritis is suspected. Laboratory tests including rheumatoid factor, antinuclear antibody (ANA), and complement levels are useful in identifying autoimmune diseases associated with scleritis. In contrast, laboratory investigations in episcleritis are typically unremarkable, as systemic associations are rare (Mikhail *et al*., 2022). In our case, the patient's laboratory tests, including complete blood count, erythrocyte sedimentation rate (ESR), and rheumatoid factor, were all normal, suggesting that her episcleritis was not related to any underlying systemic condition.

Management Strategies

The management of episcleritis and scleritis differs markedly due to the differences in their severity and systemic associations.

Management of Episcleritis

Episcleritis is a relatively mild condition and usually resolves on its own within a few weeks. Treatment focuses on alleviating symptoms and controlling inflammation. Topical nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac or ketorolac, are the first-line treatment for episcleritis (Galor *et al*., 2016). These medications help reduce the inflammation and pain associated with the condition. In some cases, preservative-free lubricating eye drops are also used to maintain ocular surface health and provide symptomatic relief (Harris *et al*., 2014).

Topical corticosteroids are not typically required for episcleritis as the condition is self-limiting, and steroids may lead to complications such as elevated intraocular pressure or cataract formation when used inappropriately (Lightman & McCluskey, 2004). In the case presented, the patient's condition resolved completely with topical NSAIDs and lubricants, which is consistent with the typical course of episcleritis.

Management of Scleritis

In contrast, scleritis is a more serious condition that often requires systemic treatment. Management typically includes oral NSAIDs for pain control, but more aggressive treatments may be necessary depending on the severity and underlying cause. If systemic autoimmune disease is suspected or confirmed, systemic immunosuppressive therapy may be indicated (Mikhail *et al*., 2022). These treatments include corticosteroids (oral or intravenous), immunosuppressive agents such as methotrexate, or biologic agents targeting specific inflammatory pathways, such as tumor necrosis factor inhibitors (TNFi) (Rosenbaum, 2015).

Patients with scleritis should be monitored closely for complications such as scleral thinning, necrosis, or perforation. Surgical intervention may be required in severe cases of necrotizing scleritis that threaten the integrity of the globe (Harris *et al*., 2014). In contrast, episcleritis rarely leads to complications or requires invasive procedures, emphasizing the importance of distinguishing between the two conditions early in the diagnostic process.

Prognosis

The prognosis for episcleritis is excellent, with most cases resolving spontaneously without long-term consequences. In rare cases, recurrent

episcleritis may occur, but these episodes are usually less severe and self-limiting (Galor *et al*., 2016).

On the other hand, scleritis carries a more guarded prognosis, especially in cases where there is significant scleral involvement or where an underlying autoimmune condition is present. If left untreated or inadequately managed, scleritis can lead to severe complications, including vision loss, globe perforation, and even death (Rosenbaum, 2015). Prompt recognition and treatment of scleritis are crucial to preventing these potentially sight-threatening complications.

Conclusion

Differentiating episcleritis from scleritis is critical to ensuring appropriate and effective management. While episcleritis is a benign, self-limiting condition that responds well to topical NSAIDs and lubricants, scleritis requires more aggressive systemic treatment due to its potential for significant complications and its association with systemic autoimmune diseases. The phenylephrine blanching test, alongside careful clinical evaluation and laboratory investigations, can assist clinicians in distinguishing these two conditions. This case highlights the importance of clinical vigilance in accurately diagnosing anterior segment ocular inflammation, ensuring patients receive the most appropriate care based on their specific condition.

References

1. Galor A, Lee DA, Rhee MK. Episcleritis: A review. Surv Ophthalmol. 2016;61(6):646-50.
2. Mikhail MA, Seldomridge SL, Gergely ML. Scleritis and episcleritis: Clinical features and management strategies. Am J Ophthalmol. 2022;233:100-7.
3. Rosenbaum JT. The diagnosis and management of scleritis. Int J Rheum Dis. 2015;18(2):133-41.
4. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60(3):163-91.
5. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: Clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469-76.
6. McCluskey P, Wakefield D. Prediction of the risk of systemic vasculitis in patients with scleritis or peripheral ulcerative keratitis. Curr Opin Ophthalmol. 2005;16(6):475-9.

7. Harris JL, Rojas L, McCulley TJ. Management of scleritis: Diagnosis, treatment, and outcomes. Int Ophthalmol Clin. 2014;54(4):65-72.
8. Lightman S, McCluskey P. Scleritis and episcleritis: Current perspectives. Ophthalmology. 2004;111(12):2351-6.